Methods and compositions for targeted protein degradation

ABSTRACT

Provided herein are methods and compositions for targeted protein degradation. In one aspect, a protein degradation chimera is provided, comprising: a first moiety that is capable of binding to a chaperone complex component; a second moiety that is capable of binding to a target protein or proteins, wherein the target protein (s) is targeted for degradation; and a tether configured to covalently couple the first moiety and the second moiety.

RELATED APPLICATIONS

This application claims priority to International Application No. PCT/CN2019/081919, filed Apr. 9, 2019, the entire contents of which are incorporated herein.

FIELD

The present application relates generally to methods and compositions for targeted protein degradation, and more specifically, compositions that are able to induce targeted protein degradation for the treatment of cancers and other diseases.

BACKGROUND

Protein homeostasis, or proteostasis, refers to the ability of cells to properly regulate the synthesis, folding, trafficking and degradation of cellular proteins. Properly regulated protein degradation is required for the normal functioning of cells, including their proliferation, differentiation and death, and is often dysregulated in cancers and other diseases.

The ubiquitin-proteasome system (UPS) is one of the major pathways in cells that mediates the disposal and metabolic recycling of proteins (Yu and Matouschek, Annu Rev Biophys, 2017, 46:149-173; Navon and Ciechanover, J Biol Chem, 2009, 284:33713-33718). Ubiquitin is a 76 amino acid-residue protein that is ubiquitously expressed. With respect to protein degradation by the UPS, the process of ubiquitination occurs when a ubiquitin is attached to a lysine amino acid residue in a substrate protein, which involves a series of enzymatic steps. First, ubiquitin is transferred to an E1 ubiquitin-activating enzyme. Second, activated ubiquitin is transferred from the E1 to an E2 ubiquitin-conjugating enzyme. And third, one of the several hundred different E3 ubiquitin ligase enzymes links the ubiquitin to a lysine residue in a substrate protein. Repetition of this enzymatic process results in tagging substrate proteins with polyubiquitin chains which are then delivered to the proteasome, a large multi-subunit complex that degrades ubiquitin-tagged proteins. The ability of some cellular chaperone proteins and chaperone complexes to direct proteins towards the UPS is facilitated by their direct interaction with E3 ubiquitin ligases (Amm et al., Biochim Biophys Acta, 2014, 1843:182-196; Taipale et al., Cell, 2012, 150:987-1001). In addition to protein degradation, the ubiquitination of proteins can also regulate other processes, such as the subcellular localization, activity and protein-protein interactions of substrates.

Chemically induced, targeted protein degradation has emerged as a new modality for small molecule drug development. A small molecule can be used to promote the interaction of a target protein or proteins with a component of various cellular protein degradation pathways, there by inducing the degradation of the targeted protein or proteins as a way to treat disease.

In particular, proteolysis-targeting chimeras (PROTACs) are an example of such small molecules that purposely induce protein degradation of specific proteins by coopting the UPS (Burslem and Crews, Cell, 2020, 181:102-114; Pettersson and Crews, Drug Discov Today Technol, 2019, 31:15-27). PROTAC molecules are bifunctional small molecules that simultaneously bind to a target protein or proteins and an E3 ubiquitin ligase. The induced proximity of the target protein(s) and the E3 ligase causes the ubiquitination and subsequent degradation of the target protein(s) by the proteasome). Although PROTACs that incorporate target protein binders that promiscuously bind to multiple proteins can often degrade multiple proteins, in some cases charge repulsion and steric clashing between individual targets and an E3 ligase can increase the observed selectivity of degradation (Pettersson and Crews, Drug Discov Today Technol, 2019, 31:15-27; Bondeson et al, Cell Chem Biol, 2018, 25:78-87; Gadd et al., Nat Chem Biol, 2017, 13:514-521; Zengerle et al., ACS Chem Biol, 2015, 10:1770-1777).

AUTAC technology follows a similar principle of induced proximity, but targets proteins for degradation via autophagy (Daiki et al., Mol Cell, 2019, 76:797-810).

However, some disadvantages are associated with current targeted protein degradation technologies. These include the promiscuous degradation of the target protein in many tissues and organs, not just the tissue and organ where the target protein is involved in a disease process, which is expected to result in unwanted side effects of treatment. Also, resistance to a PROTAC can develop through mutations in components of the UPS such as E3 ligases (Ottis et al., ACS Chem Biol, 2019, 14:2215-2223; Zhang et al., Mol Cancer Ther, 2019, 18:1302-1311), resulting in loss of therapeutic efficacy. As such, a need exists for improved/alternative methods and compositions for targeted protein degradation.

SUMMARY

Provided herein are compounds, their prodrugs, pharmaceutically acceptable salts, isotopes and compositions thereof, for the treatment of cancers and other diseases. Such compounds can be chimeric constructs and are designed to be retained in tumor tissues and cause cancer cell death. These drugs may also possess other mechanisms of action. Of specific interest are the compounds that are able to induce targeted oncogenic protein degradation in a tumor-selective fashion. These molecules are termed T-PEACHs (tumor-targeted protein degradation chimeras).

In one aspect, a protein degradation chimera is provided, comprising: a first moiety that is capable of binding to a chaperone complex component; a second moiety that is capable of binding to a target protein or proteins, wherein the target protein(s) is directed for degradation; and third, a tether configured to covalently couple the first moiety and the second moiety.

In some embodiments, the chaperone complex component is selected from HSP90 (heat shock protein 90), HSP70 (heat shock protein 70), IAPs (inhibitor of apoptosis proteins) and E3 ligases such as CHIP (carboxyl terminus of Hsc70-interacting protein), HECTD3 (Homologous to the E6-associated protein carboxyl terminus domain containing 3), CUL5 (Cullin 5), as well as other cofactors and cochaperones.

In some embodiments, the target protein(s) comprise one or more members of the bromodomain and extra-terminal domain (BET) protein family, specifically bromodomain-containing protein 2 (BRD2), bromodomain-containing protein 3 (BRD3), bromodomain-containing protein 4 (BRD4), and bromodomain testis-specific protein (BRDT).

In some embodiments, the target protein is one or more of the following proteins: ERK5 (MAPK7); BTK; ALK; EGFR; RAF1; KRAS; MDM2; STAT3; HIF1A; NTRK1; IRAK4; AR; ABL1; KDR; CDK4; CDK6; CDK7; MAP3K11; MET; PDGFRA; ESR1; IGF1R; and TERT, etc.

In some embodiments, the tether is a chemical construct that covalently couples the first moiety and the second moiety through non-cleavable chemical bonds. In some embodiments, the first moiety is able to bind to chaperone complexes through its affinity for HSP90, HSP70, IAPs, AHA1, CDC37, or E3 ligases.

In some embodiments, the tether contains a certain number (2-4) of ring structures to provide rigidity and length which favor a spatial arrangement of the chaperone complex components and the targeted protein or proteins to promote maximal degradation of the target protein(s). In some embodiments, the length of the tether is optimized based on the distance between the N-terminal ATP-binding pocket of HSP90, which is bound by the chaperone binding moiety, and the middle domain of HSP90 that is known to interact with substrate proteins. In some embodiments, the tethers contain salt forming functional groups which enhance the drug-like properties of the molecules.

In some embodiments, when administered to a patient having cancer, the protein degradation chimera is selectively retained in tumor tissues due to binding to the high levels of active HSP90 present in tumors.

Use of the compounds disclosed herein is also provided, e.g., for the treatment of cancers or other diseases where targeted protein degradation is needed.

In another aspect, a method for treating cancer is provided, comprising administering a therapeutically effective amount of the protein degradation chimera disclosed herein to a patient in need thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a representative chaperone complex with ubiquitinated substrate protein.

FIG. 2 shows an exemplary tumor-targeted protein degradation chimera (T-PEACH).

FIG. 3 shows an exemplary T-PEACH.

FIG. 4 shows an exemplary tether.

FIG. 5 shows an exemplary tether.

FIG. 6 shows a western blot of BRD4 degradation induced by compound 074.

FIG. 7 shows a western blot of BRD4 after treatment with compound 074 and/or proteasome inhibitor bortezomib.

FIG. 8a shows average tumor volume in an MV4-11 AML xenograft model in mice treated with compound 074.

FIG. 8b shows average body weight in an MV4-11 AML xenograft model in mice treated with compound 074.

FIG. 9a shows average tumor volume in an SU-DHL-4 DLCBL xenograft model in mice treated with compounds 074 and 078.

FIG. 9b shows average body weight in an SU-DHL-4 DLCBL xenograft model in mice treated with compounds 074 and 078.

DETAILED DESCRIPTION

The present disclosure provides, in some embodiments, a small molecule compound containing a first moiety to bind to a target protein or proteins and a second moiety to bind to a chaperone protein or protein component of a chaperone complex.

The applications of the drugs/compositions, their metabolites and derivatives include, but are not limited to, tumor-targeted protein degradation chimeras (T-PEACHs), which can be used for anticancer therapy as single agents or in combination with other anticancer drugs. Their mechanisms of action include, but are not limited to, degrading BRD4 and/or other members of the BET protein family, and thereby impeding down-stream signals and resulting in cancer cell death. T-PEACH molecules also demonstrate unique properties in being selectively retained in tumors due to their binding affinity for highly expressed and active chaperone complexes including those containing activated HSP90 and/or HSP70.

T-PEACH molecules can disrupt tumor biology through three distinct mechanisms: 1) direct inhibition of the target protein or proteins through the target protein(s) binding moiety; 2) induction of target protein(s) degradation; and 3) an extended pharmacokinetic half-life in tumors relative to non-tumor tissues and organs, resulting in a prolongation of the preceding two mechanisms.

T-PEACH technology has several advantages over other approaches to targeted protein degradation, such as PROTAC technology. First, because HSP90 and HSP90-containing chaperone complexes interact with many different E3 ligases (Taipale et al., Cell, 2012, 150:987-1001), targeted protein degradation is not restricted to occurring through a single E3 ligase. This is in contrast to PROTAC technology, where certain protein targets can be efficiently degraded by PROTACs that engage one E3 ligase, but not by PROTACs that engages a different E3 ligase (Ashton et al., Angew Chem Int Ed Engl, 2016, 55:807-810).

Similarly, since multiple E3 ligases interact with HSP90 and HSP90-containing chaperone complexes, mutation of a single E3 ligases is unlikely to cause resistance to a T-PEACH compound. This is in contrast to PROTAC technology, where mutation of the single E3 ligase engaged by a PROTAC is the most common mechanism underlying the development of drug resistance (Ottis et al., ACS Chem Biol, 2019, 14:2215-2223; Zhang et al., Mol Cancer Ther, 2019, 18:1302-1311).

Finally, in contrast to other targeted protein degradation technologies such as PROTAC, T-PEACH compounds that include a HSP90-binding or HSP90 complex-binding moiety selectively accumulate in tumors and tumor tissues relative non-tumor tissues and organs. This decreases the side effects of treatment and enhance the therapeutic index of such compounds (Heske et al., Oncotarget, 2016, 7:65540-65552; Bobrov, Oncotarget, 2017, 8:4399-4409; Proia et al., Mol Cancer Ther, 2015, 14:2422-2432).

Definitions

Certain terms are defined herein below. Additional definitions are provided throughout the application.

As used herein, the articles “a” and “an” refer to one or more than one, e.g., to at least one, of the grammatical object of the article. The use of the words “a” or “an” when used in conjunction with the term “comprising” herein may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements.

Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values. The term “substantially” means more than 50%, preferably more than 80%, and most preferably more than 90% or 95%.

As used herein the term “comprising” or “comprises” are used in reference to compositions, methods, and respective component(s) thereof, that are present in a given embodiment, yet open to the inclusion of unspecified elements.

As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the disclosure.

The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.

Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

As used herein, the term “subject” refers to human and non-human animals, including veterinary subjects. The term “non-human animal” includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, mice, rabbits, sheep, dog, cat, horse, cow, chickens, amphibians, and reptiles. In a preferred embodiment, the subject is a human and may be referred to as a patient.

As used herein, the terms “treat,” “treating” or “treatment” refer, preferably, to an action to obtain a beneficial or desired clinical result including, but not limited to, alleviation or amelioration of one or more signs or symptoms of a disease or condition, diminishing the extent of disease, stability (i.e., not worsening) of the state of disease, amelioration or palliation of the disease state, diminishing rate of or time to progression, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment. Treatment does not need to be curative.

A “therapeutically effective amount” is that amount sufficient to treat a disease in a subject. A therapeutically effective amount can be administered in one or more administrations.

The terms “administer,” “administering” or “administration” include any method of delivery of a pharmaceutical composition or agent into a subject's system or to a particular region in or on a subject. In certain embodiments of the invention, an agent is administered intravenously, intramuscularly, subcutaneously, intradermally, intranasally, orally, transcutaneously, or mucosally. In a preferred embodiment, an agent is administered intravenously. In another preferred embodiment, an agent is administered orally. Administering an agent can be performed by a number of people working in concert. Administering an agent includes, for example, prescribing an agent to be administered to a subject and/or providing instructions, directly or through another, to take a specific agent, either by self-delivery, e.g., as by oral delivery, subcutaneous delivery, intravenous delivery through a central line, etc.; or for delivery by a trained professional, e.g., intravenous delivery, intramuscular delivery, intratumoral delivery, etc.

The terms “cancer” or “tumor” are well known in the art and refer to the presence, e.g., in a subject, of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, decreased cell death/apoptosis, and certain characteristic morphological features. Cancer cells are often in the form of a solid tumor. However, cancer also includes non-solid tumors, e.g., blood tumors, e.g., leukemia, wherein the cancer cells are derived from bone marrow. As used herein, the term “cancer” includes pre-malignant as well as malignant cancers. Cancers include, but are not limited to, acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin and non-Hodgkin), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin, and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, and Wilms' tumor. Other cancers include primary cancer, metastatic cancer, oropharyngeal cancer, hypopharyngeal cancer, liver cancer, gall bladder cancer, bile duct cancer, small intestine cancer, urinary tract cancer, kidney cancer, urothelium cancer, female genital tract cancer, uterine cancer, gestational trophoblastic disease, male genital tract cancer, seminal vesicle cancer, testicular cancer, germ cell tumors, endocrine gland tumors, thyroid cancer, adrenal cancer, pituitary gland cancer, hemangioma, sarcoma arising from bone and soft tissues, Kaposi's sarcoma, nerve cancer, ocular cancer, meningial cancer, glioblastomas, neuromas, neuroblastomas, Schwannomas, solid tumors arising from hematopoietic malignancies such as leukemias, metastatic melanoma, recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer, gastrointestinal stromal tumors, colorectal cancer, gastric cancer, melanoma, glioblastoma multiforme, non-squamous non-small-cell lung cancer, malignant glioma, epithelial ovarian cancer, primary peritoneal serous cancer, metastatic liver cancer, neuroendocrine carcinoma, refractory malignancy, triple negative breast cancer, HER2-amplified breast cancer, nasopharageal cancer, oral cancer, biliary tract, hepatocellular carcinoma, squamous cell carcinomas of the head and neck (SCCHN), non-medullary thyroid carcinoma, recurrent glioblastoma multiforme, neurofibromatosis type 1, CNS cancer, liposarcoma, leiomyosarcoma, salivary gland cancer, mucosal melanoma, acral/lentiginous melanoma, paraganglioma, pheochromocytoma, advanced metastatic cancer, solid tumor, triple negative breast cancer, colorectal cancer, sarcoma, melanoma, renal carcinoma, endometrial cancer, thyroid cancer, rhabdomysarcoma, multiple myeloma, ovarian cancer, glioblastoma, gastrointestinal stromal tumor, mantle cell lymphoma, and refractory malignancy.

“Solid tumor,” as used herein, is understood as any pathogenic tumor that can be palpated or detected using imaging methods as an abnormal growth having three dimensions. A solid tumor is differentiated from a blood tumor such as leukemia. However, cells of a blood tumor are derived from bone marrow; therefore, the tissue producing the cancer cells is a solid tissue that can be hypoxic.

“Tumor tissue” or “tumorous tissue” are understood as cells, extracellular matrix, and other naturally occurring components associated with the solid tumor.

As used herein, “binding” is understood as having at least a 10{circumflex over ( )}2 or more, 10{circumflex over ( )}3 or more, preferably 10{circumflex over ( )}4 or more, preferably 10{circumflex over ( )}5 or more, preferably 10{circumflex over ( )}6 or more preference for binding to a specific binding partner as compared to a non-specific binding partner (e.g., binding an antigen to a sample known to contain the cognate antibody).

The term “moiety” refers generally to a portion of a molecule, which may be a functional group, a set of functional groups, and/or a specific group of atoms within a molecule, that is responsible for a characteristic chemical, biological, and/or medicinal property of the molecule.

As used herein, “binder” is understood to be a small molecule or moiety that has affinity for a protein or proteins, but when bound to that protein(s) may or may not act as an inhibitor or activator of that protein(s). In one aspect, a “binder” is an inhibitor of the protein to which it binds. In another aspect, a “binder” is an activator of the protein to which it binds. In yet another aspect, a “binder” has affinity for a protein or proteins, but does not affect the activity of that protein(s).

The term “linker” or “tether,” used interchangeably, refers to a chemical moiety that joins two other moieties (e.g., a first binding moiety and a second binding moiety). A linker can covalently join a first binding moiety and a second binding moiety. In one aspect, the linker is uncleavable in vivo. In one aspect, the linker comprises one or more cyclic ring systems. In another aspect, the linker comprises an alkyl chain optionally substituted by and/or interrupted with one or more chemical groups. In one aspect, the linker comprises optimal spatial and chemical properties to effectuate optimal therapeutic activity. In one aspect, the linker does not interfere with the ability of the first binding moiety and the second binding moiety to bind their respective targets e.g., a chaperone complex component (such as HSP90) and a target protein (such as BRD4). In one aspect, the linker is of the formula -Het¹-X¹—, -Het¹-X¹-Het²-X²—, -Het¹-X¹—(C₁-C₄)alkylene-Het²-X²—, -Het¹-X¹-Het²-X²(C₁-C₄)alkylene-, —(CH₂CH₂O)_(o)—(CH₂)_(p)-Het¹-X¹-Het²-(CH₂CH₂O)_(n), —(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹-Het²-X², -Het¹-X¹-Phe-X²—NR^(c)—X³—, —(CH₂CH₂O)_(o)—(CH₂)_(p)-Het¹-X¹-Phe-X²—NR^(c)—(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)NR^(c)-Phe-X¹—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)-Phe-(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)—C(O)—NR^(d)—(CH₂CH₂O)_(o)—(CH₂)_(p)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹-Het²-X²—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹-Het²-X²—(CH₂CH₂O)_(o), —NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-NH—X¹-Het¹-X², —NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-NH—X¹-Het¹-X²—(CH₂CH₂O)_(o), —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-X¹—NR^(c)—(CH₂CH₂O)_(o)—(CH₂)_(p)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹- X¹—(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)—NR^(c)—(CH₂)_(m)—C(O)—NR^(d)-Het¹-X¹-Het²-(CH₂CH₂O)_(o)—(CH₂)_(p), or —NR^(c)—(CH₂)_(m)—C(O)—NR^(d)—(CH₂)_(m)-Het¹-X¹-Het²-X², wherein

Het¹ and Het² are each independently phenyl, a 4- to 6-membered heterocyclyl, 5- to 7-membered heteroaryl, or a 4- to 6-membered cycloalkyl;

X¹, X², and X³, are each independently C(O) or (CH₂)_(r);

R^(c) and Rd are each independently hydrogen or (C₁-C₄)alkyl; and

m, n, o, p, q and r are each independently integers selected from 0, 1, 2, 3, 4, 5, and 6.

As used herein, a “ligand” is a substance (e.g., a binding moiety) that can form a complex with a biomolecule. The ligand and/or formation of the ligand-biomolecule complex can have a biological or chemical effect, such as a therapeutic effect, cytotoxic effect, and/or imaging effect.

As used herein, the term “alkyl” means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, 3,3-dimethylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diethylhexyl, 2,2-diethylhexyl, 3,3-diethylhexyl and the like. The term “(C.sub.1-C.sub.6)alkyl” means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 6 carbon atoms. Representative (C.sub.1-C.sub.6)alkyl groups are those shown above having from 1 to 6 carbon atoms. Alkyl groups included in compounds of this invention may be optionally substituted with one or more substituents.

As used herein, the term “alkenyl” means a saturated straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and having at least one carbon-carbon double bond. Representative straight chain and branched (C.sub.2-C.sub.10)alkenyls include vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl and the like. Alkenyl groups may be optionally substituted with one or more substituents.

As used herein, the term “alkynyl” means a saturated straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and having at least one carbon-carbon triple bond. Representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 5-hexynyl, 1-heptynyl, 2-heptynyl, 6-heptynyl, 1-octynyl, 2-octynyl, 7-octynyl, 1-nonynyl, 2-nonynyl, 8-nonynyl, 1-decynyl, 2-decynyl, 9-decynyl, and the like. Alkynyl groups may be optionally substituted with one or more substituents.

As used herein, the term “cycloalkyl” means a saturated, mono- or polycyclic alkyl radical having from 3 to 20 carbon atoms. Representative cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, -cyclodecyl, octahydro-pentalenyl, and the like. Cycloalkyl groups may be optionally substituted with one or more substituents.

As used herein, the term “cycloalkenyl” means a mono- or poly-cyclic non-aromatic alkyl radical having at least one carbon-carbon double bond in the cyclic system and from 3 to 20 carbon atoms. Representative cycloalkenyls include cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclooctatetraenyl, cyclononenyl, cyclononadienyl, cyclodecenyl, cyclodecadienyl, 1,2,3,4,5,8-hexahydronaphthalenyl and the like. Cycloalkenyl groups may be optionally substituted with one or more substituents.

As used herein, the term “haloalkyl” means and alkyl group in which one or more (including all) the hydrogen radicals are replaced by a halo group, wherein each halo group is independently selected from —F, —Cl, —Br, and —I. The term “halomethyl” means a methyl in which one to three hydrogen radical(s) have been replaced by a halo group. Representative haloalkyl groups include trifluoromethyl, bromomethyl, 1,2-dichloroethyl, 4-iodobutyl, 2-fluoropentyl, and the like.

As used herein, an “alkoxy” is an alkyl group which is attached to another moiety via an oxygen linker.

As used herein, an “haloalkoxy” is an haloalkyl group which is attached to another moiety via an oxygen linker.

As used herein, the term an “aromatic ring” or “aryl” means a hydrocarbon monocyclic or polycyclic radical in which at least one ring is aromatic. Examples of suitable aryl groups include, but are not limited to, phenyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. Aryl groups may be optionally substituted with one or more substituents. In one embodiment, the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as “(C.sub.6)aryl.”

As used herein, the term “aralkyl” means an aryl group that is attached to another group by a (C.sub.1-C.sub.6)alkylene group. Representative aralkyl groups include benzyl, 2-phenyl-ethyl, naphth-3-yl-methyl and the like. Aralkyl groups may be optionally substituted with one or more substituents.

As used herein, the term “alkylene” refers to an alkyl group that has two points of attachment. The term “(C.sub.1-C.sub.6)alkylene” refers to an alkylene group that has from one to six carbon atoms. Straight chain (C.sub.1-C.sub.6)alkylene groups are preferred.

Non-limiting examples of alkylene groups include methylene (—CH.sub.2-), ethylene (—CH.sub.2CH.sub.2-), n-propylene (—CH.sub.2CH.sub.2CH.sub.2-), isopropylene (—CH.sub.2CH(CH.sub.3)-), and the like. Alkylene groups may be optionally substituted with one or more substituents.

As used herein, the term “heterocyclyl” means a monocyclic (typically having 3- to 10-members) or a polycyclic (typically having 7- to 20-members) heterocyclic ring system which is either a saturated ring or an unsaturated non-aromatic ring. A 3- to 10-membered heterocycle can contain up to 5 heteroatoms; and a 7- to 20-membered heterocycle can contain up to 7 heteroatoms. Typically, a heterocycle has at least on carbon atom ring member. Each heteroatom is independently selected from nitrogen, which can be oxidized (e.g., N(O)) or quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The heterocycle may be attached via any heteroatom or carbon atom. Representative heterocycles include morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like. A heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group. Furthermore, the heterocyclyl may be optionally substituted with one or more substituents. Only stable isomers of such substituted heterocyclic groups are contemplated in this definition.

As used herein, the term “heteroaromatic”, “heteroaryl” or like terms means a monocyclic or polycyclic heteroaromatic ring comprising carbon atom ring members and one or more heteroatom ring members. Each heteroatom is independently selected from nitrogen, which can be oxidized (e.g., N(O)) or quaternized; oxygen; and sulfur, including sulfoxide and sulfone. Representative heteroaryl groups include pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, a isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, a triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl, azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, imidazo[1,2-a]pyridyl, and benzothienyl. In one embodiment, the heteroaromatic ring is selected from 5-8 membered monocyclic heteroaryl rings. The point of attachment of a heteroaromatic or heteroaryl ring to another group may be at either a carbon atom or a heteroatom of the heteroaromatic or heteroaryl rings. Heteroaryl groups may be optionally substituted with one or more substituents.

As used herein, the term “(C.sub.5)heteroaryl” means an aromatic heterocyclic ring of 5 members, wherein at least one carbon atom of the ring is replaced with a heteroatom such as, for example, oxygen, sulfur or nitrogen. Representative (C.sub.5)heteroaryls include furanyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyrazinyl, triazolyl, thiadiazolyl, and the like.

As used herein, the term “(C.sub.6)heteroaryl” means an aromatic heterocyclic ring of 6 members, wherein at least one carbon atom of the ring is replaced with a heteroatom such as, for example, oxygen, nitrogen or sulfur. Representative (C.sub.6)heteroaryls include pyridyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl and the like.

As used herein, the term “heteroaralkyl” means a heteroaryl group that is attached to another group by a (C.sub.1-C.sub.6)alkylene. Representative heteroaralkyls include 2-(pyridin-4-yl)-propyl, 2-(thien-3-yl)-ethyl, imidazol-4-yl-methyl and the like. Heteroaralkyl groups may be optionally substituted with one or more substituents.

As used herein, the term “halogen” or “halo” means F, Cl, Br or I.

Suitable substituents for an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroaralkyl groups include any substituent which will form a stable compound of the invention. Examples of substituents for an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl include an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, or a haloalkyl.

In addition, alkyl, cycloalkyl, alkylene, a heterocyclyl, and any saturated portion of a alkenyl, cycloalkenyl, alkynyl, aralkyl, and heteroaralkyl groups, may also be substituted with ═O, or ═S.

When a heterocyclyl, heteroaryl, or heteroaralkyl group contains a nitrogen atom, it may be substituted or unsubstituted. When a nitrogen atom in the aromatic ring of a heteroaryl group has a substituent, the nitrogen may be a quaternary nitrogen.

As used herein, the term “lower” refers to a group having up to four atoms. For example, a “lower alkyl” refers to an alkyl radical having from 1 to 4 carbon atoms, “lower alkoxy” refers to “—O—(C.sub.1-C.sub.4)alkyl and a “lower alkenyl” or “lower alkynyl” refers to an alkenyl or alkynyl radical having from 2 to 4 carbon atoms, respectively.

Unless indicated otherwise, the compounds of the invention containing reactive functional groups (such as (without limitation) carboxy, hydroxy, thiol, and amino moieties) also include protected derivatives thereof. “Protected derivatives” are those compounds in which a reactive site or sites are blocked with one or more protecting groups. Examples of suitable protecting groups for hydroxyl groups include benzyl, methoxymethyl, allyl, trimethylsilyl, tert-butyldimethylsilyl, acetate, and the like. Examples of suitable amine protecting groups include benzyloxycarbonyl, tert-butoxycarbonyl, tert-butyl, benzyl and fluorenylmethyloxy-carbonyl (Fmoc). Examples of suitable thiol protecting groups include benzyl, tert-butyl, acetyl, methoxymethyl and the like. Other suitable protecting groups are well known to those of ordinary skill in the art and include those found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc., 1981.

Chaperone Complex Components and their Binding Moieties

Multi-subunit chaperone complexes are composed of chaperone proteins such as HSP90 and HSP70, as well as a variety of co-chaperones such as AHSA1, CDC37 and STIP1 and other components (Biebl and Buchner, Cold Spring Harb Perspect Biol, 2019, 11:a034017; Morin Luengo et al., Trends Cell Biol, 2019, 29:164-177; Schopf et al., Nat Rev Mol Cell Biol, 2017, 18:345-360; Trepel et al., Nat Rev Cancer, 2010, 10:537-549). These chaperones and chaperone complexes mediate the proper folding, maturation and activation of a wide array of substrate proteins, which are commonly referred to as client proteins. Importantly, these clients include many important regulatory proteins, such as protein kinases and growth factor receptors, that are often deregulated in disease states.

Chaperones and chaperone complexes can also recognize miss-folded proteins and direct them towards degradation by the UPS and other degradation pathways. This is facilitated in part by the direct interaction of many E3 ubiquitin ligases, such as CHIP, CUL5, HECD3 and IAPs with components of chaperone complexes such as HSP90 and HSP70 (Taipale et al., Cell, 2012, 150:987-1001; Dogan et al., Nat Cell Biol, 2008, 10:1447-1455; Zhang et al., Mol Cell, 2005, 20:525-538; McDonough and Patterson, Cell Stress Chaperones, 2003, 8:303-308). Importantly, mutations associated with the development of cancer have often been found to occur in client proteins, and the stabilization of such aberrant oncoproteins by chaperones prevents their degradation and promotes the growth and survival of cancer cells (Amm et al., Biochim Biophys Acta, 2014, 1843:182-196; McDonough and Patterson, Cell Stress Chaperones, 2003, 8:303-308). Therefore, the interactions between oncoproteins, chaperones, E3 ligases and the UPS play critical roles in the growth and survival of cancer cells. A similar phenomenon has also been observed for the degradation of mutated proteins in diseases other than cancer (Meacham et al., Nat Cell Biol, 2001, 3:100-105).

HSP90 has 3 major domains: first, an N-terminal ATP-binding domain; second a middle domain that interacts with client proteins; and third, a C-terminal domain (Biebl and Buchner J, Cold Spring Harb Perspect Biol, 2019, 11:a034017). Compounds which bind to either the N-terminal ATP-binding or C-terminal domains of HSP90 have previously been described. Some representative compounds include the natural product geldanamycin and its analogs, resorcinol and its analogs, ganetespib and its analogs, luminespib and its analogs, onalespib and its analogs, PU-H71 and its analogs, XL-888 and its analogs, NVP-BEP800 and its analogs, SNX-5422 and its analogs, KW-2478 and its analogs, NMS-E973 and its analogs, CH5138303 and its analogs, and VER-50589 and its analogs. Additional HSP90 inhibitors include those disclosed in U.S. Pat. Nos. 8,362,055 and 7,825,148, incorporated herein by reference.

Exemplary HSP70 binders include VER155008 and its analogs, apoptozole, MKT-077, Methylene Blue, (−)-epigallocatechin-3-gallate (EGCG), JS-98 and its analogs, and YM-01 and its analogs.

IAP binders can, in some embodiments, include birinapant, GDC-0152, AT406, LCL161, AZD5582 and BV-6.

If chaperone function is interfered with, such as by small molecule inhibitors of chaperones, client proteins can also be directed for degradation by the UPS. The degradation of HSP90 client proteins following treatment with HSP90 inhibitors is mediated by E3 ligases (Li et al., Cell Rep, 2017, 19:2515-2528; Samant et al., Proc Natl Acad Sci USA, 2014, 111:6834-6839; Ehrlich E S et al., Proc Natl Acad Sci USA, 2009, 106:20330-20335; Xu et al., Proc Natl Acad Sci USA, 2002, 99:12847-12852). Similarly, inhibition of HSP70 can also lead to client protein degradation (Cesa et al., J Biol Chem, 2018, 293:2370-2380; Srinivasan et al., Mol Cancer Res, 2018, 16:58-68). Consistent with this, inhibitors of HSP90 and HSP70 have shown promise in pre-clinical animal models, and in the former case in cancer patients in the clinic (Yuno et al., Methods Mol Biol, 2018, 1709:423-441; Kumar et al., Cancer Lett, 2016, 374:156-166).

HSP90 and HSP70 are frequently overexpressed in tumor tissues and this is believed to contribute to the ability of cancer cells to survive in hypoxic, nutrient-deprived and acidotic microenvironments, and to maintain the expression of the mutated or overexpressed oncoprotens to which they are addicted (Rodina et al., Nature, 2016, 538:397-401; Trepel et al., Nat Rev Cancer, 2010, 10:537-549). Moreover, in normal cells HSP90 is largely found in a latent, uncomplexed state, whereas cancer cells contain an abundance of catalytically active HSP90 in chaperone complexes. Importantly, this active HSP90 displays greater affinity for HSP90 inhibitors than the resident pool of HSP90 found in normal cells (Barrott and Haystead, FEBS J, 2013, 280:1381-1396; Chiosis and Neckers, ACS Chem Biol, 2006, 1:279-284; Kamal et al., Nature, 2003, 425:407-410). Relative to normal cells, the rate of HSP90 chaperone cycling accelerates in tumor cells in part due to increased SUMOylation, which recruits co-chaperones required to maximally stimulate HSP90 ATPase activity (Mollapour et al, Mol Cell, 2014, 53:317-329). SUMOylation of HSP90 also facilitates the binding of ATP-competitive inhibitors to HSP90, helping to explain the affinity of these agents for tumor-associated HSP90. HSP90 inhibitors across many structural classes that bind to the N-terminal ATP-binding site of HSP90 have been found to display dramatically increased pharmacokinetic half-lives in tumor tissues relative to non-tumor tissues in pre-clinical animal models and in cancer patients in the clinic (Pillarsetty et al., Cancer Cell, 2019, 36:559-573; Vermeulen et al., Theranostics, 2019, 9:554-572; Crowe et al., ACS Chem Biol, 2017, 12:1047-1055; Heske et al., Oncotarget, 2016, 7:65540-65552; Bobrov, Oncotarget, 2017, 8:4399-4409; Proia et al., Mol Cancer Ther, 2015, 14:2422-2432; Graham et al., Cancer Sci, 2012, 103:522-527).

T-PEACH technology is designed to access the important role of chaperones and chaperone complexes in regulating protein degradation and also to take advantage of the selective tumor retention of HSP90 binding compounds, thereby enabling the development of small molecule inducers of protein degradation with prolonged pharmacokinetic half-lives in tumor tissues.

BRD4 and BET Proteins

Epigenetic changes, such as histone modifications, play important roles in regulating gene expression in normal and diseased states. There are more than 40 known bromodomain proteins, which can recognize acetylated lysines through one or more bromodomains. In particular, the bromodomain and extraterminal (BET) family, which includes the BRD2, BRD3, BRD4 and BRDT proteins, are epigenetic readers that bind acetylated lysines on histones and transcription factors, thereby regulating the expression of a wide variety of genes, including many genes that have been implicated in cancer (Belkina and Denis, Nat Rev Cancer, 12:465-477). BRD4 has been implicated in regulating the MYC gene, the amplification of which is one of the most common genetic alterations observed in human cancers (Delmore et al., Cell, 2011, 146: 904-917; Mertz et al., Proc Natl Acad Sci USA, 2011, 108:16669-16674; Beroukhim et al., Nature, 2010, 463:899-905). Hence, there been great interest in developing small molecule BET inhibitors, and preclinical studies with BET inhibitors have demonstrated their ability to modulate gene expression, induce cytotoxicity in cancer cell lines and inhibit tumor growth in pre-clinical models (Chung et al., J Med Chem, 2011, 54:3827-3838; Dawson et al., Nature, 2011, 478:529-533; Filippakopoulos et al., Nature, 2010, 468:1067-1073). Additionally, some BET inhibitors have shown evidence of efficacy in cancer patients in the clinic (Stathis and Bertoni, Cancer Discov, 2018, 8:24-36; Xu and Vakoc, Cold Spring Harb Perspect Med, 2017, 7, pii:a026674). PROTAC molecules targeting BET proteins for degradation have also shown efficacy in cell culture and in preclinical models (Zhou et al., J Med Chem, 2018, 61:462-481; Raina et al., Proc Natl Acad Sci USA, 2016, 113:7124-7129). It is therefore of great interest to develop T-PEACH molecules targeting all or some members of the BET protein family, particularly BRD4, for the treatment of cancer and other diseases.

Targeted Protein Degradation by T-PEACH Molecules

FIG. 1 illustrates a representative chaperone complex with ubiquitinated substrate protein (adapted from Dogan et al., Nat Cell Biol, 2008, 10:1447-1455). A number of chaperones, such as HSP90 and HSP70, cofactors and cochaperones such as AHA1 and CDC37, and E3 ligases such as CHIP and IAPs have been identified in such complexes, along with substrate proteins that may be ubiquitinated and targeted for degradation by the UPS. Small molecule ligands have also been described that can bind to HSP90, HSP70, IAPs, E3 ligases, etcetera in these complexes.

In various embodiments, the present disclosure provides for small molecule compounds termed tumor-targeted protein degradation chimeras (T-PEACHs) that can be constructed and perform functions which can lead to ubiquitylation of the desired target protein or proteins and delivery of such ubiquitin-tagged proteins to the proteasomal degradation machinery.

One embodiment is related to FIG. 2, which shows an exemplary schematic representation of a tumor-targeted protein degradation chimera (T-PEACH). The design of such molecules have a chaperone or chaperone complex binding moiety that is tethered to a binding moiety for a protein target or protein targets intended to be degraded.

In another embodiment related to FIG. 3, the T-PEACH construct contains a HSP90 binding moiety or a HSP70 binding moiety at one end and a BRD4 protein binder or binder that can bind one or more BET proteins at the other end. The two moieties are connected by a tether specifically designed to allow the T-PEACH molecule to engage both the chaperone complex component and the target(s).

In another embodiment related to FIG. 4, the tether can be a linear and flexible construct, or a more rigid construct. For example, the tether can: (a) contain a linear length of 5-20 atoms of C, N, O and S; (b) contain a number of 3-, 4-, 5-, 6-, 7-, 8-member ring structures to enhance the rigidity of the linkage; (c) contain a number of hetero atoms such an N, O, S; or (d) contain salt forming moieties such basic amine and carboxylic salts.

In another embodiment pertaining to FIG. 5, the tether is constructed in a manner that a number of rings are incorporated to introduce rigidity and the length of the tether between 15-50A allows efficient binding to both the chaperone complex component and the target protein(s), where X, XX, Y, and Z can be O, N, —(CH₂)_(n)—, and the ring size can be 4, 5, 6, 7 and 8 and A, AA, AAA can be —(CH₂)₁₋₁₅—, —(CH₂O)₁₋₁₅—, —(CH₂NR)₁₋₁₅—, —CONR—, —O—, —NR—, —S—, —S(O)_(1 or 2)—, —S(O)_(1 or 2)NH—, —(CH₂CH₂O)₁₋₈—, —(CH₂CH₂NHR)₁₋₈—, where R is H or (un)substituted alkyl.

In another embodiment, the HSP90 inhibitors are resorcinol based 5-member heterocyclic compounds:

where X is either C or N, Y/Z are N, O, S, C and R is —SH, —SR¹, —OH, —OR¹, —NH₂, —NHR¹, —NHR¹R², —CONH₂, —CONHR¹, —CONR¹R² where R and R² is H or (un)substituted alkyl.

In another embodiment, the HSP90 binders are compounds:

where R is H, CF₃, NH₂, OH, (substituted)alkyl, alkoxy, dialkylaminoalkyl, (substituted)cycloalkyl, (substituted)heterocycloalkyl, (substituted)arylalkyl. In one aspect, R can be selected from one or more linkers as defined herein.

In another embodiment, the HSP90 binders are compounds:

where R is independently H, halo, (un)substituted C₁₋₁₅(hetero)alkyl. In one aspect, R can be selected from one or more linkers as defined herein.

In another embodiment, the HSP90 binders are compounds:

where R is independently H, halo, (un)substituted C₁₋₁₅(hetero)alkyl. In one aspect, R can be selected from one or more linkers as defined herein.

In another embodiment, the HSP90 binders are compounds:

where R is independently H, halo, (un)substituted C₁₋₁₅(hetero)alkyl. In one aspect, R can be selected from one or more linkers as defined herein.

In another embodiment, the HSP70 binders are MKT-007, VER-155008, JG98, etc.

In another embodiment, the HSP70 binders are compounds:

where R is H, CF₃, NH₂, OH, (substituted)alkyl, alkoxy, dialkylaminoalkyl, (substituted)cycloalkyl, (substituted)heterocycloalkyl, (substituted)arylalkyl. In one aspect, R can be selected from one or more linkers as defined herein.

In another embodiment, the IAP binders are birinapant, GDC-0152, etc.

EXEMPLIFICATION Example 1a: Compound 039 Synthesis

A representative synthesis scheme for compound 039. Specific synthesis routes of intermediates are shown below.

Intermediate 2 tert-butyl 4-nitrophenethylcarbamate

To a solution of intermediate 1 (8.00 g, 39.5 mmol) and (Boc)₂O (8.60 g, 39.5 mmol) in THF (50 mL) and water (50 mL) was added NaOH (3.1 g, 79.0 mmol). Then the reaction solution was stirred at room temperature for 3 hours. The reaction solution was extracted with EtOAc (50 mL*3). The combined organic layers were washed with brine and dried over Na₂SO₄ and concentrated to give the intermediate 2 (10.0 g, yield 79.3%) as an oil.

Intermediate 3 tert-butyl 4-aminophenethylcarbamate

The solution of intermediate 2 (10.0 g, 33.1 mmol) and Pd/C (10%, 1.5 g) in MeOH (150 mL) was stirred under H₂ atmosphere overnight. The mixture was filtered and the filtrate was concentrated to give the intermediate 3 (8.8 g, yield 99%) as a yellow solid.

Intermediate 4 tert-butyl 4-(2,4-dihydroxy-5-isopropylphenylthioamido)phenethylcarbamate

The solution of intermediate 4-1 (1.0 g, 4.38 mmol), ClH₂CCOONa (765 mg, 6.57 mmol) and NaHCO₃ (1.1 g, 13.14 mmol) in DMF (10 mL) was stirred at 30° C. for 3 hours. Intermediate 3 (1.03 g, 4.38 mmol) was added to the reaction mixture. After the resulting mixture was stirred at 80° C. for 4 hours, the mixture was poured into ice-water and extracted with EA (20 mL*3). The combine organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated and purified by SGC eluted with PE:EA=1:1 to give intermediate 4 (1.50 g, yield 79.7%) as an oil.

Intermediate 5 tert-butyl 4-(7-hydroxy-6-isopropyl-2-oxo-4-thioxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)phenethylcarbamate

The solution of intermediate 4 (1.5 g 3.2 mmol) and CDI (1.07 g, 6.57 mmol) in THF (3 mL) was stirred at room temperature for 4 hours. The reaction solution was poured into brine (5 mL) and extracted with EA (5 mL). The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated to give the intermediate 5 (2.5 g, crude) which was used for further reaction without purification.

Intermediate 6 tert-butyl 4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenethylcarbamate

To a solution of intermediate 5 (2.5 g, crude) in EtOH (5 mL) was added (NH₂)₂ (238 mg, 7.4 mmol). Then the resulting mixture was stirred overnight at room temperature. The precipitated solid was filtered and dried to give intermediate 6 (500 mg, yield 20%) as a white solid.

Intermediate 7 4-(4-(4-(2-aminoethyl)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol

A solution of intermediate 6 (500 mg, 1.41 mmol) in HCl-MeOH (3N, 10 mL) was stirred at room temperature for 16 hours. The reaction solution was concentrated to give intermediate 7 (360 mg, yield 92%) as a white solid.

Compound 039 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenethyl)acetamide

To a solution of intermediate 7-1 (50 mg, 0.125 mmol), HATU (71.3 mg, 0.188 mmol) and DIEA (48.4 mg, 0.375 mmol) in DMF (3 mL) was added intermediate 7 (48.8 mg, 0.125 mmol). The resulting mixture was stirred at room temperature for 3 hours. The mixture was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: CAN) to give Compound 039 15 mg, yield 16.3%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 9.58 (s, 1H), 9.39 (s, 1H), 8.36-8.30 (m, 1H), 7.45 (dd, J=24.9, 8.6 Hz, 4H), 7.24 (d, J=8.4 Hz, 2H), 7.10 (d, J=8.3 Hz, 2H), 6.80 (s, 1H), 6.25 (s, 1H), 4.51 (t, J=7.0 Hz, 1H), 3.32-3.27 (m, 2H), 3.23-3.20 (m, 2H), 2.97-2.95 (m, 1H), 2.75-2.70 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 1.62 (s, 3H), 0.97 (d, J=6.9 Hz, 6H).

LCMS (ESI): RT=1.524 min, LCMS-004 (LCMS 2020-002) Method: A70B30+−, (A: 0.1% FA/H2O B: 0.1% FA/ACN Col. SunFire C18) mass Calculated for C₃₈H₃₇ClN₈O₄S, 736.2, m/z found 737.6 [M+H⁺]).

Example 1b: Compound 074 Synthesis

A representative synthesis scheme for compound 074 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 2 tert-butyl 4-((4-(4-nitrobenzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of 1-(4-nitrobenzyl)piperazine (intermediate 1) (96 g, 0.434 mol), tert-butyl 4-formylpiperidine-1-carboxylate (92 g, 0.434 mol) and CH₃COOH (26 g, 0.434 mol) in DCE (1 L) was added NaBH(OAc)₃ (138 g, 0.65 mol). Then the resulting mixture was stirred at room temperature overnight. The reaction solution was poured into aq. NaHCO₃ solution and extracted with DCM (500 mL*3). The combine organic layers were washed with brine, dried over Na₂SO₄ and concentrated to give intermediate 2 (163 g, yield 90%) as a white solid.

Intermediate 3 tert-butyl 4-((4-(4-aminobenzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 2 (163 g, 0.39 mol) and NH₄Cl (210 g, 3.9 mol) in EtOH(1 L) and H₂O (100 mL) was added Fe power (109 g, 1.95 mmol). The resulting mixture was heated at 80° C. for 3 hours. It was cooled to room temperature and filtered. The filtrate was poured into aq. NaHCO₃ solution and extracted with EtOAc (1 L*3). The combine organic layers was washed with brine, dried over Na₂SO₄ and concentrated. The residue was titrated with PE:EA=10:1 to give intermediate 3 (120 g, yield 73%) as a white solid.

Intermediate 4 tert-butyl 4-((4-(4-(2,4-dihydroxy-5-isopropylphenylthioamido)benzyl) piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 3 (77.5 g, 340 mmol), ClCH₂CO₂Na (49.5 g, 424.5 mmol) and NaHCO₃ (90 g, 849 mmol) in DMF (500 mL) was stirred at 40° C. for 3 hours. Compound 4 (110 g, 283 mmol) was added to the reaction. After the resulting mixture was heated at 80° C. overnight. The reaction mixture was poured into ice-water solid precipitated was collected by filtration to give intermediate 4 (132 g, 80% yield) as a yellow solid.

Intermediate 5 tert-butyl 4-((4-(4-(7-hydroxy-6-isopropyl-2-oxo-4-thioxo-2H-benzo[e][1,3] oxazin-3(4H)-yl)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

The solution of intermediate 4 (132 g, 226 mmol) and CDI (73.4 g, 452 mmol) in THF (1 L) was stirred for 2 hours at room temperature. The reaction solution was poured into brine (1 L) and extracted with EtOAc (500 mL*3). The combine organic layers was washed with brine, dried over Na₂SO₄ and concentrated to give intermediate 5 (138 g, crude) which was used for further reaction without purification.

Intermediate 6 tert-butyl 4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 5 (138 g, crude) in EtOH (1 L) was added NH₂NH₂H2O (22.6 g, 452 mmol). Then the resulting mixture was stirred at room temperature overnight. The precipitated solid was filtered and dried to give intermediate 6 (62 g, 45% yield for 2 steps) as a white solid.

Intermediate 7 4-(5-hydroxy-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol

The solution of intermediate 6 (62 g, 102 mmol) in HCl-MeOH (3N, 300 mL) was stirred at room temperature for 16 hours. The reaction solution was concentrated to give intermediate 7 (63 g, 100% yield) as a white solid.

Compound 074 (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one hydrochloride

To a solution of intermediate 7-1 (13 g, 32.5 mmol), BOP (21.55 g, 48.75 mmol) and DIEA (41.86 g, 325 mmol) in DMF (130 mL) was added intermediate 7 (20 g, 32.5 mmol). The resulting mixture was stirred at room temperature overnight. H₂O was added and solid precipitated was collected by filtration. It was in dried then purified by silica gel chromatography (gradient, DCM:MeOH=50:1 to 30:1 to 20:1) to give 8 g of a white solid. To a solution of this white solid in MeOH (200 mL) was added HCl-MeOH (9 mL, 3N) and stirred. It was stirred at r.t. for 1 hour and concentrated. H₂O (60 mL) was added and stirred for 10 min. It was filtered, the filter cake was washed with H₂O (30 mL*2). It was dried under vacuum to give compound 074 (7.5 g) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 10.68 (m, 1H), 9.62 (s, 1H), 9.38 (s, 1H), 7.64-7.44 (m, 6H), 7.25 (d, J=8.4 Hz, 2H), 6.93 (s, 1H), 6.31 (s, 1H), 4.63 (t, J=6.7 Hz, 1H), 4.41-4.15 (m, 3H), 3.79-3.40 (m, 12H), 3.43-3.00 (m, 4H), 2.76-2.55 (m, 5H), 2.42 (s, 3H), 2.05-2.02 (m, 1H), 1.90-1.68 (m, 2H), 1.63 (s, 3H), 0.98 (d, J=6.9 Hz, 6H).

LCMS (ESI): RT=1.31 min, LCMS-004 (LCMS 2020-002) Method: A90B10+−, (A: 0.1% FA/H2O B: 0.1% FA/ACN Col. SunFire C18) mass calcd. for C₄₇H₅₄Cl₂N₁₀O₄S, 924.34 m/z found 889.6 [M−HCl+H⁺]).

Example 1c: Compound 078 Synthesis

A representative synthesis scheme for compound 078 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 2 tert-butyl 4-((4-(4-(5-ethyl-2,4-dihydroxyphenylthioamido)benzyl)piperazin-1-yl) methyl)piperidine-1-carboxylate

To a mixture of 5-ethyl-2,4-dihydroxybenzodithioic acid (3.00 g, 14.02 mmol) and NaHCO₃ (1.57 g, 18.70 mmol) in DMF (30 mL) was added ClCH₂CO₂Na (1.20 g, 10.29 mmol). After stirred at 40° C. for 1.5 h, intermediate 1 (3.64 g, 9.35 mmol) in DMF (30 mL) was added and stirred at 80° C. for 2 h. It was poured into ice water (50 mL). The precipitated solid was collected by filtration and dried under vacuum to give intermediate 2 (5.0 g) as a yellow solid.

Intermediate 3 tert-butyl 4-((4-(4-(5-ethyl-2,4-dihydroxybenzohydrazonamido)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 2 (5 g, 5.27 mmol) in dioxane (70 mL) was added hydrazine hydride (1.6 g, 21.08 mmol). It was stirred at r.t. for 3 h and extracted with EtOAc (200 mL*2). Combined organic phase was washed with H2O and brine, dried over Na₂SO₄, filtered and concentrated to give intermediate 3 (5.4 g) as a brown solid.

Intermediate 4 tert-butyl 4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-((2,2,2-trifluoroethyl) carbamoyl)-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 3 (5.4 g, 9.5 mmol) in i-PrOH (55 mL) was added ethyl 2-oxo-2-((2,2,2-trifluoroethyl)amino)acetate (3.8 g, 19.0 mmol) and AcOH (0.15 mL). After stirred at 85° C. overnight, it was cooled to room temperature. The precipitated solid was collected filtration and dried under vacuum to give intermediate 4 (2.5 g) as a white solid.

Intermediate 5 5-(5-ethyl-2,4-dihydroxyphenyl)-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide

Intermediate 4 (2.5 g, 3.56 mmol) was dissolved in HCl-Dioxane (3 N, 10 mL). The mixture was stirred at r.t. overnight and concentrated under vacuum to give the title compound Intermediate 5 (3.0 g) as a yellow solid.

Compound 078 4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide hydrochloride

To a solution of intermediate 5-1 (300 mg, 0.8 mmol) and intermediate 5 (530 mg, 0.8 mmol) in DMF (15 mL) was added DIEA (4 mg, 3.8 mmol) and HATU (290 mg, 0.8 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give a white solid (211 mg). Saturated NaHCO₃ (20 mL) was added and extracted with EtOAc (20 mL*2). Combined organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered and concentrated. H₂O (20 mL) was added to the residue and then HCl (2N, 1 mL) was added. It was lyophilized to give compound 078 as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): 9.75-9.66 (m, 2H), 7.61-7.37 (m, 8H), 6.75 (s, 1H), 6.34 (s, 1H), 4.60-4.57 (m, 1H), 4.37-4.34 (m, 2H), 4.21-4.16 (m, 2H), 3.99-3.95 (m, 2H), 3.66-3.30 (m, 11H), 3.18-3.12 (m, 3H), 2.67-2.57 (m, 4H), 2.44 (s, 3H), 2.33-2.29 (m, 2H), 1.76-1.60 (m, 4H), 1.63 (s, 3H), 1.24 (s, 1H), 0.95-0.91 (m, 4H). LCMS (ESI): Shimadzu LCMS-017 R_(T)=1.415 min, Method: A90B10, (A: 0.1% FA/H₂O B: 0.1% FA/CAN Col. SunFire C18) mass calcd. For C₄₉H₅₄Cl₂F₃N₁₁O₄S Chemical Formula: 1019.34 m/z found 984.4 [M−HCl+H]⁺.

Example 1d: Compound 016 Synthesis

A representative synthesis scheme for compound 016 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 2 methyl 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)isoxazole-3-carboxylate

The mixture of intermediate 1 (15.5 g, 33.70 mmol) and hydroxylamine hydrochloride in EtOH (50 mL) was stirred at reflux for 4 h, then cooled to r.t and concentrated. H₂O was added and it was extracted with DCM (100 mL*3). The combined organic phase was dried over Na₂SO₄, filtered and concentrated. The residue was triturated with EtOH/H₂O (200 mL/200 mL). It was collected by filtration to give intermediate 2 (15 g, yield 97%) as a yellow solid.

Intermediate 3 methyl 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-bromoisoxazole-3-carboxylate

The mixture of methyl intermediate 2 (15 g, 32.82 mmol), NBS (6.43, 36.11 mmol) and CAN (9.0 g, 16.41 mmol) in CH₃CN (200 mL) was stirred at reflux for 14 h. After cooled to r.t it was concentrated. H₂O was added and it was extracted with EA (100 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography (DCM:MeOH=20:1) to give compound intermediate 3 (14.2 g, yield 81) as a yellow solid.

Intermediate 4 methyl 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-(4-formylphenyl)isoxazole-3-carboxylate

To a solution intermediate 3 (3 g, 5.6 mmol) in DMF/H₂O (140 mL/28 mL) was added (4-formylphenyl)boronic acid (1.34 g, 8.4 mmol), NaHCO₃ (1.4 g, 16.8 mmol) and Pd(PPh₃)₂Cl₂ (0.4 g, 0.56 mmol). It was stirred at 80° C. for 3 h under Ar atmosphere. The resulting mixture was poured into H₂O and extracted with EtOAc (100 mL*3). The combined organic phase was washed with water, brine, dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography (DCM:MeOH=20:1) to give intermediate 4 (1.7 g, yield 54%) as a yellow solid.

Intermediate 5 methyl 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)phenyl)isoxazole-3-carboxylate

The mixture of intermediate 4 (1.7 g, 3.03 mmol), tert-butyl piperazine-1-carboxylate (0.56 g, 3.03 mmol) in DCE (15 mL) was stirred at room temperature for 1 h. NaBH(OAc)₃ (1.4 g, 6.4 mmol) was added and stirred for 2 h. The resulting mixture was diluted with H₂O and extracted with EtOAc (20 mL*2). The combined organic phase was washed with water, brine, dried over Na₂SO₄ and concentrated to give intermediate 5 (1.5 g, yield 68%) as a yellow solid.

Intermediate 6 tert-butyl 4-(4-(5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-3-(ethylcarbamoyl)isoxazol-4-yl)benzyl)piperazine-1-carboxylate

The mixture of intermediate 6 (1.5 g, 2.05 mmol) in EtNH₂-THF (2N, 10 mL) was stirred at reflux for 18 h. The resulting mixture was diluted with water and extracted with EtOAc (20 mL*2). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and filtered. It was concentrated to give intermediate 6 (1.5 g, yield 98%) as a yellow solid.

Intermediate 7 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-N-ethyl-4-(4-(piperazin-1-ylmethyl)phenyl)isoxazole-3-carboxamide

The mixture of intermediate 6 (1.5 g, 2.02 mmol) in HCl-MeOH (3 N, 10 mL) was stirred at room temperature for 3 hours. The resulting mixture was concentrated to give of intermediate 7 HCl (1.37 g) as a white solid. It was added into H₂O then K₂CO₃ was added until pH=10-11. It was extracted with EtOAc (20 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 7 (1.28 g, 100%).

Intermediate 8 tert-butyl 4-((4-(4-(5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-3-(ethylcarbamoyl)isoxazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

The mixture intermediate 7 (1.28 g, 1.98 mmol), tert-butyl 4-formylpiperidine-1-carboxylate (0.42 g, 1.98 mmol) and AcOH (1 mL) in DCE (15 mL) was stirred at room temperature for 1 h. NaBH(OAc)₃ (0.96 g, 4.34 mmol) was added and stirred for 2 h. The resulting mixture was diluted with water and extracted with EA (20 mL*2). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 8 (1.64 g, yield 98%) as yellow solid.

Intermediate 9 tert-butyl 4-((4-(4-(5-(2,4-dihydroxy-5-isopropylphenyl)-3-(ethylcarbamoyl)isoxazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

The solution of intermediate 8 (1.64 g, 4.51 mmol) and Pd/C (10%, 600 mg) in MeOH (50 mL) was stirred at room temperature overnight under H₂ atmosphere. The reaction solution was filtered and the filtrate was concentrated in vacuo to give intermediate 9 (1.27 g, yield 100%) as a white solid.

Intermediate 10 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)isoxazole-3-carboxamide hydrochloride

The mixture of intermediate 9 (1.27 g) in HCl-MeOH (3 N, 20 mL) was stirred at room temperature for 3 hours. The resulting mixture was concentrated to give intermediate 10 (1.12 g, yield 98%) as a white solid.

Compound 16 4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethylisoxazole-3-carboxamide, trifluoroacetic acid

The mixture of intermediate 10 (50 mg, 0.084 mmol), intermediate 10-1 (33.6 mg, 0.084 mmol), HATU (48 mg, 0.126 mmol) and DIEA (43 mg, 0.336 mmol) in DMF (2 mL) was stirred at room temperature for 1 h. The resulting mixture was extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄. It was filtered and concentrated then purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give compound 016 (12.66 mg, yield 16%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 9.67 (s, 1H), 8.87 (s, 1H), 7.55-7.19 (m, 9H), 6.76 (s, 1H), 6.44 (s, 1H), 4.57 (t, J=6.7 Hz, 1H), 4.35 (d, J=11.5 Hz, 2H), 4.15-4.13 (m, 2H), 3.64-3.59 (m, 7H), 3.39-3.33 (m, 3H), 3.26-3.20 (m, 3H), 3.13-3.10 (m, 4H), 3.02-2.95 (m, 3H), 2.60-2.58 (m, 4H), 2.42 (s, 3H), 1.77-1.66 (m, 2H), 1.63 (s, 3H), 1.09 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.9 Hz, 6H). LCMS (ESI): Shimadzu LCMS-009, RT=1.486 min, Method: A90B10+−, (A: 0.1% FA/H2O B: 0.1% FA/ACN Col.sunFire C18) mass calcd. For C51H58ClN9O5S, 943.40 m/z found 944.6 [M−CF₃COOH+H]⁺.

Example 1e: Compound 008 Synthesis

A representative synthesis scheme for compound 008 is shown below. Specific synthesis routes of intermediates are also shown.

Compound 008 Intermediate 1 1-(2-((tert-butoxycarbonyl)amino)ethyl)-2-methylpyridin-1-ium bromide

The mixture of tert-butyl (2-bromoethyl)carbamate (2.0 g, 7.1 mmol) and 2-methylpyridine (5 mL) was stirred at 90° C. for 4 hours. After cooled to room temperature it was poured into EtOAc (15 mL). The resulting precipitated solid were collected by filtration and dried to give intermediate 1 (2.8 g, yield 41%) which was used for the following reaction without further purification.

Intermediate 2 1-(2-((tert-butoxycarbonyl)amino)ethyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium chloride

To a solution of intermediate 1 (2.8 g, 8.92 mmol) and intermediate 1-1 (3.3 g, 8.92 mmol) in acetonitrile (25 mL) was added Et₃N (2.7 g, 26.8 mmol). The resulting mixture was stirred at 80° C. for 4 hours. The reaction solution was cooled to room temperature and EtOAc (50 mL) was added. The precipitated solid was collected by filtration, washed with EA (20 mL) and dried to give a solid. The solid was dissolved in chloroform/methanol (½, 30 mL) and the solution was passed through a Cl-ion exchange column to give intermediate 2 (1.5 g, yield 31%) as a red solid.

Intermediate 3 1-(2-aminoethyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium chloride

The solution of intermediate 2 (1.5 g, 0.293 mmol) in HCl-MeOH (3N, 10 mL) was stirred at room temperature overnight. The reaction solution was concentrated in vacuum to give intermediate 3 (1.1 g, yield 92%) as red solid.

Compound 008 1-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium

To a solution of intermediate 3 (50 mg, 0.125 mmol), HATU (71 mg, 0.187 mmol) and DIEA (48 mg, 0.375 mmol) in DMF (3 mL) was added intermediate 3-1 (66.9 mg, 0.15 mmol). Then the resulting mixture was stirred for 2 hours at room temperature. The mixture was purified by Prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: CAN) to give compound 008 (13 mg, yield 12.5%) as a red solid.

¹H NMR (400 MHz, DMSO-d₆): δ 8.78-8.42 (m, 2H), 8.26 (t, J=7.7 Hz, 1H), 8.07 (d, J=8.8 Hz, 1H), 7.88 (d, J=7.7 Hz, 1H), 7.61 (d, J=8.3 Hz, 1H), 7.55-7.34 (m, 6H), 7.30 (t, J=7.6 Hz, 1H), 6.18 (s, 1H), 4.63-4.60 (m, 2H), 4.47 (t, J=7.1 Hz, 1H), 4.08-4.03 (m, 5H), 3.64-3.50 (m, 2H), 3.27-24 (m, 2H), 2.55 (s, 3H), 2.42 (s, 3H), 2.09-1.82 (m, 2H), 1.62 (s, 3H), 1.14 (t, J=7.0 Hz, 3H).

Purity (HPLC): 95.65% (214 nm), 93.54% (254 nm).

LC-MS (ESI): RT=1.450 min Method: A90B10+(A;0.1% FA/H₂O B:0.1% FA/CAN Col.SunFire (C18) mass calcd. for C₄₀H₃₈ClN₈O₂S₃ ⁺, 793.20 m/z found 793.3 [M]⁺.

Example 1e: Compound 145 Synthesis

A representative synthesis scheme for compound 145 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 2 benzyl 5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)isoindoline-2-carboxylate

To a solution of benzyl 5-formylisoindoline-2-carboxylate (630 mg, 2.24 mmol) in DCE (50 mL) were added tert-butyl piperazine-1-carboxylate (417 mg, 2.24 mmol). AcOH (0.2 mL) was added and the mixture was stirred at r.t. for 1 h. NaBH(OAc)₃ (948 mg, 4.48 mmol) was added and stirred at r.t. overnight. Saturated NaHCO₃ solution (10 mL) was added and it was extracted with DCM (100 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. It was purified by silica gel chromatography (PE:EA=2:1) to give intermediate 2 (840 mg, 90% yield) as yellow solid.

Intermediate 3 tert-butyl 4-(isoindolin-5-ylmethyl)piperazine-1-carboxylate

To a solution of intermediate 2 (840 mg, 1.86 mmol) in MeOH (20 mL) was added Pd—C (10%, 300 mg). The mixture was stirred at r.t. for 18 h under H₂ atmosphere. It was filtered and concentrated to give intermediate 3 (550 mg, 93% yield) as yellow oil.

Intermediate 4: tert-butyl 4-((2-(2,4-dihydroxy-5-propylbenzoyl)isoindolin-5-yl)methyl)piperazine-1-carboxylate

To a solution of intermediate 3 (300 mg, 0.945 mmol) and 2,4-dihydroxy-5-propylbenzoic acid (204 mg, 1.04 mmol) in DMF (5 mL) was added DIEA (365 mg, 4.73 mmol) and HATU (396 mg, 1.04 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by silica gel chromatography (DCM:MeOH=50:1) to give the title product intermediate 4 (100 mg, 21% yield) as a yellow solid.

Intermediate 5: (2,4-dihydroxy-5-propylphenyl)(5-(piperazin-1-ylmethyl)isoindolin-2-yl)methanone

The solution of intermediate 4 (150 mg, 0.3 mmol) in HCl-MeOH (3N, 3 mL) was stirred at r.t. for 18 h. It was concentrated to give intermediate 5 (130 mg, 100% yield) as light yellow solid.

Compound 145 (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(2,4-dihydroxy-5-propylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

To a solution of intermediate 5 (30 mg, 0.07 mmol) and intermediate 5-1 (28 mg, 0.07 mmol) in DMF (2 mL) was added DIEA (42 mg, 0.35 mmol) and HATU (29 mg, 0.084 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give compound 145 (5 mg, 9% yield) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.20-10.10 (m, 2H), 9.62 (s, 1H), 7.51-7.42 (m, 1H), 7.01 (s, 1H), 6.41 (s, 1H), 4.83-4.72 (m, 4H), 4.53-4.35 (m, 5H), 3.82-3.40 (m, 8H), 3.20-2.80 (m, 4H), 2.60 (s, 3H), 2.41 (s, 3H), 2.47-2.41 (m, 1H), 1.63 (s, 3H), 1.54-1.48 (m, 2H), 0.88 (t, J=6.8 Hz, 3H).

Purity (HPLC): 94.09% (254 nm), 90.00% (214 nm)

LCMS (ESI): Shimadzu LCMS-009 R_(T)=0.860 min, Method: A30B70, (A: 0.1% FA/H₂O B: 0.1% FA/CAN Col.sunFire C18) mass calcd. For C₄₂H₄₄ClN₇O₄S Chemical Formula: 777.29 m/z found 778.6 [M+H]⁺.

Example 1f: Compound 024 Synthesis

A representative synthesis scheme for compound 024 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 2 tert-butyl 4-(2-(2-((2-cyano-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)ethoxy)ethyl)piperazine-1-carboxylate

To a solution of intermediate 1 (32 mg, 0.117 mmol) in toluene (2 mL) was added 2-bromo-4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile (40 mg, 0.117 mmol), KOt-Bu (22.5 mg, 0.234 mmol), dppf (10 mg, 0.02 mmol) and Pd(OAc)₂ (5 mg, 0.02 mmol). The mixture was stirred at reflux for 16 hours under N₂ atmosphere. After cooled to e.t., it was extracted with EtOAc (10 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. It was purified by prep-TLC (DCM:MeOH=10:1) to give intermediate 2 (15 mg, yield 23%) as yellow solid.

Intermediate 3 tert-butyl 4-(2-(2-((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)ethoxy)ethyl)piperazine-1-carboxylate

To a solution of intermediate 2 (15 mg, 0.027 mmol) in EtOH/DMSO (0.5 mL/0.5 mL) was added NaOH (5 mg, 0.135 mmol) and H₂O₂ (5 mg, 0.135 mmol). The mixture was stirred at r.t. for 5 hours. It was extracted with EtOAc (10 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 3 (15 mg, yield 97%) as yellow solid.

Intermediate 4 2-((2-(2-(piperazin-1-yl)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide

The solution of intermediate 3 (15 mg, 0.026 mmol) in HCl-MeOH (45 mL) was stirred at r.t. for 5 hours. It was concentrated to give intermediate 4 (12 mg, yield 100%) as yellow solid.

Compound 024 2-((2-(2-(4-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperazin-1-yl)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide

To a solution of intermediate 4 (20 mg, 0.05 mmol) and intermediate 4-1 (20 mg, 0.05 mmol) in DMF (2 mL) was added DIEA (19 mg, 0.15 mmol) and HATU (28 mg, 0.075 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give compound 024 (2 mg, 4.7% yield) as a yellow solid.

¹H NMR (400 MHz, CD₃OD) δ 7.75-7.73 (m, 1H), 7.47-7.40 (m, 5H), 6.91-6.90 (m. 1H), 6.74-6.71 (m, 1H), 4.72-4.71 (m, 1H), 3.93-3.83 (m, 4H), 3.70-3.60 (m, 4H), 3.50-3.48 (m, 7H), 3.21-3.20 (m, 1H), 2.90-2.70 (m, 7H), 2.48-2.33 (m, 10H), 2.10-2.02 (m, 1H), 1.76 (s, 3H), 1.06 (d, J=3.6 Hz, 6H).

Purity (HPLC): 75.15% (254 nm), 59.06% (214 nm)

LCMS (ESI): Shimadzu LCMS-009 R_(T)=1.285 min, Method: A70B30+−, (A: 0.1% FA/H₂O B: 0.1% FA/CAN Col.sunFire C18) mass calcd. For C₄₄H₅₁ClN₁₀O₄S Chemical Formula: 850.35 m/z found 851.4[M+H]⁺.

Example 1g: Compound 025 Synthesis

A representative synthesis scheme for compound 025 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 1 1-(4-bromobenzyl)piperazine hydrochloride

The mixture of tert-butyl 4-(4-bromobenzyl)piperazine-1-carboxylate (12 g, 33.9 mmol) in HCl-MeOH (3 N, 100 mL) was stirred at r.t. for 5 hours and concentrated. Saturated NaHCO₃ (100 mL) was added and extracted with EtOAc (100 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 1 (8 g, yield 93%) as yellow solid.

Intermediate 2 tert-butyl 4-((4-(4-bromobenzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 1 (3.9 g, 15.85 mmol) in DCE (50 mL) was added tert-butyl 4-formylpiperidine-1-carboxylate (3.38 g, 15.85 mmol). AcOH (951 mg, 15.85 mmol) was added and the mixture was stirred at r.t. for 1 h. NaBH(OAc)₃ (5.0 g, 23.78 mmol) was added and stirred at r.t. overnight. Saturated NaHCO3 solution (100 mL) was added and it was extracted with DCM (100 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. It was purified by silica gel chromatography (PE:EA=1:1) to give intermediate 2 (3.0 g, yield 42%) as yellow solid.

Intermediate 3 tert-butyl 4-((4-(4-bromobenzyl)piperazin-1-yl)methyl)piperidine-1-carboxylate

To a solution of intermediate 2 (2.6 g, 5.76 mmol) in THF (30 mL) was added n-BuLi (1.6 M in hexanes, 4.3 mL) at −78° C. After stirred at −78° C. for 0.5 h, 6-chloro-N-methoxy-N-methylnicotinamide (1.15 g, 5.76 mmol) was added at −78° C. and the resulting mixture was stirred r.t. for 1 h. It was added to NH₄Cl solution (aq, 30 mL) and extracted with EtOAc (50 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 3 (2 g, yield 97%) as yellow solid.

Intermediate 4 (6-chloropyridin-3-yl)(4-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)phenyl)methanone hydrochloride

The mixture of intermediate 3 (2.8 g, 5.45 mmol) in HCl-MeOH (3 N, 50 mL) was stirred at r.t. for 5 hours and concentrated to give intermediate 4 (2.44 g, yield 100%) as yellow solid.

Intermediate 5 (S)-1-(4-((4-(4-(6-chloronicotinoyl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethan-1-one

To a solution of intermediate 4 (300 mg, 0.8 mmol) and intermediate 4-1 (200 mg, 0.445 mmol) in DMF (5 mL) was added DIEA (201 mg, 1.56 mmol) and HATU (254 mg, 0.668 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give intermediate 5 (120 mg, 0.24 mmol) as a white solid.

Intermediate 6 tert-butyl ((1R,3r,5S)-8-(5-(4-((4-((1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)benzoyl)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate

To a solution of intermediate 5 (50 mg, 0.063 mmol) in DME (2 mL) was added DIEA (0.5 mL) and intermediate 5-1 (21 mg, 0.094 mmol). The mixture was stirred at 125° C. for 8 h. It was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give intermediate 6 (40 mg, 65% yield) as a white solid.

Intermediate 7 1-(4-((4-(4-(6-((1R,3r,5S)-3-amino-8-azabicyclo[3.2.1]octan-8-yl)nicotinoyl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethan-1-one

The mixture of intermediate 6 (40 mg, 0.04 mmol) in HCl-MeOH (3 N, 5 mL) was stirred at r.t. for 5 hours and concentrated to give intermediate 7 (35 mg, 95% yield) as yellow solid.

Compound 025 5-(((R)-sec-butyl)amino)-N1-((1R,3r,5S)-8-(5-(4-((4-((1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)benzoyl)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-methylterephthalamide

To a solution of intermediate 7 (59 mg, 0.064 mmol) and (R)-5-(sec-butylamino)-4-carbamoyl-2-methylbenzoic acid (26 mg, 0.1 mmol) in DMF (2 mL) was added DIEA (24.7 mg, 0.192 mmol) and HATU (36.5 mg, 0.096 mmol) at r.t. After stirred at r.t. overnight, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL*3). The combined organic phase was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. The crude product was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give compound 025 (6 mg, 8% yield) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.50-8.28 (m, 5H), 7.97-7.69 (m, 3H), 7.67-7.65 (m, 2H), 7.50-7.42 (m, 7H), 7.20-7.08 (m, 1H), 6.83 (d, J=9.2 Hz, 1H), 6.56 (s, 1H), 4.70-4.55 (m, 3H), 4.40-4.30 (m, 1H), 4.20-4.10 (m, 1H), 3.88-3.86 (m, 1H), 3.50-3.46 (m, 4H), 3.20-3.10 (m, 2H), 2.67-2.56 (m, 5H), 2.32-2.30 (m, 8H), 2.28-1.97 (m, 13H), 1.79-1.60 (m, 3H), 1.63 (s, 3H), 1.52-1.48 (m, 1H), 1.14-1.12 (m, 3H), 1.03-0.98 (m, 6H).

Purity (HPLC): 97.11% (254 nm), 92.80% (214 nm)

LCMS (ESI): Shimadzu LCMS-009R_(T)=1.305 min, Method: A70B30+−, (A: 0.1% FA/H₂O B: 0.1% FA/CAN Col.sunFire C18) mass calcd. For C₆₂H₇₃ClN₁₂O₄S Chemical Formula: 1116.53 m/z found 1117.5[M+H]⁺.

Example 1h: Compound 139 Synthesis

A representative synthesis scheme for compound 139 is shown below. Specific synthesis routes of intermediates are also shown.

Intermediate 1 4′-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-2-(methoxymethoxy)-[1,1′-biphenyl]-4-yl 4-methylbenzenesulfonate

To a solution of compound A (0.95 g, 2.38 mmol) in DMF (40 mL) was added compound B (0.61 g, 2.38 mmol). Et₃N (0.72 g, 7.13 mmol) and HATU (1 g, 2.62 mmol) were added. The mixture was stirred at r.t. for 12 hours. It was extracted with EtOAc (100 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 1 (1.1 g, yield 72%) as yellow solid.

Intermediate 2 N-(4′-hydroxy-2′-(methoxymethoxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

To a solution of intermediate 1 (0.22 g, 0.34 mmol) in EtOH (5 mL) was added KOH (3.2 M, 5 mL). The mixture was stirred at 90° C. for 3 h, then cooled to r.t. It was concentrated and the pH of the residue was adjusted to pH=5-6 by HCl (2N). The solid precipitated was collected by filtration and dried to give intermediate 2 (0.15 g, 91% yield) as yellow solid.

Intermediate 3 tert-butyl 4-((4′-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-2-(methoxymethoxy)-[1,1′-biphenyl]-4-yl)oxy)piperidine-1-carboxylate

To a solution of intermediate 2 (0.9 g, 1.85 mmol) in dry THF (15 mL) were added tert-butyl 4-hydroxypiperidine-1-carboxylate (0.56 g, 2.78 mmol), PPh3 (0.98 g, 3.71 mmol) and DIAD (0.75 g, 3.71 mmol). The mixture was stirred at r.t. for 18 h. It was concentrated and extracted with EtOAc (5 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated then purified by silica gel chromatography (PE:EA=1:1) to give intermediate 3 (0.4 g, 32% yield) as yellow solid.

Intermediate 4 tert-butyl 4-((4′-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-2-(methoxymethoxy)-[1,1′-biphenyl]-4-yl)oxy)piperidine-1-carboxylate

The solution of intermediate 3 (0.4 g, 0.6 mmol) in HCl-MeOH (3N, 5 mL) was stirred at r.t. for 16 hours. It was concentrated to give intermediate 4 (336 mg, yield 100%) as yellow solid.

Intermediate 5 tert-butyl 4-((4′-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-2-hydroxy-[1,1′-biphenyl]-4-yl)oxy)piperidine-1-carboxylate

To a solution of intermediate 4 (100 mg, 0.19 mmol) in DCM (3 mL) was added Boc₂O (42 mg, 0.19 mmol) and Et₃N (0.08 mL, 0.57 mmol). The mixture was stirred at r.t. for 2 h. It was extracted with DCM (50 mL*2). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to give intermediate 5 (100 mg, yield 84%) as yellow solid.

Intermediate 6 tert-butyl 4-((4′-(3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamido)-2-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-4-yl)oxy)piperidine-1-carboxylate

To a solution of intermediate 5 (40 mg, 0.064 mmol) in dry toluene (4 mL) were added 2-(dimethylamino)ethan-1-ol (29 mg, 0.32 mmol), PBu3 (33 mg, 0.16 mmol) and TMAD (28 mg, 0.16 mmol). The mixture was stirred at 110° C. for 15 h under N2 atmosphere. It was concentrated and purified by silica gel chromatography (DCM:MeOH=20:1) to give intermediate 6 (30 mg, 67% yield) as yellow solid.

Intermediate 7 N-(2′-(2-(dimethylamino)ethoxy)-4′-(piperidin-4-yloxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

The solution of intermediate 6 (0.15 g, 0.22 mmol) in HCl-MeOH (3N, 2 mL) was stirred at r.t. for 16 hours. It was concentrated to give intermediate 7 (140 mg, yield 100%) as yellow solid.

Compound 139 (S)—N-(4′-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)piperidin-4-yl)oxy)-2′-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

To a solution of intermediate 7 (30 mg, 0.047 mmol) in DCE (2 mL) were added intermediate 7-1 (22 mg, 0.057 mmol). AcOH (15 mg, 0.237 mmol) was added and the mixture was stirred at r.t. for 1 h. NaBH(OAc)₃ (50 mg, 0.237 mmol) was added and stirred at r.t. overnight. Saturated NaHCO₃ solution (10 mL) was added and it was extracted with DCM (10 mL*3). The combined organic layers was washed with H₂O, brine, dried over Na₂SO₄ and concentrated. It was purified by prep-HPLC (Waters 2767/Qda, Column: SunFire 19*250 mm 10 um, Mobile Phase A: 0.1% TFA/H₂O, B: ACN) to give compound 139 (6.6 mg, yield 12%) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆): δ 10.21-9.96 (m, 3H), 7.97-7.80 (m, 4H), 7.52-7.37 (m, 7H), 7.30-7.25 (m, 2H), 7.13-6.97 (m, 3H), 4.88-4.70 (m, 1H), 4.34 (s, 3H), 3.86 (s, 3H), 3.76 (s, 3H), 3.71-3.44 (m, 6H), 3.30-3.29 (m, 2H), 2.94-2.77 (m, 8H), 2.62 (s, 3H), 2.41 (s, 3H), 2.14-1.85 (m, 4H), 1.63 (s, 3H).

Purity (HPLC): 96.88% (254 nm), 96.48% (214 nm)

LCMS (ESI): Shimadzu LCMS-010 R_(T)=1.152 min, Method: A70B30+−, (A: 0.1% FA/H₂O B: 0.1% FA/CAN Col.sunFire C18) mass calcd. For C₅₅H₅₈ClN₇O₅S Chemical Formula: 963.39 m/z found 964.3[M+H]⁺.

Additional compounds were made according to the general procedure and scheme noted in the Examples 1a-1h including the following:

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone

¹H NMR (400 MHz, DMSO-d₆): δ 11.90 (s, 1H), 9.56 (s, 1H), 9.37 (s, 1H), 7.47 (m, 4H), 7.27 (d, J=8.1 Hz, 2H), 7.11 (d, J=8.2 Hz, 2H), 6.82 (s, 1H), 6.24 (s, 1H), 4.56 (t, J=6.8 Hz, 1H), 4.34 (m, 1H), 4.11 (m, 1H), 3.60 (s, 1H), 3.43 (s, 3H), 3.10 (s, 1H), 2.59 (s, 4H), 2.43-2.24 (m, 11H), 2.12 (s, 2H), 1.99 (s, 1H), 1.78 (s, 2H), 1.63 (s, 4H), 1.23 (s, 2H), 1.11 (s, 1H), 0.96 (t, J=7.4 Hz, 3H). LCMS (ESI): R_(T) 1.083 min, m/z found 875.2 [M+H]⁺.

4-(4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-ethylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.60 (s, 1H), 9.36 (s, 1H), 7.51 (s, 2H), 7.40 (s, 2H), 7.22 (s, 2H), 6.87 (s, 1H), 6.24 (s, 1H), 5.32 (s, 1H), 4.29 (s, 1H), 2.85-2.58 (m, 11H), 2.36 (m, 6H), 2.00 (m, 5H), 1.62 (s, 3H), 1.23 (s, 10H), 0.99 (t, J=7.5 Hz, 3H), 0.84 (d, J=7.0 Hz, 2H). LCMS (ESI): R_(T)=1.023 min, m/z found 861.2 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H), 9.61-9.50 (m, 2H), 7.51-7.44 (m, 4H), 7.21 (d, J=8.3 Hz, 2H), 7.11 (d, J=8.0 Hz, 2H), 6.77 (s, 1H), 6.27 (s, 1H), 4.58 (t, J=6.4 Hz, 2H), 4.34 (d, J=12.1 Hz, 2H), 4.11 (d, J=13.2 Hz, 1H), 3.60-3.59 (m, 1H), 3.38-3.35 (m, 1H), 3.6-2.95 (m, 2H), 2.60-2.57 (m, 3H), 2.52-2.50 (m, 2H), 2.42 (s, 3H), 1.85-1.51 (m, 6H), 1.24-1.00 (m, 2H), 0.96 (t, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.817 min, m/z found 791.2 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.59-9.50 (m, 2H), 7.50-7.37 (m, 6H), 7.21-7.06 (m, 3H), 6.25-6.17 (m, 2H), 5.20-4.88 (m, 4H), 4.59-4.56 (m, 2H), 4.37-4.34 (m, 2H), 3.98-3.90 (m, 2H), 3.67-3.61 (m, 2H), 3.40-3.33 (m, 2H), 3.17-2.73 (m, 7H), 2.60-2.58 (m, 4H), 2.49 (s, 3H), 1.99 (s, 1H), 1.75-1.69 (m, 2H), 1.63 (s, 3H). LCMS (ESI): R_(T)=1.282 min, m/z found 845.7 [M−CF₃COOH−H]⁻.

2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.61 (s, 1H), 9.37 (s, 1H), 7.55-7.15 (m, 8H), 6.82 (s, 1H), 6.26 (s, 1H), 4.59-4.54 (m, 1H), 4.35-4.30 (m, 1H), 4.15-4.10 (m, 2H), 3.75-3.50 (m, 8H), 3.37-3.30 (m, 2H), 3.24-2.90 (m, 8H), 2.63 (s, 4H), 2.42 (s, 3H), 1.77-1.70 (m, 2H), 1.63 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LC-MS(ESI): R_(T)=1.235 min, m/z found 889.5[M−CF₃COOH+H]⁺

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methyl)phenyl)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H), 10.05-9.15 (m, 3H), 8.76 (d, J=7.8 Hz, 1H), 7.55-7.45 (m, 6H), 7.37-7.30 (m, 2H), 7.14-7.09 (m, 4H), 6.77 (s, 1H), 6.27 (d, J=4.5 Hz, 1H), 5.04-4.95 (m, 1H), 4.50-4.46 (m, 1H), 4.26-4.24 (m, 2H), 3.43-3.17 (m, 5H), 2.98-2.96 (m, 1H), 2.67-2.60 (m, 2H), 2.61 (s, 3H), 2.39 (s, 3H), 1.71-1.62 (m, 2H), 1.55-1.40 (m, 3H), 1.38-1.28 (m, 5H), 0.94 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.433 min, m/z found 924 [M−CF₃COOH+H]⁺.

1-(3-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium chloride

¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (d, J=6.1 Hz, 1H), 8.44-8.42 (m, 1H), 8.29 (t, J=8.0 Hz, 1H), 8.09 (d, J=8.5 Hz, 1H), 7.88 (d, J=7.8 Hz, 1H), 7.62 (d, J=8.3 Hz, 1H), 7.56-7.39 (m, 5H), 7.30 (t, J=7.6 Hz, 1H), 5.99 (s, 1H), 4.62-4.60 (m, 2H), 4.52-4.50 (m, 1H), 4.06-4.04 (m, 4H), 3.30-3.24 (m, 4H), 2.59 (s, 3H), 2.40 (s, 3H), 2.06-1.98 (m, 2H), 1.61 (s, 3H), 1.23-1.18 (m, 6H). LC-MS(ESI): R_(T)=1.194 min, m/z found 807.2 [M]⁺

1-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium

¹H NMR (400 MHz, DMSO-d₆): δ 8.78-8.42 (m, 2H), 8.26 (t, J=7.7 Hz, 1H), 8.07 (d, J=8.8 Hz, 1H), 7.88 (d, J=7.7 Hz, 1H), 7.61 (d, J=8.3 Hz, 1H), 7.55-7.34 (m, 6H), 7.30 (t, J=7.6 Hz, 1H), 6.18 (s, 1H), 4.63-4.60 (m, 2H), 4.47 (t, J=7.1 Hz, 1H), 4.08-4.03 (m, 5H), 3.64-3.50 (m, 2H), 3.27-24 (m, 2H), 2.55 (s, 3H), 2.42 (s, 3H), 2.09-1.82 (m, 2H), 1.62 (s, 3H), 1.14 (t, J=7.0 Hz, 3H). LC-MS (ESI): R_(T)=1.450 min, m/z found 793.3 [M]⁺

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-methylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.60 (s, 1H), 9.31 (s, 1H), 7.51-7.42 (m, 6H), 7.22 (d, J=8.4 Hz, 2H), 6.95 (s, 1H), 6.24 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.35 (d, J=12.9 Hz, 1H), 4.15-4.01 (m, 2H), 3.68-3.33 (m, 3H), 3.07-2.85 (m, 6H), 2.60 (s, 3H), 2.55-2.50 (m, 6H), 2.42 (s, 3H), 2.02-1.99 (m, 1H), 1.97 (s, 3H), 1.86-1.75 (m, 2H), 1.63 (s, 3H), 1.35-0.88 (m, 2H). LCMS (ESI): R_(T)=1.35 min, m/z found 861.4 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one hydrochloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (s, 1H), 11.33 (s, 1H), 9.70-9.40 (m, 2H), 7.65-7.63 (m, 2H), 7.53-7.43 (m, 4H), 7.24 (d, J=8.2 Hz, 2H), 6.96 (s, 1H), 6.32 (s, 1H), 4.63 (t, J=6.8 Hz, 1H), 4.39-4.33 (m, 4H), 3.79-3.43 (s, 10H), 3.16-3.06 (m, 3H), 2.65-2.60 (m, 4H), 2.43-2.38 (m, 5H), 2.12-1.88 (m, 4H), 1.63 (s, 3H), 0.96 (t, J=7.4 Hz, 3H). LCMS (ESI): R_(T)=1.07 min, m/z found 875.1 [M−HCl+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-propylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (s, 1H), 9.70-9.40 (m, 2H), 8.38 (s, 4H), 7.50-7.42 (m, 6H), 7.26 (d, J=8.2 Hz, 2H), 7.11 (d, J=8.2 Hz, 2H), 6.77 (s, 1H), 6.26 (s, 1H), 4.56 (t, J=6.8 Hz, 1H), 4.39-4.20 (m, 2H), 3.33-3.30 (m, 4H), 2.59-2.56 (m, 5H), 250-2.13 (m, 11H), 1.62-1.63 (m, 8H), 1.36-1.00 (m, 4H), 0.76 (t, J=7.4 Hz, 3H). LCMS (ESI): R_(T)=1.47 min, m/z found 889.3 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 13.92 (s, 1H), 9.66 (s, 1H), 9.43 (s, 1H), 7.51-7.26 (m, 5H), 7.27 (d, J=8.0 Hz, 2H), 6.84 (s, 1H), 6.25 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.35 (d, J=12.9 Hz, 1H), 4.15-4.13 (m, 1H), 3.80-3.30 (m, 13H), 3.15-3.10 (m, 2H), 3.03-2.87 (m, 2H), 2.60-2.58 (m, 4H), 2.42 (s, 3H), 2.24-1.94 (m, 5H), 1.87 (s, 2H), 0.97 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.123 min, m/z, Found 905.1 [M−CF₃COOH+H]⁺.

4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.45 (s, 1H), 9.75-9.58 (m, 2H), 7.50-7.30 (m, 6H), 6.62 (s, 1H), 6.34 (s, 1H), 4.58-4.55 (m, 1H), 4.36-4.33 (m, 1H), 4.13-4.10 (m, 1H), 3.98-3.94 (m, 2H), 3.60-3.49 (m, 4H), 3.15-3.11 (m, 1H), 2.93-2.90 (m, 1H), 2.60 (s, 4H), 2.41-2.30 (m, 10H), 2.14-2.13 (m, 2H), 1.82-1.79 (m, 3H), 1.63 (s, 3H), 1.23-1.12 (m, 1H), 1.16 (t, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.190 min, m/z found 998.3 [M+H]⁺.

4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.71-9.65 (m, 2H), 7.52-7.30 (m, 8H), 6.68 (s, 1H), 6.31 (s, 1H), 5.32-5.30 (m, 1H), 5.00-4.50 (m, 4H), 4.58 (t, J=6.8 Hz, 2H), 4.36-4.32 (m, 2H), 4.16-1.10 (m, 2H), 4.03-3.91 (m, 3H), 3.81-3.58 (m, 3H), 3.40-2.90 (m, 6H), 2.64-2.50 (m, 5H), 2.42 (s, 3H), 2.26-2.24 (m, 2H), 2.00-1.98 (m, 1H), 1.87-1.74 (m, 1H), 1.63 (s, 3H), 0.89 (t, J=7.4 Hz, 3H). LCMS (ESI): R_(T)=1.193 min, m/z found 984.1 [M−CF₃COOH+H]⁺.

4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-methylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.70-9.62 (m, 2H), 9.38-9.02 (m, 1H), 7.60-7.20 (m, 8H), 6.72 (s, 1H), 6.28 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.36 (d, J=12.4 Hz, 2H), 4.15-4.13 (m, 2H), 4.01-3.90 (m, 10H), 3.64-3.63 (m, 3H), 3.37-3.35 (m, 1H), 3.07-2.95 (m, 7H), 2.60-2.58 (m, 4H), 2.42 (s, 3H), 1.87 (s, 4H), 1.73-1.70 (m, 1H), 1.63 (s, 3H). LCMS (ESI): R_(T)=1.385 min, m/z found 970.1 [M−CF₃COOH+H]⁺.

4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethylisoxazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.79 (s, 1H), 9.67 (s, 1H), 8.87 (s, 1H), 7.55-7.19 (m, 9H), 6.76 (s, 1H), 6.44 (s, 1H), 4.57 (t, J=6.7 Hz, 1H), 4.35 (d, J=11.5 Hz, 2H), 4.15-4.13 (m, 2H), 3.64-3.59 (m, 7H), 3.39-3.33 (m, 3H), 3.26-3.20 (m, 3H), 3.13-3.10 (m, 4H), 3.02-2.95 (m, 3H), 2.60-2.58 (m, 4H), 2.42 (s, 3H), 1.77-1.66 (m, 2H), 1.63 (s, 3H), 1.09 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.486 min, m/z found 944.6 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-2-fluorobenzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.00 (s, 1H), 9.64 (s, 1H), 9.39 (s, 1H), 7.51-7.42 (m, 5H), 7.14-7.00 (m, 2H), 6.91 (s, 1H), 6.26 (s, 1H), 4.58-4.55 (m, 1H), 4.36-4.33 (m, 1H), 4.15-4.10 (m, 1H), 3.70-3.35 (m, 5H), 3.10-2.90 (m, 8H), 2.60-2.50 (m, 6H), 2.50-2.48 (m, 5H), 2.33-2.30 (m, 1H), 2.10-2.00 (m, 1H), 1.85-1.80 (m, 2H), 1.63 (s, 3H), 1.23-1.12 (m, 1H), 1.03 (t, J=6.8 Hz, 6H). LCMS (ESI): R_(T) 1.130 min, m/z found 907.4[M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-3-fluorobenzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆) δ 7.50-7.37 (m, 5H), 7.05-6.95 (m, 2H), 6.46-6.30 (m, 1H), 6.25 (s, 1H), 5.33 (s, 1H), 4.57 (t, J=6.7 Hz, 2H), 4.32-4.30 (m, 2H), 4.09-4.07 (m, 2H), 3.60-3.53 (m, 4H), 3.10-3.08 (m, 1H), 2.59-2.58 (m, 4H), 2.450-2.40 (m, 5H), 2.33 (s, 3H), 2.26-2.08 (m, 5H), 2.04-1.94 (m, 2H), 1.77-1.75 (m, 2H), 1.63 (s, 3H), 1.23-1.20 (m, 3H). LCMS (ESI): R_(T)=1.073 min, m/z found 893.1 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methyl)phenyl)ethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.59 (s, 2H), 7.46-7.33 (m, 5H), 7.35 (t, J=8.1 Hz, 1H), 7.03 (d, J=11.2 Hz, 1H), 6.95 (d, J=7.9 Hz, 1H), 6.88 (s, 1H), 6.24 (s, 1H), 4.56 (t, J=6.5 Hz, 1H), 4.33 (d, J=12.3 Hz, 1H), 4.10 (d, J=11.9 Hz, 1H), 3.60-3.59 (s, 1H), 3.49 (s, 2H), 3.10-3.00 (m, 1H), 2.59-2.58 (m, 4H), 2.41-2.34 (m, 7H), 2.09-2.08 (m, 3H), 1.95 (s, 3H), 1.76-1.75 (m, 3H), 1.63-1.60 (m, 4H), 1.27-0.81 (m, 4H). LCMS (ESI): R_(T)=1.355 min, m/z found 877.2 [M−H]⁻.

2-((2-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide

¹H NMR (400 MHz, DMSO-d₆) δ 7.75 (d, J=8.4 Hz, 1H), 7.47-7.40 (m, 5H), 6.90-6.69 (m, 6H), 4.52-4.48 (m, 1H), 3.70-3.60 (m, 2H), 3.53-3.50 (m, 2H), 3.30-3.22 (m, 5H), 2.92 (s, 2H), 2.59 (s, 3H), 2.39 (s, 6H), 2.32-2.30 (m, 2H), 1.60 (s, 3H), 1.03-1.00 (m, 6H). LCMS (ESI): R_(T)=1.840 min, m/z found 782.3 [M+H]⁺.

2-((2-(2-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆) δ 7.75-7.70 (m, 4H), 7.47-6.90 (m, 4H), 4.52-4.48 (m, 1H), 3.70-3.54 (m, 10H), 3.34-3.22 (m, 6H), 2.92 (s, 2H), 2.67-2.65 (m, 1H), 2.58-2.56 (m, 3H), 2.43-2.40 (m, 6H), 2.32-2.30 (m, 4H), 1.62 (s, 3H), 1.03-1.00 (m, 6H). LCMS (ESI): R_(T)=1.660 min, m/z found 826.4[M−CF₃COOH+H]⁺.

(S)-2-((1-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)amino)-4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.69 (d, J=8.1 Hz, 1H), 7.42 (dd, J=22.6, 8.5 Hz, 4H), 6.84 (s, 1H), 6.69 (d, J=8.4 Hz, 1H), 4.63 (s, 1H), 3.77-3.57 (m, 14H), 3.40-3.35 (m, 5H), 2.90 (s, 2H), 2.69 (s, 3H), 2.50-2.35 (m, 9H), 1.69 (s, 3H), 1.06 (d, J=3.6 Hz, 6H). LCMS (ESI): R_(T)=1.573 min, m/z found 870.2 [M−CF₃COOH+H]⁺.

2-((2-(2-(1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD) δ 7.74-7.71 (m, 1H), 7.46-7.39 (m, 5H), 6.90-6.89 (m. 1H), 6.72-6.70 (m, 1H), 4.72-4.69 (m, 1H), 4.50-4.49 (m, 1H), 4.20-4.18 (m, 1H), 3.77-3.38 (m, 7H), 2.92-2.91 (m, 2H), 2.71-2.60 (m, 4H), 2.48-2.41 (m, 8H), 1.80-1.70 (m, 6H), 1.60-1.22 (m, 8H), 1.06 (d, J=3.6 Hz, 6H). LCMS (ESI): R_(T)=1.660 min, m/z found 850.5[M−CF₃COOH+H]⁺.

2-((2-(2-(4-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperazin-1-yl)ethoxy)ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.75-7.73 (m, 1H), 7.47-7.40 (m, 5H), 6.91-6.90 (m. 1H), 6.74-6.71 (m, 1H), 4.72-4.71 (m, 1H), 3.93-3.83 (m, 4H), 3.70-3.60 (m, 4H), 3.50-3.48 (m, 7H), 3.21-3.20 (m, 1H), 2.90-2.70 (m, 7H), 2.48-2.33 (m, 10H), 2.10-2.02 (m, 1H), 1.76 (s, 3H), 1.06 (d, J=3.6 Hz, 6H). LCMS (ESI): R_(T)=1.285 min, m/z found 851.4[M−CF₃COOH+H]⁺.

5-((R)-sec-butylamino)-N1-((1R,5R)-8-(5-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)benzoyl)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-methylterephthalamide, formic acid

¹H NMR (400 MHz, CDCl₃): δ 8.50-8.28 (m, 5H), 7.97-7.69 (m, 3H), 7.67-7.65 (m, 2H), 7.50-7.42 (m, 7H), 7.20-7.08 (m, 1H), 6.83 (d, J=9.2 Hz, 1H), 6.56 (s, 1H), 4.70-4.55 (m, 3H), 4.40-4.30 (m, 1H), 4.20-4.10 (m, 1H), 3.88-3.86 (m, 1H), 3.50-3.46 (m, 4H), 3.20-3.10 (m, 2H), 2.67-2.56 (m, 5H), 2.32-2.30 (m, 8H), 2.28-1.97 (m, 13H), 1.79-1.60 (m, 3H), 1.63 (s, 3H), 1.52-1.48 (m, 1H), 1.14-1.12 (m, 3H), 1.03-0.98 (m, 6H). LCMS (ESI): R_(T)=1.305 min, m/z found 1117.5[M−HCOOH+H]⁺.

5-((R)-sec-butylamino)-N1-((1R,5R)-8-(5-((4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)carbamoyl)pyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-methylterephthalamide, formic acid

¹H NMR (400 MHz, CDCl₃): δ 10.03-10.01 (s, 1H), 8.74-8.73 (m, 1H), 8.13-8.11 (m, 1H), 8.08-8.06 (m, 1H), 7.82-7.80 (m, 3H), 7.51-7.42 (m, 6H), 6.86-6.83 (m, 1H), 6.58 (s, 1H), 4.57-4.56 (m, 3H), 4.37-4.34 (m, 1H), 4.18-4.10 (m, 1H), 3.88-3.77 (m, 3H), 3.56-3.43 (m, 16H), 3.32-3.20 (m, 5H), 2.67-2.56 (m, 5H), 2.46 (s, 3H), 2.32-2.30 (m, 3H), 2.20 (s, 3H), 2.18-1.70 (m, 8H), 1.63 (s, 3H), 1.52-1.48 (m, 2H), 1.14-1.12 (m, 3H), 0.86-0.83 (m, 3H). LCMS (ESI): R_(T)=1.400 min, m/z found 1133.6[M−HCOOH+2H]⁺.

2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.62 (s, 1H), 9.38 (s, 1H), 7.50-7.20 (m, 8H), 6.87 (s, 1H), 6.24 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.46-4.11 (m, 8H), 3.72-3.63 (m, 2H), 3.40-3.35 (m, 2H), 312-3.04 (m, 4H), 2.42-2.40 (m, 4H), 2.39 (s, 3H), 2.35-2.33 (m, 2H), 1.85-1.72 (m, 3H), 1.63 (s, 3H), 1.20-1.10 (m, 2H), 1.01 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.420 min, m/z found 875.2[M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)benzyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 9.56 (s, 1H), 8.79 (s, 1H), 8.07 (s, 1H), 7.52 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.0 Hz, 2H), 7.18 (d, J=8.4 Hz, 2H), 6.84 (s, 1H), 6.23 (s, 1H), 4.58-4.55 (m, 1H), 4.42-4.32 (m, 2H), 3.35-3.30 (m, 2H), 3.00-2.95 (m, 1H), 2.67 (s, 3H), 2.41 (s, 3H), 1.61 (s, 3H), 0.99-0.95 (m, 6H). LCMS (ESI): R_(T)=1.715 min, m/z found 739.2 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenyl)piperidine-4-carbonyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 10.36 (s, 1H), 10.14 (s, 1H), 9.89 (s, 1H), 7.51-7.42 (m, 6H), 7.33 (s, 1H), 6.97 (d, J=8.8 Hz, 2H), 6.50 (s, 1H), 4.61-4.57 (m, 1H), 3.73-3.40 (m, 12H), 3.15-3.11 (m, 1H), 2.70-2.67 (m, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 2.00-1.95 (m, 1H), 1.73-1.64 (m, 4H), 1.63 (s, 3H), 1.16 (t, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.551 min, m/z found 889.5 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)phenoxy)ethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 13.84 (s, 1H), 9.61 (s, 1H), 9.42 (s, 1H), 8.48 (t, J=5.6 Hz, 1H), 7.44 (dd, J=22.7, 8.7 Hz, 4H), 7.15 (d, J=8.9 Hz, 2H), 6.95 (d, J=9.0 Hz, 2H), 6.87 (s, 1H), 6.24 (s, 1H), 4.52 (t, J=7.0 Hz, 1H), 4.01 (t, J=5.6 Hz, 2H), 3.49-3.43 (m, 2H), 3.27-3.25 (m, 2H), 2.98-2.91 (m, 1H), 2.59 (s, 3H), 2.41 (s, 3H), 1.61 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.568 min, m/z found 769.1[M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)phenoxy)ethoxy)ethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 8.31 (s, 1H), 7.49 (d, J=8.8 Hz, 2H), 7.43 (d, J=8.4 Hz, 2H), 7.13 (d, J=8.0 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H), 6.24 (s, 1H), 4.58-4.55 (m, 1H), 4.11-4.09 (m, 2H), 3.76-3.74 (m 2H), 3.53-3.50 (m, 2H), 3.30-3.22 (m, 4H), 3.00-2.95 (m, 1H), 2.67 (s, 3H), 2.41 (s, 3H), 1.62 (s, 3H), 0.99-0.95 (m, 6H). LCMS (ESI): R_(T)=1.730 min, m/z found 813.2 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(2-(2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)phenoxy)ethoxy)ethoxy)ethyl)acetamide

¹H NMR (400 MHz, DMSO): δ 13.83 (s, 1H), 9.60 (s, 1H), 9.39 (s, 1H), 8.29-8.27 (m, 1H), 7.48 (d, J=8.5 Hz, 2H), 7.42 (d, J=8.5 Hz, 2H), 7.12 (d, J=8.9 Hz, 2H), 6.92 (d, J=8.9 Hz, 2H), 6.86 (s, 1H), 6.24 (s, 1H), 4.50 (t, J=7.1 Hz, 1H), 4.08-4.07 (m, 2H), 3.73 (d, J=4.4 Hz, 2H), 3.58 (d, J=8.0 Hz, 4H), 3.46 (t, J=5.8 Hz, 2H), 3.28-3.16 (m, 5H), 3.02-2.92 (m, 1H), 2.59 (s, 3H), 2.40 (s, 3H), 2.00-1.99 (m, 1H), 1.62 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)1.748 min, m/z found 857.7 [M+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(2-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)ethoxy)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.61 (s, 1H), 9.41 (s, 1H), 9.03-8.98 (m, 1H), 8.31 (s, 1H), 7.49-7.38 (m, 4H), 7.13-7.01 (m, 4H), 6.74 (s, 1H), 6.26 (s, 1H), 4.51 (t, J=7.2 Hz, 2H), 3.73 (s, 2H), 3.49 (d, J=5.3 Hz, 4H), 3.27 (d, J=7.5 Hz, 6H), 2.93-2.85 (m, 2H), 2.67 (s, 1H), 2.59 (s, 3H), 2.39 (s, 3H), 2.33 (s, 1H), 1.71-1.69 (m, 3H), 1.61 (s, 3H), 1.43-1.42 (m, 1H), 0.92 (d, J=6.2 Hz, 6H). LCMS (ESI): R_(T)=1.120 min, m/z found 878.2[M−CF₃COOH+H⁺]).

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.99 (s, 1H), 9.64 (s, 1H), 9.36 (s, 1H), 7.53-7.27 (m, 8H), 6.90 (s, 1H), 6.25 (s, 1H), 4.43 (s, 2H), 4.33 (d, J=33.0 Hz, 4H), 3.68-3.60 (m, 4H), 3.20-3.11 (m, 4H), 2.99 (s, 3H), 2.60 (s, 3H), 2.42 (s, 3H), 1.63 (s, 3H), 1.02 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.129 min, m/z found 792.4[M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 9.58 (s, 1H), 9.39 (s, 1H), 8.36-8.30 (m, 1H), 7.45 (dd, J=24.9, 8.6 Hz, 4H), 7.24 (d, J=8.4 Hz, 2H), 7.10 (d, J=8.3 Hz, 2H), 6.80 (s, 1H), 6.25 (s, 1H), 4.51 (t, J=7.0 Hz, 1H), 3.32-3.27 (m, 2H), 3.23-3.20 (m, 2H), 2.97-2.95 (m, 1H), 2.75-2.70 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 1.62 (s, 3H), 0.97 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.524 min, m/z found 737.6 [M+H⁺]).

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.62 (s, 1H), 9.38 (s, 1H), 7.58-7.31 (m, 6H), 7.17 (t, J=22.5 Hz, 2H), 6.83 (s, 1H), 6.26 (s, 1H), 4.57 (t, J=6.7 Hz, 1H), 4.35 (d, J=12.9 Hz, 1H), 4.15 (s, 1H), 3.66-3.60 (m, 8H), 3.43-3.31 (m, 2H), 3.21-2.81 (m, 7H), 2.76-2.55 (m, 5H), 2.42 (s, 3H), 2.05-2.02 (m, 1H), 1.90-1.68 (m, 2H), 1.63 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.097 min, m/z found 889.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenyl)piperazin-1-yl)methyl)piperidin-1-yl)ethanone

¹H NMR MeOD-d₄ (400 MHz): δ 7.46-7.40 (m, 4H), 7.17 (m, 2H), 7.08 (m, 2H), 6.69 (s, 1H), 6.28 (s, 1H), 4.69 (d, J=6.6 Hz, 1H), 4.57 (m, 2H), 3.76-3.58 (m, 4H), 3.23 (m, 7.4 Hz, 2H), 2.99 (s, 1H), 2.70 (s, 4H), 2.45 (s, 3H), 2.18 (t, J=3.8 Hz, 1H), 2.02 (s, 1H), 1.70 (s, 3H), 1.60-1.57 (m, 1H), 1.37 (d, J=1.3 Hz, 4H), 1.28 (s, 5H), 0.91 (s, 3H), 0.89 (s, 3H). LCMS (ESI): R_(T)=1.112 min, m/z found 875.7 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 9.61 (s, 1H), 9.38 (s, 1H), 8.44 (s, 1H), 7.51-7.42 (m, 6H), 7.21 (d, J=7.6 Hz, 2H), 6.82 (s, 1H), 6.26 (s, 1H), 4.57-4.50 (m, 2H), 4.26-4.20 (m, 2H), 4.00-3.95 (m, 2H), 3.69-3.50 (m, 6H), 3.33-2.95 (m, 7H), 2.67 (s, 4H), 2.55 (s, 3H), 2.36 (s, 3H), 1.62 (s, 3H), 0.97 (t, J=6.8 Hz, 6H). LCMS (ESI): R_(T) 0.720 min, m/z found 875.3 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenyl)piperazin-1-yl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.88 (s, 1H), 9.61 (s, 2H), 9.43 (s, 1H), 7.62-7.40 (m, 6H), 7.25-6.92 (m, 5H), 6.78 (s, 1H), 6.27 (s, 1H), 4.55-4.53 (m, 2H), 4.36-4.33 (m, 1H), 3.90 (d, J=12.6 Hz, 2H), 3.60-3.59 (m, 4H), 3.22-3.18 (m, 4H), 2.99-2.97 (m, 4H), 2.61 (s, 3H), 2.42 (s, 3H), 2.41-2.06 (m, 4H), 1.64 (s, 3H), 0.96 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.371 min, m/z found 861.7 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(3-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(methyl)amino)methyl)phenoxy)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (s, 1H), 9.61 (s, 1H), 9.33 (s, 2H), 8.64 (s, 1H), 7.56-6.83 (m, 13H), 6.23 (s, 1H), 4.27-4.25 (m, 2H), 4.09-4.06 (m, 2H), 3.19-3.10 (m, 1H), 3.02-2.93 (m, 1H), 2.68 (s, 3H), 2.58-2.55 (m, 4H), 2.35 (s, 3H), 1.53-1.50 (m, 3H), 1.25-1.20 (m, 4H), 0.97-0.93 (m, 6H). LCMS (ESI): R_(T)=1.381 min, m/z found 886.3 [M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (s, 1H), 9.61 (s, 1H), 9.33 (s, 1H), 8.44 (s, 1H), 7.50-7.42 (m, 6H), 7.26 (d, J=6.8 Hz, 2H), 6.86 (s, 1H), 6.24 (s, 1H), 4.48-4.45 (m, 1H), 4.26-4.20 (m, 2H), 3.69-3.50 (m, 6H), 3.33-3.10 (m, 2H), 3.02-2.95 (m, 2H), 2.67 (s, 3H), 2.55 (s, 3H), 2.38-2.36 (m, 4H), 2.25 (s, 3H), 1.86-1.82 (m, 4H), 1.61 (s, 3H), 1.01-0.99 (m, 6H). LCMS (ESI): R_(T)=1.30 min, m/z found 917.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)amino)-2-oxoethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (s, 1H), 9.61 (s, 1H), 9.33 (s, 2H), 8.58-8.56 (m, 1H), 7.78-7.65 (m, 1H), 7.53-7.46 (m, 6H), 7.25 (d, J=8.0 Hz, 2H), 6.87 (s, 1H), 6.24 (s, 1H), 4.54-4.51 (m, 1H), 4.40-4.30 (m, 2H), 3.98-3.60 (m, 4H), 3.50-3.40 (m, 6H), 3.02-2.85 (m, 7H), 2.61-2.51 (m, 4H), 2.41 (s, 3H), 2.38-2.35 (m, 1H), 1.86-1.60 (m, 9H), 1.01-0.99 (m, 6H). LCMS (ESI): R_(T)=1.298 min, m/z found 988.3 [M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)amino)-2-oxoethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (s, 1H), 9.61 (s, 1H), 9. 9.34 (s, 2H), 8.58-8.56 (m, 1H), 7.89-7.85 (m, 1H), 7.50-7.46 (m, 6H), 7.28-7.24 (m, 2H), 6.86 (s, 1H), 6.25 (s, 1H), 4.54-4.51 (m, 1H), 4.40-4.30 (m, 2H), 3.98-3.60 (m, 3H), 3.50-3.40 (m, 5H), 3.02-2.85 (m, 4H), 2.61-2.51 (m, 4H), 2.41 (s, 3H), 2.38-2.35 (m, 2H), 1.86-1.60 (m, 10H), 1.01-0.99 (m, 6H). LCMS (ESI): R_(T)=1.295 min, m/z found 974.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)phenoxy)ethyl)amino)-2-oxoethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 8.59 (s 1H), 8.07 (s, 1H), 7.50-7.47 (m, 4H), 7.12 (d, J=8.4 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.24 (s, 1H), 4.54-4.51 (m, 1H), 4.01-3.98 (m, 2H), 3.83-3.68 (m, 2H), 3.55-3.40 (m, 2H), 3.00-2.95 (m, 1H), 2.67-2.61 (m, 2H), 2.60 (s, 3H), 2.41 (s, 3H), 2.37-2.32 (m, 2H), 1.61 (s, 3H), 0.99-0.95 (m, 6H). LCMS (ESI): R_(T) 1.666 min, m/z found 826.2 [M+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(2-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)ethoxy)ethyl)acetamide, trifluoroacetic acid, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.61 (s, 1H), 9.40 (s, 1H), 8.28 (s, 1H), 7.49-7.38 (m, 4H), 7.27 (d, J=8.2 Hz, 2H), 7.12 (d, J=8.3 Hz, 3H), 6.76 (s, 1H), 6.27 (s, 1H), 4.49 (t, J=6.0 Hz, 1H), 3.43-3.30 (m, 8H), 3.27-3.15 (m, 4H), 2.97-2.92 (m, 1H), 2.59-2.55 (m, 8H), 2.43-2.38 (m, 6H), 1.62 (s, 3H), 0.93 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.074 min, m/z found 879.3[M−CF₃COOH+H⁺]).

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(3-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(methyl)amino)methyl)phenoxy)ethyl)acetamide, trifluoroacetic acid, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.98 (s, 1H), 9.65 (s, 1H), 9.37 (s, 1H), 8.54 (s, 1H), 7.64-6.98 (m, 13H), 6.87 (s, 1H), 6.25 (s, 1H), 4.55-4.48 (m, 1H), 4.40-4.15 (m, 3H), 4.08-4.04 (m, 2H), 3.56-3.53 (m, 2H), 3.23-3.20 (m, 2H), 3.06-2.91 (m, 1H), 2.59 (s, 3H), 2.40 (s, 3H), 2.00-1.95 (m, 1H), 1.59 (s, 3H), 1.25-1.23 (m, 4H), 0.99 (d, J=6.0 Hz, 6H). LCMS (ESI): R_(T)=1.24 min, m/z found 886.5 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(3-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(methyl)amino)methyl)phenoxy)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.58 (s, 1H), 9.38 (s, 1H), 8.53 (s, 1H), 7.62-6.57 (m, 14H), 6.25 (s, 1H), 4.54-4.47 (m, 1H), 4.05-3.98 (m, 2H), 3.50-3.30 (m, 5H), 2.96-2.91 (m, 3H), 2.67 (s, 3H), 2.40 (s, 3H), 2.33 (s, 1H), 1.62-1.57 (m, 3H), 1.24 (s, 4H), 0.96-0.93 (m, 6H). LCMS (ESI): R_(T)=1.355 min, m/z found 886.2 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)oxy)ethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 9.57 (s, 1H), 9.36 (s, 1H), 8.33 (t, J=5.4 Hz, 1H), 7.55-7.25 (m, 6H), 7.14 (d, J=8.3 Hz, 2H), 6.86 (s, 1H), 6.24 (s, 1H), 4.51-4.48 (m, 3H), 3.52-3.47 (m, 2H), 3.32-3.24 (m, 4H), 3.02-2.93 (m, 1H), 2.59 (s, 3H), 2.41 (s, 3H), 1.61 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.549 min, m/z found 767.2[M+H⁺]).

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (s, 1H), 9.62 (s, 2H), 9.35 (s, 1H), 8.24 (s, 1H), 7.51-7.40 (m, 6H), 7.25 (d, J=7.6 Hz, 2H), 6.86 (s, 1H), 6.25 (s, 1H), 4.53-4.51 (m, 1H), 4.38-3.92 (m, 5H), 3.19-3.10 (m, 3H), 3.02-2.65 (m, 7H), 2.67 (s, 3H), 2.35 (s, 3H), 1.77-1.62 (m, 10H), 1.25-1.20 (m, 2H), 0.97-0.93 (m, 8H). LCMS (ESI): R_(T)=1.392 min, m/z found 931.7 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)ethyl)amino)-2-oxoethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.85 (s, 1H), 9.56 (s, 1H), 9.37 (s, 1H), 8.60 (t, J=6.0 Hz, 1H), 8.06 (t, J=5.4 Hz, 1H), 7.47 (q, J=8.9 Hz, 4H), 7.08 (d, J=8.9 Hz, 2H), 6.92 (d, J=8.9 Hz, 2H), 6.83 (s, 1H), 6.24 (s, 1H), 4.52 (t, J=7.2 Hz, 1H), 3.99 (t, J=5.7 Hz, 2H), 3.49-3.43 (m, 4H), 3.36-3.30 (m, 2H), 3.03-2.93 (m, 1H), 2.58 (s, 3H), 2.41 (s, 3H), 1.62 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.645 min, m/z found 810.6 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((2-(2-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenoxy)ethoxy)ethyl)amino)-2-oxoethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.86 (s, 1H), 9.57 (s, 1H), 9.37 (s, 1H), 8.58-8.56 (m, 1H), 7.91-7.89 (m, 1H), 7.50-7.44 (m, 4H), 7.07 (d, J=9.0 Hz, 2H), 6.93 (t, J=10.4 Hz, 2H), 6.82 (s, 1H), 6.24 (s, 1H), 4.52 (t, J=7.3 Hz, 1H), 4.08-4.06 (m, 3H), 3.76-3.64 (m, 5H), 3.30-3.25 (m, 4H), 3.00-2.92 (m, 1H), 2.59 (s, 3H), 2.40 (s, 3H), 1.62 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.636 min, m/z found 852.2 [M−H]⁻.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)acetamide

¹H NMR (400 MHz, DMSO): δ 8.76 (s, 1H), 7.49 (d, J=8.7 Hz, 2H), 7.40 (d, J=8.5 Hz, 2H), 7.28 (d, J=8.4 Hz, 2H), 7.12 (d, J=8.4 Hz, 2H), 6.91 (s, 1H), 6.23 (s, 1H), 4.57-4.51 (m, 1H), 4.34 (m, 3H), 2.60 (s, 3H), 2.41 (s, 3H), 2.38-2.33 (m, 2H), 2.00 (d, J=7.7 Hz, 1H), 1.61 (s, 3H), 1.23 (s, 4H), 1.00 (t, J=7.5 Hz, 3H). LCMS (ESI): LCMS-010(LCMS 2020-004) R_(T)=1.525 min, m/z found 709.6 [M+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)amino)-2-oxoethyl)acetamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.90 (s, 1H), 9.55 (s, 1H), 9.36 (s, 1H), 8.74 (t, J=5.8 Hz, 1H), 8.29 (t, J=6.0 Hz, 1H), 7.54-7.41 (m, 4H), 7.17 (d, J=8.3 Hz, 2H), 7.07 (t, J=11.9 Hz, 2H), 6.87 (s, 1H), 6.23 (s, 1H), 4.52 (t, J=7.4 Hz, 1H), 4.32-4.28 (m, 2H), 3.89-3.84 (m, 1H), 3.76-3.71 (m, 1H), 3.63-3.40 (m, 3H), 3.39-3.35 (m, 1H), 3.30-3.26 (m, 3H), 2.41 (s, 3H), 1.62 (s, 3H), 1.00 (dd, J=6.8, 1.5 Hz, 6H). LCMS (ESI): R_(T)=1.641 min, m/z found 780.6 [M+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(2-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)ethyl)piperidin-1-yl)ethanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.87 (s, 1H), 9.61 (s, 1H), 9.42 (s, 1H), 7.52-7.42 (m, 4H), 7.04 (dd, J=30.5, 8.8 Hz, 4H), 6.80 (s, 1H), 6.27 (s, 1H), 4.61-4.54 (m, 1H), 4.34-4.30 (m, 1H), 4.15-4.14 (m, 1H), 3.87-3.83 (m, 2H), 3.57-3.50 (m, 4H), 3.24-2.89 (m, 10H), 2.60 (s, 3H), 2.42 (s, 3H), 1.79-1.75 (m, 1H), 1.68-1.63 (m, 8H), 0.97 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.112 min, m/z found 889.4 [M−CF₃COOH+H⁺]).

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)azetidin-3-yl)methyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.55 (d, J=8.1 Hz, 2H), 7.52-7.24 (m, 6H), 6.87 (s, 1H), 6.20 (s, 1H), 4.64 (s, 1H), 4.33 (s, 3H), 4.05 (s, 2H), 3.74 (s, 1H), 3.58-3.33 (m, 6H), 3.01 (m, 4H), 2.69 (d, J=3.2 Hz, 3H), 2.45 (s, 3H), 1.97 (m, 5H), 1.69 (s, 3H), 1.29 (s, 4H), 1.05-0.92 (m, 6H). LCMS (ESI): R_(T)=1.039 min, m/z found 903.4 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)azetidin-3-yl)methyl)amino)-2-oxoethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.45 (m, 8H), 6.87 (s, 1H), 6.20 (s, 1H), 4.65 (t, J=6.6 Hz, 1H), 4.31 (s, 3H), 3.99 (m, 3H), 3.81-3.64 (m, 2H), 3.47 (s, 5H), 3.05 (m, 3H), 2.86 (s, 1H), 2.69 (s, 3H), 2.58 (s, 1H), 2.44 (s, 3H), 2.20 (m, 1H), 1.95 (m, 5H), 1.69 (d, J=2.2 Hz, 3H), 1.30 (s, 4H), 1.01 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.063 min, m/z found 960.3 [M−CF₃COOH+H]⁺.

4-(4-(4-((2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.60 (s, 1H), 9.31 (s, 1H), 8.89-8.80 (m, 2H), 7.51-7.46 (m, 6H), 7.24-7.22 (m, 2H), 6.95 (s, 1H), 6.24 (s, 1H), 4.35-4.24 (m, 3H), 3.75-3.33 (m, 3H), 3.07 (d, J=47.4 Hz, 6H), 2.76-2.66 (m, 3H), 2.60 (s, 3H), 2.42 (s, 3H), 1.97 (s, 3H), 1.63 (s, 3H), 1.01-0.88 (m, 6H). LCMS (ESI): R_(T)=1.347 min, m/z found 709.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-(4-(2-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)ethoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.87 (s, 1H), 9.58 (s, 1H), 9.37 (s, 1H), 8.84-8.81 (m, 2H), 7.49 (s, 4H), 7.14 (d, J=8.9 Hz, 2H), 6.98 (d, J=9.0 Hz, 2H), 6.84 (s, 1H), 6.25 (s, 1H), 4.33 (d, J=7.6 Hz, 1H), 4.26-4.23 (m, 2H), 3.72-3.60 (m, 2H), 3.03-2.93 (m, 1H), 2.72-2.69 (m, 3H), 2.61 (s, 3H), 2.40 (s, 3H), 2.35-2.33 (m, 1H), 1.62 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.358 min, m/z found 739.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-(4-(2-(2-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)ethoxy)ethoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.87 (s, 1H), 9.59 (s, 1H), 9.38 (s, 1H), 8.68-8.50 (m, 2H), 7.50 (s, 4H), 7.09 (d, J=8.9 Hz, 2H), 6.91 (d, J=9.0 Hz, 2H), 6.82 (s, 1H), 6.25 (s, 1H), 4.33-4.28 (m, 1H), 4.12-4.11 (m, 2H), 3.80-3.70 (m, 5H), 3.44-3.40 (m, 1H), 3.30-3.25 (m, 2H), 3.02-2.93 (m, 1H), 2.68-2.55 (m, 2H), 2.60 (s, 3H), 2.40 (s, 3H), 1.61 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.385 min, m/z found 783.5 [M−CF₃COOH+H]⁺.

(4-(((2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)methyl)piperidin-1-yl)(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methanone, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.57 (d, J=8.3 Hz, 2H), 7.51 (d, J=8.5 Hz, 2H), 7.42 (m, 4H), 6.87 (s, 1H), 6.22 (s, 1H), 4.42 (s, 1H), 4.34 (s, 2H), 3.58 (m, 6H), 3.06 (d, J=8.3 Hz, 6H), 2.77 (d, J=6.5 Hz, 2H), 2.71 (s, 3H), 2.44 (s, 3H), 2.21-2.15 (m, 1H), 1.99 (m, 7H), 1.70 (s, 3H), 1.30 (s, 7H), 1.01 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.042 min, m/z found 917.3 [M−CF₃COOH+H]⁺.

(S)-4-(4-(4-(2-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)(methyl)amino)ethoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol

¹H NMR (400 MHz, DMSO-d₆): δ 7.49 (s, 4H), 7.14 (d, J=8.9 Hz, 2H), 6.79-6.77 (m, 3H), 6.25 (s, 1H), 4.33 (t, J=7.6 Hz, 1H), 3.96-3.94 (m, 2H), 3.03-2.93 (m, 1H), 2.78-2.75 (m, 4H), 2.61 (s, 3H), 2.40 (s, 3H), 2.33 (s, 1H), 1.62 (s, 3H), 0.99 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T) 1.417 min, m/z found 753.7 [M+H]⁺.

(3-(((2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)methyl)pyrrolidin-1-yl)(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methanone, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.48 (m, 7.9 Hz, 8H), 6.88 (s, 1H), 6.21 (s, 1H), 4.38 (m, 3H), 3.88 (m, 2H), 3.56 (m, 5H), 3.22 (d, J=5.6 Hz, 2H), 3.06 (d, J=7.3 Hz, 3H), 2.79 (s, 3H), 2.71 (s, 3H), 2.60 (s, 1H), 2.44 (s, 3H), 2.34-2.11 (m, 2H), 2.07-1.81 (m, 5H), 1.70 (s, 3H), 1.27 (m, 4H), 1.02 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T) 0.978 min, m/z found 903.3 [M−CF₃COOH+H]⁺.

(3-(((2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)methyl)pyrrolidin-1-yl)(1-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.99 (s, 1H), 9.64 (s, 2H), 9.36 (s, 1H), 8.68-8.65 (m, 2H), 7.52-7.49 (m, 6H), 7.26 (d, J=8.3 Hz, 2H), 6.91 (s, 1H), 6.24 (s, 1H), 4.31-4.29 (m, 3H), 3.47-3.25 (m, 7H), 3.10-2.80 (m, 4H), 2.64-2.60 (m, 5H), 2.43-2.29 (m, 5H), 2.05-1.78 (m, 6H), 1.62 (s, 3H), 1.23-1.20 (m, 3H), 1.01 (t, J=7.5 Hz, 3H). LCMS (ESI): R_(T)=0.946 min, m/z found 889.3 [M−CF₃COOH+H]⁺.

(4-(((2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)methyl)piperidin-1-yl)(1-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methanone, trifluoroacetic acid

¹H NMR (400 MHz, DMSO): δ 11.98 (s, 1H), 9.63 (s, 2H), 9.35 (s, 1H), 8.56 (s, 2H), 7.49 (m, 5H), 7.27 (d, J=8.2 Hz, 2H), 6.91 (s, 1H), 6.23 (s, 1H), 4.30 (m, 4H), 2.96 (s, 5H), 2.64 (m, 8H), 2.43-2.34 (m, 4H), 1.99 (s, 3H), 1.80 (s, 4H), 1.62 (s, 3H), 1.51-1.42 (m, 1H), 1.23 (s, 5H), 1.01 (t, J=7.5 Hz, 3H). LCMS (ESI): R_(T)=0.958 min, m/z found 903.3 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)phenyl)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.61 (s, 1H), 9.34 (s, 1H), 8.73 (s, 1H), 7.56-7.31 (m, 10H), 7.19 (s, 2H), 6.84 (s, 1H), 6.27 (s, 1H), 4.99 (s, 1H), 4.47 (d, J=8.6 Hz, 1H), 4.30 (s, 1H), 3.36-3.30 (m, 7H), 3.23-3.20 (m, 2H), 2.98-2.96 (m, 2H), 2.65-2.58 (m, 7H), 2.39 (s, 3H), 1.56 (s, 3H), 1.39 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.7 Hz, 6H). LCMS (ESI): R_(T)=1.081 min, m/z found 925.5[M−CF₃COOH+H]⁺.

(S)-4-(4-(4-(2-(2-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)(methyl)amino)ethoxy)ethoxy)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.55-7.37 (m, 4H), 7.11-7.09 (m, 1H), 6.88 (d, J=8.1 Hz, 2H), 6.69 (s, 1H), 6.26 (s, 1H), 4.37-4.35 (m, 1H), 4.06-3.67 (m, 9H), 3.11-2.96 (m, 4H), 2.79-2.70 (m, 2H), 2.66 (d, J=8.6 Hz, 3H), 2.43 (s, 3H), 1.67 (s, 3H), 1.29-1.25 (m, 3H), 0.90-0.89 (m, 6H). LCMS (ESI): R_(T)=1.347 min, m/z found 797.3 [M−CF₃COOH+H]⁺.

N-(4-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)phenyl)-1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.64-7.31 (m, 13H), 6.89 (s, 1H), 6.21 (s, 1H), 4.71 (dd, J=8.6, 5.5 Hz, 1H), 4.36-4.33 (m, 2H), 3.64-3.47 (m, 6H), 3.13-3.09 (m, 3H), 2.71 (s, 3H), 2.45 (s, 3H), 2.19-1.95 (m, 3H), 1.70 (s, 3H), 1.02 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)1.748 min, m/z found 925.9 [M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)acetamide hydrochloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.99 (s, 1H), 10.20 (s, 1H), 9.61 (s, 1H), 9.33 (s, 2H), 8.44 (s, 1H), 7.55-7.41 (m, 6H), 7.25 (d, J=6.8 Hz, 2H), 6.87 (s, 1H), 6.28 (s, 1H), 4.27-4.25 (m, 1H), 4.09-4.06 (m, 2H), 3.69-3.20 (m, 11H), 3.02-2.85 (m, 4H), 2.61-2.51 (m, 4H), 2.41 (s, 3H), 1.86-1.82 (m, 5H), 1.61 (m, 3H), 1.01-0.99 (m, 6H). LCMS (ESI): R_(T)=1.305 min, m/z found 917.4 [M−HCl+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethenone hydrochloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 10.68 (m, 1H), 9.62 (s, 1H), 9.38 (s, 1H), 7.64-7.44 (m, 6H), 7.25 (d, J=8.4 Hz, 2H), 6.93 (s, 1H), 6.31 (s, 1H), 4.63 (t, J=6.7 Hz, 1H), 4.41-4.15 (m, 3H), 3.79-3.40 (m, 12H), 3.43-3.00 (m, 4H), 2.76-2.55 (m, 5H), 2.42 (s, 3H), 2.05-2.02 (m, 1H), 1.90-1.68 (m, 2H), 1.63 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.31 min, m/z found 889.6 [M−HCl+H]⁺.

mono(1-(6-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)hexyl)-2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium) dichloride

¹H NMR (400 MHz, CD₃OD): δ 8.54-8.52 (m, 2H), 8.15-8.10 (m, 1H), 7.71 (d, J=7.8 Hz, 1H), 7.57-7.15 (m, 6H), 6.52-6.46 (m, 2H), 5.89 (s, 1H), 4.66-4.49 (m, 2H), 4.13-3.99 (m, 3H), 3.93-3.53 (m, 12H), 3.25-3.12 (m, 2H), 2.73-2.60 (m, 3H), 2.44-2.30 (m, 3H), 1.95-1.85 (m, 1H), 1.64 (d, J=18.5 Hz, 2H), 1.64-1.58 (m, 1H), 1.50-1.49 (m, 2H), 1.30 (t, J=7.1 Hz, 2H). LCMS(ESI): R_(T)=1.225 min, m/z found 849.4[M]⁺

4-(4-(4-((4-((1-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)piperidin-4-yl)methyl)piperidin-1-yl)methyl)phenyl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.58-7.45 (m, 8H), 6.83 (s, 1H), 6.23 (s, 1H), 4.38 (t, J=6.1 Hz, 1H), 4.16 (s, 2H), 3.75-3.70 (m, 4H), 3.21-2.95 (m, 12H), 2.71 (s, 3H), 2.65-2.61 (m, 2H), 2.44 (s, 3H), 2.17-2.04 (m, 3H), 1.70 (s, 3H), 1.55-1.50 (m, 2H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.224 min, m/z found 875.5 [M−CF₃COOH+H]⁺.

2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(1-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.46 (m, 8H), 6.89 (s, 1H), 6.18 (s, 1H), 4.64 (s, 1H), 4.32 (s, 2H), 3.51 (s, 7H), 3.06 (s, 2H), 2.85 (s, 2H), 2.70 (s, 3H), 2.44 (s, 6H), 1.96 (m, 6H), 1.69 (s, 4H), 1.30 (s, 5H), 1.03 (s, 3H). LCMS (ESI): R_(T)=1.054 min, m/z found 903.1 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide hydrochloride

¹H NMR (400 MHz, DMSO-d₆): 9.75-9.66 (m, 2H), 7.61-7.37 (m, 8H), 6.75 (s, 1H), 6.34 (s, 1H), 4.60-4.57 (m, 1H), 4.37-4.34 (m, 2H), 4.21-4.16 (m, 2H), 3.99-3.95 (m, 2H), 3.66-3.30 (m, 11H), 3.18-3.12 (m, 3H), 2.67-2.57 (m, 4H), 2.44 (s, 3H), 2.33-2.29 (m, 2H), 1.76-1.60 (m, 4H), 1.63 (s, 3H), 1.24 (s, 1H), 0.95-0.91 (m, 4H). LCMS (ESI): R_(T)=1.415 min, m/z found 984.4 [M−HCl+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)phenyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 11.85 (s, 1H), 9.59 (s, 2H), 7.50-7.43 (m, 4H), 7.07-6.96 (m, 4H), 6.80 (s, 1H), 6.27 (s, 1H), 4.62-4.59 (t, 1H), 3.81-3.77 (m, 2H), 3.70-3.66 (m, 2H), 3.48-3.40 (m, 2H), 3.29-3.26 (m, 2H), 3.00-2.97 (m, 1H), 2.63 (s, 3H), 2.45 (s, 3H), 1.64 (s, 3H), 0.98-0.97 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.573 min, m/z found 778.1[M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(2-(4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)ethyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 9.63 (s, 1H), 9.42 (s, 1H), 7.51-7.43 (m, 4H), 7.22-7.12 (m, 4H), 6.77 (s, 1H), 6.27 (s, 1H), 4.59-4.56 (t, J=13.2 Hz, 1H), 4.36-4.33 (m, 1H), 4.13-4.10 (m, 1H), 3.70-3.33 (m, 3H), 3.22-2.96 (m, 7H), 2.60 (s, 3H), 1.99-2.01 (m, 1H), 1.78-1.59 (m, 10H), 1.39-1.24 (m, 6H), 1.01 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.193 min, m/z found 902.2[M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(3-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)phenyl)ethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 9.60-9.40 (m, 3H), 8.73-8.71 (m, 2H), 7.52-7.10 (m, 12H), 6.76 (s, 1H), 6.26 (s, 1H), 4.02-4.00 (m, 1H), 4.48-4.46 (m, 1H), 4.27-4.26 (m, 2H), 4.94-3.59 (m, 4H), 3.43-3.33 (m, 3H), 2.98-2.86 (m, 3H), 2.68-2.66 (m, 4H), 2.40 (s, 3H), 1.76-1.72 (m, 2H), 1.56 (s, 3H), 1.43-1.24 (m, 3H), 0.94 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.410 min, m/z found 924.3[M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)phenyl)ethyl)acetamide hydrochloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H), 9.83 (s, 1H), 9.62 (s, 1H), 9.40 (s, 1H), 8.78-8.76 (m, 2H), 7.57-7.44 (m, 6H), 7.37-7.32 (m, 2H), 7.20-7.09 (m, 4H), 6.77 (s, 1H), 6.28 (s, 1H), 5.00 (t, J=6.7 Hz, 1H), 4.49-4.46 (m, 1H), 4.25-4.24 (m, 2H), 3.40-3.12 (m, 5H), 2.98-2.96 (m, 1H), 2.86-2.82 (m, 2H), 2.67-2.60 (m, 4H), 2.39 (s, 3H), 1.71-1.68 (m, 4H), 1.55 (s, 3H), 1.46-1.39 (m, 4H), 0.95 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.285 min, m/z found 924.6[M−HCl+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-(4-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(methyl)amino)methyl)benzyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.97 (s, 1H), 9.81 (s, 1H), 9.80 (s, 1H), 9.61 (s, 1H), 7.52-7.26 (m, 12H), 6.90 (s, 1H), 6.24 (s, 1H), 4.57 (t, J=6.7 Hz, 1H), 4.45-4.11 (m, 8H), 3.59 (s, 1H), 3.39-3.35 (s, 1H), 3.06-2.98 (m, 2H), 2.60-2.58 (m, 5H), 2.52-2.49 (m, 2H), 2.41 (s, 3H), 1.83 (s, 1H), 1.68-1.63 (m, 5H), 1.02 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.203 min, m/z found 924.2[M−CF₃COOH+H]⁺.

(S)-4-(4-(((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)benzyl)(methyl)amino)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): 9.70-9.64 (m, 3H), 7.57-7.31 (m, 12H), 6.77 (s, 1H), 6.29 (s, 1H), 4.59-3.94 (m, 11H), 3.72-3.63 (m, 1H), 3.40-3.33 (m, 1H), 2.96-2.92 (m, 2H), 2.60-2.49 (m, 8H), 2.42 (s, 3H), 2.09 (m, 1H), 2.01 (m, 1H), 1.66-1.63 (m, 5H), 1.01 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.293 min, m/z found 1033.1[M−CF₃COOH+H]⁺.

(S)-4-(4-((1-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, formic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.56 (s, 1H), 9.57 (s, 1H), 9.38 (s, 1H), 8.33 (s, 1H), 7.50-7.42 (m, 4H), 7.29-7.23 (m, 4H), 6.61 (s, 1H), 6.35 (s, 1H), 4.58 (m, 1H), 4.33 (m, 1H), 4.15 (m, 1H), 3.98-3.94 (m, 2H), 3.42-3.38 (m, 2H), 3.11 (m, 2H), 2.93-2.89 (m, 1H), 2.60 (s, 3H), 2.65-2.55 (m, 3H), 2.44 (s, 3H), 2.11-2.10 (m, 2H), 1.79 (m, 4H), 1.63-1.54 (m, 7H), 1.24-1.21 (m, 2H), 0.81 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.460 min, m/z found 997.3[M−CF₃COOH+H]⁺.

(S)-4-(4-((1-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.73-9.59 (m, 2H), 8.82 (s, 1H), 9.38 (s, 1H), 7.51-7.43 (m, 4H), 7.29-7.24 (m, 4H), 6.61 (s, 1H), 6.33 (s, 1H), 4.60-4.56 (m, 1H), 4.38-4.34 (m, 1H), 4.23-4.21 (m, 1H), 3.98-3.94 (m, 2H), 3.64-3.52 (m, 3H), 3.40-3.15 (m, 3H), 2.98-2.86 (m, 3H), 2.62-2.58 (m, 5H), 2.42 (s, 3H), 2.27-2.21 (m, 3H), 1.87-1.73 (m, 6H), 1.63 (s, 4H), 1.38-1.10 (m, 2H), 0.84-0.88 (m, 3H). LCMS (ESI): R_(T)=1.534 min, m/z found 983.4 [M−CF₃COOH+H]⁺.

(S)-4-(4-((1-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)phenyl)-N-ethyl-5-(5-ethyl-2,4-dihydroxyphenyl)-1H-1,2,414-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.25 (s, 1H), 8.98 (s, 1H), 7.51-7.43 (m, 4H), 7.26 (s, 4H), 6.56 (s, 1H), 6.33 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.38-4.35 (m, 1H), 4.19-4.08 (m, 1H), 3.78-3.36 (m, 5H), 3.19-3.16 (m, 4H), 2.98-2.81 (m, 3H), 2.67-2.60 (m, 6H), 2.42 (s, 3H), 2.26-2.22 (m, 3H), 1.89-1.74 (m, 5H), 1.63 (s, 3H), 1.60-1.24 (m, 4H), 1.06-1.03 (m, 3H), 0.86-0.83 (m, 3H). LCMS (ESI): R_(T)=1.409 min, m/z found 929.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(5-ethyl-2,4-dihydroxyphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)piperidin-1-yl)ethan-1-one, formic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.89 (s, 1H), 9.56 (s, 1H), 9.37 (s, 1H), 8.15 (s, 1H), 7.51-7.42 (m, 4H), 7.18-7.08 (m, 4H), 6.80 (s, 1H), 6.26 (s, 1H), 4.59-4.15 (m, 3H), 3.70-3.59 (m, 1H), 3.40-3.38 (m, 3H), 3.12-2.99 (m, 3H), 2.60 (s, 3H), 2.42 (s, 3H), 2.39-2.30 (m, 4H), 2.29-1.98 (m, 2H), 1.83-1.80 (m, 2H), 1.64-1.57 (m, 7H), 1.29-1.25 (m, 2H), 0.98-0.94 (m, 4H). LCMS (ESI): R_(T) 1.337 min, m/z found 874.1 [M−HCOOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)benzyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.50-7.22 (m, 12H), 6.69 (s, 1H), 6.26 (s, 1H), 4.66-4.65 (m, 1H), 4.51-4.49 (m, 2H), 4.28-4.26 (m, 2H), 3.45-3.35 (m, 4H), 2.99-2.91 (m, 3H), 2.68 (s, 3H), 2.64-2.62 (m, 2H), 2.35 (s, 3H), 1.89-1.85 (m, 3H), 1.68 (s, 3H), 1.48-1.44 (m, 2H), 0.89 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.153 min, m/z found 910.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-((1-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4H-1,2,4-triazole-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.69 (d, J=1.2 Hz, 1H), 9.77 (s, 1H), 8.95 (t, J=1.6 Hz, 1H), 7.50-7.41 (m, 4H), 7.26-7.25 (m, 4H), 6.75 (s, 1H), 6.35 (s, 1H), 4.58 (t, J=6.8 Hz, 1H), 4.32-4.32 (m, 1H), 4.25-4.20 (m, 1H), 3.65-3.60 (m, 1H), 3.16-3.14 (m, 4H), 2.91-2.88 (m, 3H), 2.59 (s, 3H), 2.54-2.50 (m, 3H), 2.41 (s, 3H), 2.40-2.38 (m, 1H), 2.11-2.01 (m, 2H), 1.98-1.97 (m, 2H), 1.79-1.66 (m, 4H), 1.57 (s, 3H), 1.57-1.45 (m, 5H), 1.03 (t, J=6.8 Hz, 3H), 0.83 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T) 2.294 min, m/z found 943.0[M+H]⁺.

(S)-4-(4-((1-(4-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)methyl)benzyl)piperidin-4-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): 9.74-9.62 (m, 2H), 8.81 (t, J=6.7 Hz, 1H), 7.50-7.40 (m, 8H), 7.27-7.24 (m, 4H), 6.60 (s, 1H), 6.32 (s, 1H), 4.57-4.27 (m, 5H), 3.98-3.94 (m, 2H), 3.37-3.32 (m, 4H), 2.90-2.85 (m, 2H), 2.60 (s, 3H), 2.54-2.50 (m, 2H), 2.41 (s, 3H), 2.24-2.20 (m, 2H), 1.75-1.61 (m, 6H), 1.40-1.25 (m, 3H), 0.86-0.83 (m, 3H). LCMS (ESI): R_(T)=1.383 min, m/z found 1005.2 [M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)phenyl)ethyl)-N-methylacetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): 7.50-7.31 (m, 12H), 7.30-7.29 (m, 2H), 6.76 (s, 1H), 6.24 (s, 1H), 5.98 (s, 1H), 4.78-4.75 (m, 3H), 3.48-3.37 (m, 8H), 3.18-2.89 (m, 8H), 2.71-2.55 (m, 5H), 2.46 (s, 3H), 1.74-1.29 (m, 5H), 0.93-0.92 (m, 6H). LCMS (ESI): R_(T)=1.172 min, m/z found 939.3 [M−CF₃COOH+H]⁺.

2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N—((R)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)phenyl)ethyl)-N-methylacetamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.50-7.41 (m, 8H), 7.30-7.20 (m, 4H), 6.87 (d, J=3.2 Hz, 1H), 6.26 (s, 1H), 4.78 (t, J=6.7 Hz, 1H), 4.30-4.29 (m, 2H), 3.35-3.33 (m, 2H), 3.10 (s, 3H), 3.10-3.09 (m, 1H), 2.71 (s, 3H), 2.65 (s, 3H), 2.65-2.63 (m, 3H), 2.45 (s, 3H), 1.93-1.90 (m, 3H), 1.70 (s, 3H), 1.59-1.57 (m, 2H), 1.38-1.30 (m, 4H), 0.86 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.203 min, m/z found 938.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)piperidin-1-yl)ethan-1-one, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.94 (s, 1H), 9.62 (s, 1H), 9.48 (s, 1H), 8.38 (s, 1H), 7.51 (d, J=7.6 Hz, 2H), 7.44 (d, J=7.6 Hz, 2H), 7.22 (d, J=7.6 Hz, 2H), 7.13 (d, J=7.6 Hz, 2H), 6.77 (s, 1H), 6.27 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.37-4.34 (m, 1H), 4.18-4.16 (m, 1H), 3.66-3.60 (m, 2H), 3.20-3.10 (m, 1H), 2.99-2.84 (m, 4H), 2.56 (s, 3H), 2.52-2.50 (m, 3H), 2.40 (s, 3H), 2.10-2.00 (m, 1H), 1.83-1.73 (m, 5H), 1.63 (s, 3H), 1.48-1.44 (m, 2H), 1.25-1.20 (m, 3H), 0.96 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T) 1.174 min, m/z found 888.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((1-(4-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)benzyl)piperidin-4-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.82 (s, 1H), 9.62 (s, 1H), 9.38 (s, 1H), 7.50-7.20 (m, 12H), 6.60 (s, 1H), 6.33 (s, 1H), 4.52 (t, J=6.7 Hz, 1H), 4.46-4.11 (m, 1H), 3.95-3.90 (m, 2H), 3.40-3.55 (m, 10H), 3.30-3.22 (m, 4H), 2.90-2.79 (m, 2H), 2.67-2.61 (m, 2H), 2.55 (s, 3H), 2.41 (s, 3H), 1.85-1.72 (m, 3H), 1.63 (s, 3H), 1.30-1.20 (m, 2H), 0.82 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.253 min, m/z found 1033.3 [M−CF₃COOH+H]⁺.

(S)-4-(4-((1-(4-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)methyl)benzyl)piperidin-4-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.62-9.50 (m, 2H), 8.88 (s, 1H), 7.50-7.42 (m, 8H), 7.28-7.26 (m, 4H), 6.77 (s, 1H), 6.34 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.39-4.38 (m, 3H), 4.32-4.25 (m, 3H), 3.98-3.95 (m, 5H), 3.70-3.65 (m, 2H), 3.25-3.20 (m, 1H), 1.85-2.83 (m, 3H), 2.42-2.40 (m, 4H), 2.39 (s, 3H), 1.85-1.72 (m, 3H), 1.63 (s, 3H), 1.20-1.10 (m, 2H), 0.82 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)1.255 min, m/z found 1019.3 [M−CF₃COOH+H]⁺.

4-(4-((1-(3-((R)-1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethyl)benzyl)piperidin-4-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.78 (s, 1H), 9.60-9.50 (m, 2H), 8.73 (d, J=7.6 Hz, 1H), 7.52-7.40 (m, 7H), 7.31-7.24 (m, 6H), 6.59 (s, 1H), 6.34 (s, 1H), 5.00 (t, J=6.7 Hz, 1H), 4.49-4.46 (m, 1H), 4.28-4.26 (m, 2H), 3.99-3.97 (m, 2H), 3.38-3.35 (m, 2H), 3.32-3.24 (m, 2H), 3.13-3.10 (m, 3H), 2.59 (s, 3H), 2.50-2.48 (m, 2H), 2.41 (s, 1H), 1.75-1.72 (m, 3H), 1.63 (s, 3H), 1.44-1.41 (m, 4H), 1.22 (t, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.455 min, m/z found 1033.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-1-yl)methyl)phenethyl)acetamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.91 (s, 1H), 9.62-9.38 (m, 3H), 8.31 (d, J=2.4 Hz, 1H), 7.50-7.33 (m, 8H), 7.19-7.09 (m, 4H), 6.76-6.75 (m, 1H), 6.26-6.24 (m, 1H), 4.51-4.49 (m, 1H), 4.21-3.92 (m, 2H), 3.44-3.25 (m, 2H), 2.98-2.82 (m, 7H), 2.68-2.66 (m, 4H), 2.41 (s, 3H), 1.73-1.71 (m, 3H), 1.68-1.66 (m, 3H), 1.35-1.33 (m, 2H), 0.94 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.172 min, m/z found 924.3 [M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-(4-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(methyl)amino)methyl)phenoxy)ethyl)-N-methylacetamide, formic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H), 9.75-9.30 (m, 2H), 8.37 (s, 3H), 7.43-7.12 (m, 11H), 6.95-6.90 (m, 2H), 6.76 (s, 1H), 6.26 (s, 1H), 4.58-4.55 (m, 1H), 4.31-4.24 (m, 1H), 4.06-4.04 (m, 1H), 3.45 (s, 3H), 3.42 (s, 3H), 3.27 (s, 2H), 2.95-2.92 (m, 2H), 2.59 (s, 3H), 2.42-2.41 (m, 3H), 2.04 (s, 3H), 1.62 (d, J=9.2 Hz, 3H), 0.91 (d, J=7.2 Hz, 6H). LCMS (ESI): R_(T)=1.403 min, m/z found 900.2[M−HCOOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-(((4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)(ethyl)amino)methyl)phenoxy)propyl)acetamide, formic acid

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 1H), 9.81-9.32 (m, 2H), 8.44-8.29 (m, 4H), 7.42-7.33 (m, 7H), 7.22-7.12 (m, 4H), 6.85 (d, J=8.4 Hz, 2H), 6.74 (s, 1H), 6.27 (s, 1H), 4.52-4.49 (m, 1H), 3.99-3.96 (m, 2H), 3.49 (s, 2H), 3.45 (s, 2H), 3.20-3.14 (m, 1H), 2.95-2.91 (m, 1H), 2.59 (s, 3H), 2.42-2.33 (m, 6H), 1.91-1.97 (m, 2H), 1.59 (s, 3H), 0.96 (t, J=7.2 Hz, 3H), 0.89 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.398 min, m/z found 914.2[M−HCOOH+H]⁺.

(S)-4-(4-(((4-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-methylacetamido)ethoxy)benzyl)(methyl)amino)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, formic acid

¹H NMR (400 MHz, CD₃OD): δ 7.54-7.42 (m, 2H), 7.41-7.29 (m, 8H), 7.08-7.02 (m, 2H), 6.74 (s, 1H), 6.26 (d, J=1.6 Hz, 1H), 4.76-4.72 (m, 1H), 4.57 (s, 3H), 4.22-4.21 (m, 1H), 4.08-3.96 (m, 6H), 3.40 (s, 2H), 3.13 (s, 2H), 3.01-2.89 (m, 1H), 2.68 (s, 3H), 2.55 (s, 3H), 2.44 (s, 4H), 1.68 (d, J=6.4 Hz, 3H), 0.89 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)1.457 min, m/z found 1009.2[M−HCOOH+H]⁺.

(S)-4-(4-(((4-(3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propoxy)benzyl)(ethyl)amino)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2,2,2-trifluoroethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.71-9.63 (m, 3H), 8.32-8.31 (m, 1H), 7.57-7.45 (m, 2H), 7.43-7.37 (m, 8H), 7.02 (d, J=8.4 Hz, 2H), 6.77 (s, 1H), 6.29 (s, 1H), 4.52-4.49 (m, 1H), 4.32-4.23 (m, 4H), 4.06-3.94 (m, 4H), 3.31-3.24 (m, 4H), 2.96-2.91 (m, 3H), 2.59 (s, 3H), 2.40 (s, 3H), 1.93-1.90 (m, 2H), 1.61 (s, 3H), 1.24 (t, J=7.2 Hz, 3H), 0.90 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.456 min, m/z found 1023.2[M−CF₃COOH+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one acetate

¹H NMR (400 MHz, DMSO-d₆): δ 11.92 (s, 2H), 9.58 (s, 1H), 9.40 (s, 1H), 7.50-7.42 (m, 4H), 7.30 (d, J=8.0 Hz, 2H), 7.14 (d, J=8.0 Hz, 2H), 6.77 (s, 1H), 6.27 (s, 1H), 4.59-4.55 (m, 1H), 4.36-4.32 (m, 1H), 4.13-4.10 (m, 1H), 3.60-3.58 (m, 1H), 3.46 (s, 1H), 3.38-3.32 (m, 6H), 3.11-2.95 (m, 2H), 2.51-2.50 (m, 4H), 2.41-2.33 (m, 8H), 2.15 (s, 2H), 1.91 (s, 3H), 1.81-1.68 (m, 3H), 1.63 (s, 3H), 1.24-1.22 (m, 1H), 0.94 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.512 min, m/z found 889.3[M-CH₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-N-(2-(diethylamino)ethyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.72 (s, 1H), 9.22-9.10 (m, 2H), 7.51-7.30 (m, 8H), 6.77 (s, 1H), 6.34 (s, 1H), 4.58 (t, J=6.7 Hz, 1H), 4.46-4.35 (m, 1H), 4.20-4.10 (m, 1H), 3.70-3.65 (m, 3H), 3.35-3.16 (m, 8H), 3.10-2.80 (m, 7H), 2.67 (s, 3H), 2.42 (s, 3H), 2.34-2.23 (m, 6H), 1.85-1.70 (m, 3H), 1.63 (s, 3H), 1.18 (d, J=6.9 Hz, 6H), 0.89 (t, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.275 min, m/z found 1001.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-isopropyl-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ9.69 (s, 1H), 7.51-7.28 (m, 8H), 6.62 (s, 1H), 6.31 (s, 1H), 4.59-3.92 (m, 4H), 3.77-3.61 (m, 13H), 3.26-2.88 (m, 8H), 2.67 (s, 3H), 2.38 (s, 3H), 2.33-2.22 (m, 2H), 1.87-1.72 (m, 2H), 1.63 (s, 3H), 1.13-1.06 (m, 6H), 0.89-0.85 (m, 3H). LCMS (ESI): R_(T)=1.200 min, m/z found 944.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 8.29 (s, 1H), 7.71 (s, 1H), 7.51-7.32 (m, 9H), 6.61 (s, 1H), 6.36 (s, 3H), 4.58 (t, J=6.7 Hz, 1H), 4.46-4.33 (m, 1H), 4.22-4.10 (m, 1H), 3.68-3.55 (m, 6H), 3.20-2.80 (m, 6H), 2.75-2.67 (m, 2H), 2.67 (s, 3H), 2.41 (s, 3H), 2.32-2.24 (m, 3H), 2.05-1.98 (m, 1H), 1.75-1.65 (m, 3H), 1.63 (s, 3H), 1.20-1.10 (m, 3H), 0.86 (t, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.117 min, m/z found 902.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-(2-(piperidin-1-yl)ethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ7.55-7.40 (m, 8H), 6.70 (s, 1H), 6.31 (s, 1H), 5.11-5.00 (m, 6H), 4.75-4.20 (m, 2H), 3.88-3.39 (m, 12H), 2.97-2.91 (m, 8H), 2.74-2.70 (m, 3H), 2.45-2.44 (m, 3H), 1.94-1.68 (m, 11H), 1.63-1.20 (m, 3H), 0.92-0.90 (m, 2H). LCMS (ESI): R_(T)=0.915 min, m/z found 1027.6 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-isopropyl-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.76 (s, 1H), 8.93-8.75 (m, 1H), 7.50-7.31 (m, 9H), 6.60 (s, 1H), 6.34 (s, 1H), 4.70-3.85 (m, 4H), 3.62-3.45 (m, 2H), 3.20-2.92 (m, 9H), 2.78-2.57 (m, 5H), 2.42-2.00 (m, 7H), 1.87-1.60 (m, 8H), 1.11-1.07 (m, 6H), 0.95-0.75 (m, 6H). LCMS (ESI): R_(T)=1.196 min, m/z found 958.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 1H), 8.32 (s, 1H), 7.72 (s, 1H), 7.51-7.37 (m, 8H), 6.20 (s, 1H), 6.34 (s, 1H), 4.60-4.12 (m, 3H), 3.17-2.93 (m, 11H), 2.67-2.50 (m, 4H), 2.41-2.33 (m, 4H), 2.05-2.02 (m, 6H), 1.63 (s, 3H), 1.23-0.84 (m, 10H). LCMS (ESI): R_(T) 1.136 min, m/z found 916.2[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxyphenyl)-N-(2-(piperidin-1-yl)ethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.27-9.25 (m, 2H), 7.51-7.29 (m, 9H), 6.92-6.90 (m, 2H), 6.21-6.18 (m, 2H), 4.60-4.56 (m, 1H), 4.41-4.35 (m, 1H), 4.22-4.18 (m, 1H), 3.57-3.50 (m, 5H), 3.42-3.19 (m, 3H), 2.94-2.86 (m, 5H), 2.60 (s, 3H), 2.44-2.33 (m, 8H), 2.23-2.05 (m, 2H), 1.87-1.56 (m, 12H), 1.26-0.99 (m, 5H). LCMS (ESI): R_(T)=1.131 min, m/z found 985.5[M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-N-(2-(diethylamino)ethyl)-5-(2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.24-9.22 (m, 3H), 7.52-7.29 (m, 9H), 6.91 (d, J=8.4 Hz, 1H), 6.22-6.17 (m, 2H), 4.60-4.55 (m, 1H), 4.38-4.33 (m, 2H), 4.21-4.13 (m, 2H), 3.69-3.51 (m, 4H), 3.42-3.32 (m, 1H), 3.25-2.80 (m, 15H), 2.60 (s, 4H), 2.42 (s, 5H), 2.04 (s, 1H), 1.89-1.69 (m, 2H), 1.63 (s, 3H), 1.21-1.16 (m, 6H). LCMS (ESI): R_(T) 0.946 min, m/z found 973.3 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.15-9.51 (m, 1H), 8.84 (s, 1H), 8.31 (s, 1H), 7.51-7.26 (m, 9H), 7.01-6.83 (m, 1H), 6.29-6.14 (m, 2H), 4.60-4.55 (m, 1H), 4.39-4.33 (m, 1H), 4.20-4.14 (m, 2H), 3.67-3.61 m, 6H), 3.42-3.33 (m, 2H), 3.15-2.92 (m, 6H), 2.68-2.58 (m, 5H), 2.42 (s, 4H), 2.05 (s, 1H), 1.88-1.71 (m, 2H), 1.63 (s, 3H), 1.31-0.96 (m, 2H). LCMS (ESI): R_(T)=1.190 min, m/z found 874.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-N-(2-(piperidin-1-yl)ethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.72 (s, 1H), 9.62-9.60 (m, 1H), 9.00 (s, 1H), 7.51-7.33 (m, 10H), 6.77 (s, 1H), 6.30 (s, 1H), 4.58 (t, J=6.7 Hz, 2H), 4.30-4.20 (m, 2H), 4.15-4.10 (m, 2H), 3.63-3.50 (m, 7H), 3.20-3.17 (m, 2H), 2.91-2.88 (m, 4H), 2.60 (s, 3H), 2.42 (s, 3H), 2.33-2.27 (m, 4H), 1.83-1.60 (m, 14H), 1.20-1.10 (m, 2H), 0.91-0.87 (m, 4H). LCMS (ESI): R_(T)=0.996 min, m/z found 1013.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-N-(2-(diethylamino)ethyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.55-7.38 (m, 8H), 6.70 (s, 1H), 6.31 (s, 1H), 4.76-4.68 (m, 5H), 4.30-4.20 (m, 1H), 3.86-3.50 (m, 11H), 3.12-2.96 (m, 10H), 2.71 (s, 3H), 2.45 (s, 3H), 2.20-2.10 (m, 1H), 1.98-1.90 (m, 2H), 1.70 (s, 3H), 1.40-1.38 (m, 1H), 1.31 (t, J=6.8 Hz, 6H), 0.90 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.005 min, m/z found 1015.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxyphenyl)-N-isopropyl-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, CD₃OD): δ 7.46-7.26 (m, 9H), 6.87 (d, J=8.8 Hz, 1H), 6.22 (d, J=2.4 Hz, 1H), 6.18 (dd, J₁=8.4 Hz, J₂=2.4 Hz, 1H), 4.70-4.50 (m, 3H), 4.28-4.26 (m, 2H), 4.04-4.02 (m, 1H), 3.65-3.58 (m, 4H), 3.30-3.23 (m, 1H), 2.72-2.62 (m, 12H), 2.44-2.39 (m, 5H), 1.94-1.91 (m, 3H), 1.69 (s, 3H), 1.20 (d, J=6.8 Hz, 6H). LCMS (ESI): R_(T)=1.411 min, m/z found 916.2 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide hydrochloride

¹H NMR (400 MHz, CD₃OD): δ 7.89-7.87 (m, 2H), 7.67-7.60 (m, 6H), 6.83-6.81 (m, 1H), 6.46-6.43 (m, 1H), 5.13-5.11 (m, 1H), 4.65-4.59 (m, 3H), 4.22-4.21 (m, 1H), 3.93-3.71 (m, 9H), 3.31-3.28 (m, 8H), 3.01 (s, 3H), 2.87-2.82 (m, 1H), 2.36-2.32 (m, 3H), 2.13-2.01 (m, 2H), 1.72 (s, 3H), 1.55-1.29 (m, 2H), 0.93-0.91 (m, 3H). LCMS (ESI): R_(T)1.130 min, m/z found 902.2[M−HCl+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(5-ethyl-2,4-dihydroxyphenyl)-4H-1,2,4-triazole-3-carboxamide hydrochloride

¹H NMR (400 MHz, CD₃OD): δ 7.89-7.87 (m, 2H), 7.67-7.60 (m, 6H), 6.83-6.81 (m, 1H), 6.46-6.43 (m, 1H), 5.13-5.11 (m, 1H), 4.65-4.59 (m, 3H), 4.22-4.21 (m, 1H), 3.93-3.71 (m, 9H), 3.31-3.28 (m, 8H), 3.01 (s, 3H), 2.87-2.82 (m, 1H), 2.36-2.32 (m, 3H), 2.13-2.01 (m, 2H), 1.72 (s, 3H), 1.55-1.29 (m, 2H), 0.93-0.91 (m, 3H). LCMS (ESI): R_(T)1.130 min, 937.34 m/z found 902.2[M−HCl+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-propylphenyl)-N-(2-(piperidin-1-yl)ethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.70 (s, 1H), 9.25 (s, 1H), 9.05 (s, 1H), 7.51-7.32 (m, 8H), 6.66 (s, 1H), 6.30 (s, 1H), 4.59-4.56 (m, 1H), 4.35-4.33 (m, 4H), 4.17-4.15 (m, 4H), 3.55-3.53 (m, 2H), 3.50-3.49 (m, 6H), 3.30-3.28 (m, 2H), 3.18-3.16 (m, 2H), 3.11-2.95 (m, 6H), 2.60 (s, 3H), 2.50 (s, 3H), 2.25-2.23 (m, 2H), 1.63-1.60 (m, 6H), 1.58 (s, 3H), 1.33-1.31 (m, 4H), 1.10-1.08 (m, 2H), 0.75-0.72 (m, 3H). LCMS (ESI): R_(T) 1.066 min, m/z found 1027.5 [M−CF₃COOH+H]⁺.

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-methylphenyl)-N-(2-(piperidin-1-yl)ethyl)-4H-1,2,4-triazole-3-carboxamide, trifluoroacetic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.25 (s, 1H), 9.02 (s, 1H), 7.52-7.47 (m, 2H), 7.46-7.41 (m, 2H), 7.40-7.35 (m, 2H), 7.33-7.28 (m, 2H), 6.72 (s, 1H), 6.28 (s, 1H), 4.60-4.54 (m, 1H), 4.40-4.32 (m, 1H), 4.22-4.13 (m, 1H), 3.25-3.09 (m, 10H), 3.05-2.78 (m, 12H), 2.59 (s, 3H), 2.41 (s, 3H), 2.11-1.94 (m, 3H), 1.88 (s, 4H), 1.83-1.62 (m, 12H). LCMS (ESI): R_(T)=1.017 min, m/z found 999.4 [M−CF₃COOH+H]⁺.

(R)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one hydrochloride

¹H NMR (400 MHz, DMSO-d₆): δ 11.95 (s, 1H), 11.26 (s, 1H), 9.62 (s, 1H), 9.31 (s, 1H), 7.64-7.44 (m, 6H), 7.25 (d, J=8.4 Hz, 2H), 6.93 (s, 1H), 6.31 (s, 1H), 4.63 (t, J=6.7 Hz, 1H), 4.41-4.15 (m, 3H), 3.79-3.40 (m, 12H), 3.43-3.00 (m, 4H), 2.76-2.55 (m, 5H), 2.42 (s, 3H), 2.05-2.02 (m, 1H), 1.90-1.68 (m, 2H), 1.63 (s, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): Rt=1.088 min, m/z found 889.6 [M−HCl+H⁺].

(S)-4-(4-((4-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)phenyl)-5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethylisoxazole-3-carboxamide hydrochloride

¹H NMR (400 MHz, DMSO-d₆): 9.85 (s, 1H), 9.67 (s, 1H), 8.93-8.90 (m, 1H) 7.52-7.31 (m, 8H), 6.82 (s, 1H), 6.48 (s, 1H), 4.60 (t, J=6.7 Hz, 1H), 4.37-4.23 (m, 2H), 4.17-4.02 (m, 2H), 3.74-2.98 (m, 19H), 2.67-2.65 (m, 4H), 2.42 (s, 3H), 2.16-2.14 (m, 1H), 1.94-1.92 (m, 2H), 1.63 (s, 3H), 1.23-1.11 (m, 3H), 0.98 (d, J=6.9 Hz, 6H). LCMS (ESI): R_(T)=1.420 min, m/z found 944.6[M−HCl+H]⁺.

(S)-1-((2S,5S)-14-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2-cyclohexyl-5-methyl-4,13-dioxo-9-oxa-3,6,12-triazatetradecanoyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 8.85-8.71 (m, 3H), 8.23-8.21 (m, 1H), 7.74-7.41 (m, 9H), 4.84-4.82 (m, 1H), 4.53-4.50 (m, 1H), 4.38-4.36 (m, 1H), 4.01-3.92 (m, 1H), 3.79-3.48 (m, 5H), 3.32-3.26 (m, 3H), 3.07-3.05 (m, 1H), 2.60 (s, 3H), 2.41 (s, 5H), 2.18-2.16 (m, 1H), 2.01-1.98 (m, 4H), 1.89-1.62 (m, 10H), 1.32 (d, J=6.8, 3H), 1.23-0.94 (m, 6H). LCMS (ESI): R_(T)=1.304 min, m/z found 954.2[M+H]⁺.

(S)-1-((2S,5S)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2-cyclohexyl-5-methyl-4,16-dioxo-9,12-dioxa-3,6,15-triazaheptadecanoyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 11.93 (s, 1H), 8.84-8.69 (m, 3H), 8.27-8.26 (m, 1H), 7.73-7.41 (m, 9H), 4.84-4.83 (m, 1H), 4.52-4.48 (m, 1H), 4.40-4.35 (m, 1H), 3.95-3.93 (m, 1H), 3.71-3.70 (m, 1H), 3.68-3.65 (m, 2H), 3.58 (s, 3H), 3.46-3.45 (m, 2H), 3.29-3.23 (m, 3H), 3.18-2.96 (m, 1H), 2.59 (s, 3H), 2.41 (s, 3H), 2.18-2.16 (m, 1H), 2.01-1.87 (m, 4H), 1.74-1.62 (m, 9H), 1.32-1.28 (m, 7H), 1.23 (s, 3H). LCMS (ESI): R_(T)=1.297 min, m/z found 998.1[M+H]⁺.

(S)-1-((S)-2-((S)-2-(((1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)methyl)amino)propanamido)-2-cyclohexylacetyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide

¹H NMR (400 MHz, CD₃OD): δ 7.75-7.74 (m, 2H), 7.72-7.52 (m, 3H), 7.46-7.41 (m, 4H), 4.83-4.79 (m, 2H), 4.71-4.69 (m, 1H), 4.61-4.49 (m, 2H), 4.40-4.25 (m, 1H), 3.97-3.94 (m, 2H), 3.81-3.76 (m, 1H), 3.69-3.51 (m, 3H), 3.01-2.95 (m, 1H), 2.86-2.81 (m, 1H), 2.73-2.71 (m, 4H), 2.45 (s, 3H), 2.21-2.10 (m, 3H), 2.05-2.01 (m, 4H), 1.84-1.69 (m, 11H), 1.50 (d, J=7.2 Hz, 3H), 1.33-1.08 (m, 9H). LCMS (ESI): R_(T)=1.316 min, m/z found 964.1 [M+H]⁺.

(S)-1-((S)-2-((S)-2-((2-(1-(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)ethyl)amino)propanamido)-2-cyclohexylacetyl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)pyrrolidine-2-carboxamide

¹H NMR (400 MHz, CD₃OD): δ 7.74-7.72 (m, 2H), 7.61-7.52 (m, 3H), 7.46-7.40 (m, 4H), 5.35-5.33 (m, 1H), 4.69-4.67 (m, 1H), 4.53-4.50 (m, 1H), 4.42-4.39 (m, 1H), 3.96-3.94 (m, 2H), 3.81-3.76 (m, 1H), 3.64-3.47 (m, 3H), 3.23-2.96 (m, 2H), 2.71-2.70 (m, 4H), 2.45 (s, 3H), 2.21-2.02 (m, 6H), 1.83-1.60 (m, 11H), 1.49-1.43 (m, 3H), 1.36-1.07 (m, 12H), 0.91-0.88 (m, 1H). LCMS (ESI): R_(T)=1.322 min, m/z found 978.2 [M+H]⁺.

(S)—N-(4′-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)piperidin-4-yl)oxy)-2′-hydroxy-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.15 (s, 1H), 9.62 (s, 1H), 8.00-7.96 (m, 2H), 7.77-7.76 (m, 2H), 7.53-7.47 (m, 5H), 7.38-7.36 (m, 1H), 7.35-7.27 (m, 2H), 7.12-7.11 (m, 2H), 7.10-7.09 (m, 1H), 6.58-6.55 (m, 2H), 4.58-4.56 (m, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.43-3.42 (m, 8H), 2.67-2.66 (m, 2H), 2.62 (s, 3H), 2.44 (s, 3H), 2.32-2.31 (m, 2H), 1.64-1.62 (m, 3H). LCMS (ESI): R_(T)=1.378 min, m/z found 893.2[M+H]⁺.

(S)—N-(4′-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)oxy)-2′-hydroxy-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.14 (s, 1H), 9.54 (s, 1H), 7.98-7.97 (m, 2H), 7.77-7.75 (m, 2H), 7.50-7.25 (m, 12H), 7.13-7.10 (m, 1H), 6.56-6.54 (m, 1H), 4.60-4.58 (m, 2H), 3.87-3.71 (m, 8H), 3.68-3.60 (m, 4H), 3.55-3.52 (m, 1H), 3.51 (s, 3H), 3.49-3.48 (m, 4H), 3.44-3.42 (m, 1H), 1.65-1.63 (m, 3H). LCMS (ESI): R_(T)=1.777 min, m/z found 907.7[M+H]⁺.

(S)—N-(4′-((1-((S)-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)glycyl)piperidin-4-yl)oxy)-2′-hydroxy-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.14 (br s, 1H), 9.52 (s, 1H), 8.03-7.98 (m, 2H), 7.76-7.74 (m, 2H), 7.49-6.94 (m, 12H), 6.63-6.51 (m, 2H), 4.53-4.51 (m, 2H), 4.06-4.05 (m, 2H), 3.86-3.51 (m, 7H), 3.30-3.20 (m, 4H), 2.68-2.66 (m, 2H), 2.59 (s, 3H), 2.45 (s, 3H), 2.45-2.32 (m, 3H), 1.24-1.21 (m, 3H). LCMS (ESI): R_(T)=1.629 min, m/z found 964.7 [M+H]⁺.

(S)—N-(2′-(2-((2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)(methyl)amino)ethoxy)-4′-((1-methylpiperidin-4-yl)oxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.18-10.01 (m, 2H), 8.02-7.95 (m, 2H), 7.82-7.68 (m, 2H), 7.45-6.97 (m, 15H), 4.83 (s, 1H), 4.44-4.41 (m, 4H), 3.86 (s, 3H), 3.79 (s, 3H), 3.67-3.59 (m, 2H), 3.54-3.48 (m, 2H), 3.39-3.30 (m, 2H), 3.24-3.06 (m, 2H), 2.89-2.78 (m, 6H), 2.74-2.66 (m, 2H), 2.58-2.54 (m, 3H), 2.35-2.29 (m, 3H), 2.11-2.06 (m, 2H), 1.89-1.81 (m, 1H), 1.56 (d, J=5.2 Hz, 3H). LCMS (ESI): R_(T) 1.099 min, m/z found 964.4[M+H]⁺.

(S)—N-(2′-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-methylacetamido)ethoxy)-4′-((1-methylpiperidin-4-yl)oxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.18-10.05 (m, 1H), 9.50-9.28 (m, 1H), 8.04-7.92 (m, 2H), 7.79-7.73 (m, 2H), 7.51-6.66 (m, 14H), 4.81 (s, 1H), 4.63-4.25 (m, 1H), 4.30 (s, 1H), 4.15-4.05 (m, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.44-3.39 (m, 3H), 3.37-3.28 (m, 3H), 3.15-3.10 (m, 3H), 2.87-2.79 (m, 4H), 2.57-2.53 (m, 2H), 2.37 (s, 2H), 2.34-2.24 (m, 3H), 2.14-1.90 (m, 3H), 1.79-1.69 (m, 1H), 1.55 (d, J=12.4 Hz, 3H). LCMS (ESI): R_(T)=1.251 min, m/z found 978.4 [M+H]⁺.

(S)—N-(2′-(2-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)-N-methylacetamido)ethoxy)-4′-((1-methylpiperidin-4-yl)oxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, D MSO-d₆): δ 10.21-10.11 (m, 1H), 9.54-9.35 (m, 1H), 8.35-7.96 (m, 3H), 7.75 (d, J=7.2 Hz, 2H), 7.45-6.69 (m, 16H), 4.80-4.43 (m, 2H), 4.14-4.09 (m, 4H), 3.85-3.83 (m, 3H), 3.79-3.75 (m, 3H), 3.37-3.32 (m, 2H), 3.24-3.15 (m, 2H), 2.91-2.81 (m, 7H), 2.58-2.56 (m, 3H), 2.38-2.36 (m, 3H), 2.15-1.95 (m, 3H), 1.82-1.69 (m, 1H), 1.56 (d, J=11.2 Hz, 3H). LCMS (ESI): R_(T) 1.214 min, m/z found 1035.3 [M+H]⁺.

(S)—N-(4′-((1-((S)-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)glycyl)piperidin-4-yl)oxy)-2′-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 9.60 (s, 1H), 8.36-8.35 (m, 1H), 8.00-7.77 (m, 4H), 7.45-6.74 (m, 18H), 4.53 (s, 1H), 4.51-4.49 (m, 1H), 4.30 (s, 2H), 4.05-4.04 (m, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.28-3.18 (m, 2H), 2.75-2.74 (m, 7H), 2.58 (s, 3H), 2.39 (s, 3H), 1.97-1.96 (m, 2H), 1.65-1.50 (m, 5H). LCMS (ESI): R_(T)=1.253 min, m/z found 1035.3 [M+H]⁺.

(S)—N-(4′-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)piperidin-4-yl)oxy)-2′-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.16 (s, 1H), 8.28 (s, 1H), 8.03-7.98 (m, 2H), 1.78-7.75 (m, 2H), 7.51-7.37 (m, 7H), 7.27-7.23 (m, 2H), 7.13-7.10 (m, 2H), 6.96-6.72 (m, 3H), 4.74-4.58 (m, 2H), 4.07-3.86 (m, 7H), 3.80 (s, 3H), 3.65-3.37 (m, 6H), 2.60 (s, 3H), 2.42 (s, 3H), 2.33 (s, 6H), 2.19-1.76 (m, 3H), 1.63 (s, 3H), 1.62-1.50 (m, 1H). LCMS (ESI): R_(T)=1.303 min, m/z found 978.3[M+H]⁺.

(S)—N-(4′-((1-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)piperidin-4-yl)oxy)-2′-(2-(dimethylamino)ethoxy)-[1,1′-biphenyl]-4-yl)-3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxamide

¹H NMR (400 MHz, DMSO-d₆): δ 10.21-9.96 (m, 3H), 7.97-7.80 (m, 4H), 7.52-7.37 (m, 7H), 7.30-7.25 (m, 2H), 7.13-6.97 (m, 3H), 4.88-4.70 (m, 1H), 4.34 (s, 3H), 3.86 (s, 3H), 3.76 (s, 3H), 3.71-3.44 (m, 6H), 3.30-3.29 (m, 2H), 2.94-2.77 (m, 8H), 2.62 (s, 3H), 2.41 (s, 3H), 2.14-1.85 (m, 4H), 1.63 (s, 3H). LCMS (ESI): R_(T)=1.152 min, m/z found 964.3[M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(2,4-dihydroxy-5-isopropylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 10.01-9.64 (m, 3H), 7.51-7.44 (m, 7H), 7.04 (s, 1H), 6.41 (s, 1H), 4.83 (s, 4H), 4.56-4.40 (m, 5H), 3.45-2.95 (m, 8H), 2.60 (s, 3H), 2.42 (s, 3H), 1.63 (s, 3H), 1.24-1.13 (m, 6H). LCMS (ESI): R_(T) 1.420 min, m/z found 778.3 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(5-ethyl-2,4-dihydroxybenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 10.10-10.09 (m, 2H), 9.63 (s, 1H), 7.51-7.42 (m, 8H), 7.04 (s, 1H), 6.41 (s, 1H), 4.83 (s, 4H), 4.58-4.38 (m, 5H), 3.21-2.92 (m, 4H), 2.69-2.60 (m, 4H), 2.47-2.42 (m, 3H), 2.33 (s, 3H), 1.63 (s, 3H), 1.12-1.08 (m, 3H). LCMS (ESI): R_(T)1.093 min, m/z found 764.2[M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(2,4-dihydroxybenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 10.52 (s, 1H), 9.94 (s, 1H), 7.57-7.49 (m, 4H), 7.38-7.25 (m, 4H), 6.40-6.34 (m, 2H), 4.85 (s, 4H), 4.63 (t, J=6.7 Hz, 1H), 3.71-3.63 (m, 3H), 3.58-3.55 (m, 5H), 2.74-2.66 (m, 4H), 2.51-2.40 (m, 6H), 1.69 (s, 3H). LCMS (ESI): Shimadzu LCMS-021 R_(T)=1.104 min, m/z found 736.2[M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(2,4-dihydroxy-5-methylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.80 (s, 1H), 7.56-7.25 (m, 10H), 6.42 (s, 1H), 4.88-4.86 (m, 4H), 3.78-4.56 (m, 2H), 3.65-3.60 (m, 3H), 3.30-3.27 (m, 4H), 2.66 (s, 3H), 2.50 (s, 3H), 2.41-2.33 (m, 2H), 2.03 (s, 3H), 1.72 (s, 3H). LCMS (ESI): R_(T)=1.223 min, m/z found 750.6 [M+H]⁺.

(S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-1-(4-((2-(2,4-dihydroxy-5-propylbenzoyl)isoindolin-5-yl)methyl)piperazin-1-yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆): δ 10.20-10.10 (m, 2H), 9.62 (s, 1H), 7.51-7.42 (m, 1H), 7.01 (s, 1H), 6.41 (s, 1H), 4.83-4.72 (m, 4H), 4.53-4.35 (m, 5H), 3.82-3.40 (m, 8H), 3.20-2.80 (m, 4H), 2.60 (s, 3H), 2.41 (s, 3H), 2.47-2.41 (m, 1H), 1.63 (s, 3H), 1.54-1.48 (m, 2H), 0.88 (t, J=6.8 Hz, 3H). LCMS (ESI): R_(T)=0.860 min, m/z found 778.6 [M+H]⁺.

Example 2: Testing of Various T-PEACH Molecules Materials and Methods HSP90α Binding Fluorescent Polarization (FP) Assay

A master mix was prepared with assay buffer, BSA and FITC-geldanamycin. In a 96-well plate, a serial 3-fold dilution of each compound was prepared ranging from 40 μM down until 2.0 nM. Also in a 96-well plate, recombinant HSP90α protein was diluted to 28 μg/ml. Then, in a 384-well plate, 10 μl of master mix and 5 μl of compound dilution were added per well to duplicate wells and mixed by brief shaking. Then 5 μl of diluted HSP90α protein was added per well, mixed by brief shaking, incubated at 25° C. for 30, 60 and 120 min and fluorescence was measured on an EnVision Plate Reader. Background-subtracted mP values were calculated from EnVision raw data and a four-parameter “log[inhibitor] vs. response” curve was fitted using GraphPad Prism 7.0.

Bromodomain Binding Assay

T7 phage strains displaying different human bromodomain proteins were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection=0.4) and incubated with shaking at 32° C. until lysis (90-150 min). The lysates were centrifuged at 5,000×g and 0.2 μm filtered to remove cell debris. Streptavidin-coated magnetic beads were treated with biotinylated small molecule or acetylated peptide ligands for 30 min at room temperature to generate affinity resins for bromodomain assays. The liganded beads were blocked with excess biotin and washed with SEA BLOCK blocking buffer (Pierce Scientific), with 1% BSA, 0.05% Tween 20 and 1 mM DTT to remove unbound ligand and to reduce non-specific phage binding. Binding reactions were assembled by combining bromodomains, liganded affinity beads and test compounds in 1× binding buffer (16% SEA BLOCK, 0.32×PBS, 0.02% BSA, 0.04% Tween 20, 0.004% sodium azide and 7.9 mM DTT). Test compounds were prepared as 1000× stocks in 100% DMSO and subsequently diluted 1:25 in monoethylene glycol (MEG). The compounds were then diluted directly into the assays such that the final concentrations of DMSO and MEG were 0.1% and 2.4%, respectively. All reactions were performed in polypropylene 384-well plates in a final volume of 0.02 mL. The assay plates were incubated at room temperature with shaking for 1 hr and the affinity beads were washed with wash buffer (1×PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1×PBS, 0.05% Tween 20, 2 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The bromodomain concentration in the eluates was measured by qPCR. Percent control of the compound was determined by the following equation:

% Ctrl=(SignalCOMPOUNDS−SignalPC)/(SignalNC−SignalPC)

BRD4 Binding Homogeneous Time Resolved Fluorescence (HTRF) Assay

A master mix was prepared with assay buffer, 1.8 μg/ml recombinant BRD4 (BD1+BD2 domains) protein, and 200-fold dilutions of Tb-labeled donor and dye-labeled acceptor. 40-fold dilutions of acetylated and non-acetylated ligands were prepared in 1×BRD TR-FRET assay buffer. Also, a serial 3-fold dilution of each compound was prepared ranging from 40 μM down until 2.0 nM. In a 384-well plate, 5 μl diluted ligand and 5 μl of compound dilution were added per well to duplicate wells and mixed by brief shaking. Then 10 μl of master mix was added per well, mixed by brief shaking, incubated at 25° C. for 2 hr and fluorescence was measured on an EnVision Plate Reader. The 665 nm/615 nm ratio was calculated from EnVision raw data. Data were normalized using whole-plate averages of “positive” and “negative” readings. A four-parameter “log[inhibitor] vs. response” curve was fitted using GraphPad Prism 7.0.

Protein Degradation Flow Cytometry

MV4-11 cells were plated in a 24-well tissue culture plate at a density of 350,000 cells/450 μL/well and incubated in 37° C./5% CO2 for 1 hr. Cells were then treated with compounds at various concentrations and incubated in 37° C./5% CO2 for 24 hr. Cells were harvested, washed once, counted and 200 μL of 1% paraformaldehyde/PBS was added and incubated for 15 min at room temperature. 200 μL of 1×PBS/0.4% Triton X-100 was added and incubated for 15 min at 4° C. Cells were washed three times and resuspended in 50 μL of 1×PBS/0.2% Triton X-100. 2 μL/10⁶ cells of anti-BRD4 antibody (ABCAM, #128874) was added and mixed by pipetting up and down. Cells were incubated for 30 min at room temperature in the dark, washed three times and resuspended in 50 μL of 1×PBS/0.2% Triton X-100. Goat anti-rabbit IgG H&L antibody (1:2000 dilution) was added and mixed by pipetting up and down and incubated for 30 min at room temperature in the dark. Finally, cells were washed three times and resuspended in 200 μL of PBS for flow cytometric analysis. Inhibition efficiency of the compound was determined by the following equation and analyzed using GraphPad Prism 7.0:

% Inhibition=100−(D−B)/(S−B)*100%.

S: The fluorescence intensity of MV4-11 with antibody

D: The fluorescence intensity in the presence of different compound dilutions with antibody

B: The fluorescence intensity of MV4-11 only

Similar flow cytometry experiments for ERBB2 in BT-474 human breast carcinoma cells (ATCC, #HTB-20) and IGF1R, EGFR and RAF1 in HEK-293 human embryonic kidney (ATCC, #CRL-1573) were performed using anti-ERBB2 (R&D, #FAB1129P), anti-IGF1R (Cell Signaling Technology, #9750), anti-EGFR (Cell Signaling Technology, #139690) and anti-RAF1 (ABCAM, #ab181115) antibodies.

Western Blotting

MV4-11 human acute myeloid leukemia cells (ATCC, #CRL-9591) were seeded in 6-well tissue culture plates and after 1 hr, compounds were added at various concentrations and incubated at 37° C./5% CO2 for 24 hr. Cells were then collected by centrifugation, washed one time with cold PBS, supernatants aspirated and cell pellets lysed with 4° C. RIPA lysis buffer containing a protease/phosphatase inhibitor cocktail. The total protein concentrations of cell lysates were determined by BCA Protein Assay kit. Samples were normalized for equivalent protein concentrations, 5× loading buffer added and heated to 100° C. for 10 min and cooled to room temperature. 20 μl of each sample/well was loaded on a SDS-PAGE gel and electrophoresed for 20 min at 80 V, then 120 V for 1.5 hr. Gels were then electroblotted to nitrocellulose membranes using a wet-transfer method at 250 mA for 2.5 hr. Membranes were incubated with blocking buffer for 1 hr and washed 3 times with TBST for 5 min. Then membranes were incubated with anti-BRD4 (Cell Signaling Technology, #13440) and anti-beta-Actin (Cell Signaling Technology, #3700) antibodies diluted in blocking buffer per the manufacturer's recommendation at 4° C. overnight. After washing 3 times, blots were incubated with the appropriate labeled secondary antibody for 1 hr at room temperature and washed again. Images were read on a LI-COR and the optical density values of bands determined by ImageJ software. Data was analyzed using GraphPad Prism 7.0.

Similar western blotting experiments of for BRD2 and BRD3 were performed in MV4-11 cells using anti-BRD2 (Cell Signaling Technology, #139690) and anti-BRD3 (Cell Signaling Technology, #50818).

MYC HTRF Assay

MYC protein expression was measured using the Human c-Myc Cell-based Assay Kit (Cisbio, #63ADK053PEG), a homogeneous time resolved fluorescence (HTRF) assay. MV4-11 cells were plated in a 96-well tissue culture plate at a density of 100,000 cells/90 μL/well and incubated in 37° C./5% CO₂ for 1 hr and then treated with compounds at various concentrations (a 10-point, 3-fold serial dilution series starting at 10 μM) and then incubated in 37° C./5% CO₂ for 24 hr. Cells were collected by centrifugation, supernatant removed by aspiration and 10 μL of lysis buffer was added and incubated for 45 min at room temperature while shaking. In a 384-well plate, 10 μL of cell lysate/well was combined with 10 μL of premixed antibody solution containing anti-human MYC-Eu3+ Cryptate prepared in detection buffer and incubated overnight at room temperature, whereupon the signal was measured. The ratio of the acceptor and donor emission signals for each individual well were calculated (ratio=665 nm/620 nm×104). Inhibition efficiency of each compound was determined by the following the equation and analyzed using GraphPad Prism 7.0:

% Inhibition=100−(D−B)/(S−B)*100%.

S: The ratio of the maximum (positive control)

D: The ratio of the presence of different dilution compound with cells

B: The ratio of the minimum (blank control)

Cell Cytotoxicity Assay

MV4-11 cells were plated in a 96-well tissue culture plate at a density of 4,500 cells/90 μL/well and incubated at 37° C./5% CO₂ for 24 hr. Cells were then treated with compounds at various concentrations (a 10-point, 3-fold serial dilution series starting at 20 M) with a final concentration of 0.5% DMSO/well and then incubated in 37° C./5% CO₂ for 72 hr. 10 μL the cell proliferation reagent CCK-8 (WST-8) was added into each well and incubated at 37° C./5% CO₂ for 3-4 hr and the absorbance at 450 nm measured with an EnVision Plate Reader. Inhibition efficiency of the compound was determined by the following the equation and analyzed using GraphPad Prism 7.0:

% Inhibition=100−(D−B)/(S−B)*100%.

S: The absorbance of the maximum (cells with DMSO)

D: The absorbance of the presence of different dilution compound with cells

B: The absorbance of the minimum (medium with DMSO)

Tumor Xenograft Studies in Mice

MV4-11 acute myeloid leukemia and SU-DHL-4 diffuse large B-cell lymphoma (ATCC, #CRL-2957) cells were cultured in medium supplemented with 10% fetal bovine serum at 37° C./5% CO₂. 5×10⁶ MV-4-11 or 1×10⁷ SU-DHL-4 cells were collected and re-suspended in 0.1 mL of serum-free media with Matrigel (1:1 v/v) per mouse for subcutaneous inoculation in isoflurane anesthetized male BALB/c nude or C.B-17 scid mice, respectively (treated in accordance with AAALAC animal welfare guidelines). When the average tumor volumes reached 100-200 mm³, tumor volume outliers were removed and the remaining animals randomly divided into groups of 6-8 with similar average tumor volumes in each group. Solutions of compound 074 and compound 078 were prepared in 45% PEG300 and 55% normal saline and adjusted to pH 3.0-7.0 with 0.15 M sodium bicarbonate solution. Animals were intravenously dosed at 25 mg/kg, 50 mg/kg or 100 mg/kg 1×/week for 3 or 4 weeks. The appearance and behavior of each mouse was observed and recorded daily. Body weights and tumor volumes were measured and recorded every 2-4 days and the results were expressed as group means±SEM. Pairwise statistical comparisons between groups were performed by one-way ANOVA, and p<0.05 was considered statistically significant.

Pharmacokinetics and Tissue Distribution

A solution of compound 074 was prepared in 30% PEG300 and 70% normal saline and adjusted to pH 3.0-7.0 with 0.15 M sodium bicarbonate solution. 15 female CB-17 SCID mice (treated in accordance with AAALAC animal welfare guidelines) were weighed and administered 5 mg/kg of compound 074 by a single intravenous injection. 0.10 mL of blood was collected from each mouse by submandibular vein and sodium heparin was added as an anticoagulant. Samples were collected before compound administration, and at 1 hr, 6 hr 24 hr and 48 hr time points after administration, with 3 mice sampled per time point. After collection, samples were placed on ice and the animals sacrificed to collect tumor and normal tissues. The method development and analysis of all samples were performed by the analytical laboratory at Shanghai Medicilon Inc. Intra-day accuracy evaluation of samples for quality control was carried out during sample analysis and a quality control accuracy of more than 66.7% of samples was required between to be 80-120%. Pharmacokinetic parameters were calculated using Phoenix WinNonlin7.0 software.

Results

A number of synthetic schemes have been developed to construct various T-PEACH molecules. A representative example is shown as follows between a HSP90 binder and the BET binder (+)-JQ1. Similar chemistry can be applied to other T-PEACH molecules not limited to HSP90 binders and (+)-JQ1.

A HSP90α fluorescent polarization (FP) binding assay measuring competition with FTIC-geldanamycin was applied to assess the binding capability of T-PEACH molecules to HSP90. As shown in Table 1, T-PEACH molecules containing HSP90 binding moieties documented in the literature were generally in agreement with the published structure activity relationship (SAR). Those HSP90 moieties include resorcinol-based, geldanamycin-based, purine-mimicked scaffolds, especially compounds bearing similar structures to ganetespib, 17-AAG, luminespib, SNX-5422, XL-888 and PU-H71.

The incorporation a (+)-JQ1 BET binder of similar molecular weight to the HSP90 binder into the T-PEACHs had only minimal impact on the binding of T-PEACH molecules to HSP90α in this assay. There are a number of reasons: first the co-crystal structures of these moieties with their corresponding proteins are available and allow precise structure-based molecular designs; and secondly, the tether is constructed to provide rigidity with suitable length.

TABLE 1 HSP90α Binding FP Assay Compound ID HSP90 Binding Potency*  1 B  2 A  3 B  4 C  5 B  6 B  7 C  8 C  9 B  10 B  11 A  12 A  13 B  14 B  15 B  16 B  17 B  18 B  19 B  20 C  21 C  22 C  23 C  24 C  25 C  26 C  27 B  28 B  29 C  32 B  33 B  34 C  37 A  38 B  39 B  40 A  41 B  42 B  43 B  44 B  45 A  46 A  47 A  48 A  49 A  50 B  51 B  52 A  53 B  54 A  55 B  56 B  57 B  58 B  59 B  60 B  61 B  62 B  63 B  64 B  65 B  66 B  67 B  68 B  70 B  71 B  72 C  74 B  75 N/A  76 B  77 B  78 B  79 B  80 B  81 B  82 B  83 B  84 B  85 B  86 B  87 B  88 B  89 B  90 B  91 B  92 C  93 B  94 A  95 B  96 B  97 B  98 B  99 B 100 B 101 C 102 C 103 B 104 B 105 B 106 B 107 B 108 C 109 B 110 B 111 B 112 B 117 B 118 B 119 B 120 B 121 A 123 B 124 B 125 A 126 B 127 C 128 C 129 C 130 C 132 C 133 C 134 C 135 C 136 C 137 C 138 C 139 C 140 C 141 B 142 B 143 B 144 B 145 B *A. IC₅₀ < 100 nM; B. IC₅₀ = 100-1000 nM; C. IC₅₀ > 1000 nM There are more than 40 human proteins that contain one or more bromodomain motifs, with each member of the BET family containing two separate bromodomains, termed BD1 and BD2, that can independently bind to acetylated lysines. To assess the ability of compound 074 to bind to a variety of recombinant bromodomain proteins a ligand binding site-directed competition assay was employed. As shown in Table 2, 10 μM compound 074 was able to efficiently compete for ligand binding to both bromodomains present in each of the BRD2, BRD3, BRD4 and BRD4 proteins. However, compound 074 displayed little or no binding to a variety of other bromodomain proteins.

TABLE 2 Bromodomain Binding Assay with 10 μM Compound 074 Bromodomain Bromodomain Binding % of Control*   ATAD2 C ATAD2B C BAZ2A C BAZ2B C BRD1 C BRD2 BD1 A BRD2 BD2 A BRD3 BD1 A BRD3 BD2 A BRD4 BD1 A BRD4 BD2 A BRD7 C BRD9 C BRDT BD1 A BRDT BD2 A BRPF1 C BRPF3 C CECR2 C CREBBP C EP300 B BPTF C KAT2A C PBRM1 BD2 C PBRM1 BD5 C KAT2B C SMARCA2 C SMARCA4 C TAF1 BD2 C TAF1L BD2 C TRIM24 C TRIM33 C BRWD1 BD2 C *A. <10%; B. 11-75%; C. >75%

Inhibition of BRD4 (BD1+BD2) protein binding to its substrate by a variety of T-PEACH molecules was also assessed using a HTRF assay, as shown in Table 3. T-PEACH molecules containing a BRD4-binding moiety documented in the literature are generally in agreement with the published SAR analysis. Those BRD4-binding moieties include (+)-JQ1-based scaffolds, especially compounds bearing similar structures to OTX-15 and (+)-JQ1.

The incorporation of a chaperone binding moiety, such as a HSP90 binder or HSP70 binder, had only minimal impact on the binding of T-PEACH molecules to BRD4 in this assay. There are a number of reasons: first the co-crystal structures of these moieties with their corresponding proteins are available and allow precise structure-based molecular designs; and secondly, the tether is constructed to provide rigidity with suitable length.

TABLE 3 BRD4 (BD1 + BD2) Binding HTRF Assay Compound ID BRD4 Binding Potency*  1 B  2 C  3 C  4 A  5 C  6 B  7 A  8 B  9 A  10 B  11 B  12 C  13 B  14 C  15 C  16 B  17 C  18 B  19 B  20 C  21 C  22 B  23 C  24 C  25 B  26 B  27 C  28 B  29 C  32 C  33 B  34 C  37 A  38 C  39 B  40 B  41 B  42 B  43 B  44 C  45 A  46 A  47 A  48 B  49 B  50 C  51 C  52 C  53 B  54 B  55 B  56 B  57 B  58 B  59 B  60 B  61 C  62 C  63 B  64 B  65 C  66 C  67 B  68 B  70 B  71 C  72 C  74 B  75 B  76 C  77 A  78 B  79 B  80 A  81 B  82 A  83 C  84 C  85 B  86 B  87 B  88 B  89 B  90 B  91 B  92 C  93 B  94 B  95 B  96 A  97 A  98 B  99 C 100 B 101 C 102 C 103 B 104 A 105 B 106 B 107 A 108 C 109 A 110 A 111 A 112 A 117 A 118 A 119 A 120 A 121 C 123 A 124 A 125 C 126 B 127 B 128 C 129 C 130 B 132 C 133 C 134 C 135 B 136 B 137 B 138 A 139 B 140 C 141 B 142 B 143 C 144 B 145 C *A. IC₅₀ < 100 nM; B. IC₅₀ = 100-1000 nM; C. IC₅₀ > 1000 nM

T-PEACH chimeric molecules are designed to induce targeted protein degradation. As shown in Table 4, for MV4-11 cells treated with T-PEACH molecules where the BET-binding moiety and HSP90-binding moiety are covalently linked, 50% of cellular BRD4 protein or more was degraded within 24 hr as measured in a flow cytometry assay. In contrast, no substantial BRD4 degradation was observed when MV4-11 cells were treated with ether BET inhibitor (+)-JQ1 or a HSP90 binder (1-(4-((4-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperazin-1-yl)methyl)piperidin-1-yl)ethan-1-one). Compound 005 is a control T-PEACH molecule containing a non-BET-binding (−)-JQ1 moiety and does not degrade BRD4. In addition, when cells were pretreated with a combination of a HSP90 binder and (+)-JQ1, compound 40's ability to degrade BRD4 was significantly reduced. This demonstrates the requirement for both binding moieties to be covalently linked in a T-PEACH construct.

TABLE 4 BRD4 Degradation Flow Cytometry Assay Percentage BRD4 Compound ID degradation vs untreated*^(#) 001 A 005 C 009 B 040 A 039 C 046 A HSP90 binder C Combination^(&) B *A. Degradation >50%; B. 10% < Degradation = 10-50%; C. Degradation <10% ^(#)Highest degradation percentage observed at concentrations between 40-1000 nM ^(&)Cells were pretreated with a combination of a HSP90 binder and (+)-JQ1 for 30 minutes before compound 40 was added

To further assess BRD4 degradation, MV4-11 cells were treated for 24 hr with various concentrations of T-PEACH compounds and BRD4 expression was assessed by western blotting. As shown in FIG. 6, BRD4 degradation was observed at 100 and 300 nM concentrations of compound 074. Importantly, when the MV-411 cells were treated with both compound 074 and proteasome inhibitor bortezomib, BRD4 degradation was blocked (FIG. 7). This demonstrates that T-PEACH molecules induce targeted protein degradation via the UPS.

Although (+)-JQ1 is a pan-BET protein family binder, it is possible a T-PEACH molecule incorporating a (+)-JQ1 moiety may display greater selectivity in protein degradation due to charge repulsion and/or steric clashing between individual BET family member targets and the chaperone or chaperone complex. To examine this, MV4-11 cells were treated the (+)-JQ1-based PROTAC dBET1 (Winter et al, Science, 2015, 348:1376-1381) and compound 047 for 24 hr and expression of BRD2, BRD3 and BRD4 were assessed by flow cytometry. As shown in Table 5, dBET1 induced the degradation of BRD2, BRD3 and BRD4 with similar potencies. In contrast, compound 047 only induced significant degradation of BRD4. This indicates that promiscuous target binders may be converted into selective degraders using T-PEACH technology.

TABLE 5 BET Protein Famil Degradation Flow Cytometry Assay BRD2 BRD3 BRD4 Concentration (% of (% of (% of Compound (nM) control) control) control) dBET1 300 0.5 0.3 0.4 100 9.3 1.4 4.6 30 55.1 14.5 26.1 10 94.9 43.2 52.0 3 96.4 89.7 81 047 300 102.2 91.4 9.6 100 81.2 95.0 17.3

BRD4 is known to regulate expression of the MYC gene. As shown in Table 6, selected T-PEACH molecules were found to decrease expression of MYC protein in MV4-11 cells after 24 hr treatment as assessed by HTRF assay.

TABLE 6 MYC Protein Expression HTRF Assay Compounds MYC protein expression* 005 A 040 A *A. IC₅₀ < 100 nM; B. IC₅₀ = 100-1000 nM; C. IC₅₀ > 1000 nM

T-PEACH molecules may include chaperone and chaperone complex binders that have a range of different binding affinities. In different embodiments, it is desirable to use a high-affinity binder, a moderate-affinity binder or a low-affinity binder. Since a HSP90 binding moiety that interacts with the N-terminal ATP-binding pocket of HSP90 may inhibit HSP90 activity and induce the degradation of HSP90 client proteins, some T-PEACH molecules will not only induce the degradation of the desired target protein or proteins (which may or may not be HSP90 client proteins), but also simultaneously induce the degradation of HSP90 client proteins. This combination of degradation activities may increase the activity of T-PEACH molecules over that of other targeted protein degradation technologies directed towards the same target(s). As shown in Table 1, compound 074 has moderate potency in binding to HSP90. In order to assess the selectivity of compound 074 for BRD4 (which is not a sensitive HSP90 client protein) versus known sensitive HSP90 client proteins, flow cytometry assays were performed with various cell lines expressing HSP90 client proteins: ERBB2 in HER2 breast carcinoma cells) and IGF1R, EGFR and RAF1 in HEK-293 embryonic kidney cells. As shown in Table 7, compound 074 displayed IC₅₀ values between 339-1055 nM for degradation of these HSP90 clients, which were 6- to 18-fold higher than the IC₅₀ value of 59 nM for BRD4 degradation determined by western blotting in MV4-11 cells. This indicates that a T-PEACH molecule with a moderate-affinity HSP90-binding moiety displays selectivity towards the intended degradation target BRD4 versus other known HSP90 client proteins.

TABLE 7 HSP90 Client Protein Degradation Flow Cytometry Assay with Compound 074 HSP90 client ERBB2* IGF1R** EGFR** RAF1** IC₅₀ (nM) 340 1055 405 762 *BT-474 cells; **HEK-293 cells

As shown inn Table 8, treatment with various T-PEACH molecules potently inhibited the growth and survival of MV4-11 cells in a cytotoxicity assay.

TABLE 8 MV4-11 Cytotoxicity Assay Compound ID MV4-11 cytotoxicity*  1 A  2 B  3 A  4 B  5 A  6 A  7 B  8 C  9 A  10 A  11 A  12 A  13 A  14 A  15 A  16 A  17 A  18 A  19 A  20 B  21 B  22 B  23 B  24 B  25 B  26 A  27 A  28 B  29 B  32 B  33 B  34 B  37 B  38 A  39 A  40 A  41 A  42 A  43 A  44 B  45 A  46 A  47 A  48 B  49 A  50 A  51 A  52 B  53 A  54 B  55 B  56 B  57 B  58 A  59 A  60 A  61 B  62 B  63 B  64 B  65 B  66 B  67 B  68 B  70 A  71 B  72 A  74 A  75 C  76 A  77 B  78 A  79 A  80 A  81 A  82 A  83 A  84 A  85 A  86 A  87 A  88 A  89 A  90 A  91 A  92 B  93 A  94 A  95 A  96 A  97 A  98 A  99 A 100 A 101 A 102 A 103 A 104 A 105 A 106 A 107 A 108 B 109 A 110 B 111 A 112 A 117 A 118 A 119 A 120 A 121 A 123 A 124 A 125 A 126 A 127 B 128 C 129 C 130 B 132 C 133 C 134 C 135 B 136 B 137 B 138 A 139 B 140 C 141 B 142 B 143 C 144 B 145 C *A. IC₅₀ < 100 nM; B. IC₅₀ = 100-1000 nM; C. IC₅₀ > 1000 nM

Compounds 074 and 078 were selected to test for in vivo efficacy in tumor-bearing xenograft models in mice. In the MV4-11 xenograft model, 25 mk/kg, 50 mg/kg and 100 mg/kg of compound 074 were intravenously dosed 1×/week. As shown in FIG. 8a , after 3 weeks of dosing, the 100 mg/kg group displayed significant tumor growth inhibition, with 4 out of 6 animals being tumor free at the end of the study. The 50 mg/kg group also displayed significant tumor growth inhibition, with 1 out of 6 animals being tumor free at the end of the study. In comparison, 25 mg/kg intraperitoneal dosing 1×/day of the BET inhibitor (+)-JQ1 gave moderate tumor growth inhibition. No animal deaths or significant effects on body weights were observed in any group (FIG. 8b ).

In the SU-DHL-4 xenograft model, 50 mg/kg and 100 mg/kg of compounds 074 and 078 were intravenously dosed 1×/week. As shown in FIG. 9a after 4 weeks of dosing, the 100 mg/kg groups for both compounds displayed significant tumor growth inhibition, with tumor vs control (T/C) values of 41% and 28% for compounds 074 and 078, respectively. In comparison, 100 mg/kg oral dosing 1×/day of the BET inhibitor OTX-015 (Boi, Clin Cancer Res, 2015, 21:1628-38) displayed a T/C value of 45%. No animal deaths or significant effects on body weights were observed at any dose level (FIG. 9b ).

In order to examine the tumor-selective retention of T-PEACH molecules, a pharmacokinetics and tissue distribution study was conducted in the MV4-11 xenograft tumor model in mice. 5 mg/kg of compound 074 was given by a single intravenous dose and animals were sacrificed at different time points over 48 hr to assess the pharmacokinetics of the compound in plasma, heart, liver, lung and tumor tissues. As shown in Table 9, although the initial concentrations of compound 074 in the heart, liver and lung were higher compared to that observed in tumors, its half-life in tumors of 32.10 hr was 4.6-9.5-times as long as in plasma and other organs, demonstrating the tumor-selective retention of this T-PEACH molecule.

TABLE 9 Pharmacokinetics and Distribution of Compound 074 in the MV4-11 Xenograft Model in Mice Dose AUC(0-∞) Cmax AUC(0-∞) Tissue (mg/kg) T_(1/2) (hr) Tmax (hr) Cmax (ng/mL) (h*ng/mL) (ng/g) (h*ng/g) Plasma 5 3.92 1.00 497.95 3015.79 n/a n/a Heart 5 3.70 1.00 n/a n/a 1643.16 8828.71 Liver 5 3.37 1.00 n/a n/a 5036.96 24415.49 Lung 5 6.94 1.00 n/a n/a 2027.34 14199.86 Tumor 5 32.10 1.00 n/a n/a 461.97 23857.20

Modifications and variations of the described methods and compositions of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the disclosure. Although the disclosure has been described in connection with specific embodiments, it should be understood that the disclosure as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the disclosure are intended and understood by those skilled in the relevant field in which this disclosure resides to be within the scope of the disclosure as represented by the following claims.

INCORPORATION BY REFERENCE

All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference. 

What is claimed is:
 1. A protein degradation chimera comprising: a first moiety that is capable of binding to a chaperone complex component; a second moiety that is capable of binding to a target protein or proteins, wherein the target protein or proteins is/are targeted for degradation; and a tether configured to covalently couple the first moiety and the second moiety.
 2. The protein degradation chimera of claim 1, wherein the chaperone complex component is selected from HSP90, HSP70, IAPs and E3 ligases such as CHIP, HECTD3, CUL5, as well as other cofactors and cochaperones.
 3. The protein degradation chimera of claim 1, wherein the target protein comprises Bromodomain-containing protein 4 (BRD4).
 4. The protein degradation chimera of claim 1, wherein the target protein is one or more proteins selected from BRD2, BRD3, BRD4, BRDT.
 5. The protein degradation chimera of claim 1, wherein the target protein is one or more oncogenic proteins selected from BTK, ALK, EGFR, RAF, KRAS, MDM2, STAT3, HIF-1, TRK, IRAK4, AR, ABL, VEGFR, CDK4, CDK6, CDK7, MLK3, ER, IGF-1R, telomerase, etc.
 6. The protein degradation chimera of any one of claims 1 and 3 to 5, wherein the chaperone complex component is HSP90.
 7. The protein degradation chimera of any one of claims 1 to 6, wherein the tether is a small molecule compound that covalently couples the first moiety and the second moiety through non-cleavable chemical bonds.
 8. The protein degradation chimera of any one of claims 1 to 6, wherein the tether comprises one or more cyclic ring systems.
 9. The protein degradation chimera of any one of claims 1 to 8, wherein the tether comprises an alkyl chain optionally substituted by and/or interrupted with one or more chemical groups.
 10. The protein degradation chimera of any one of claims 1 to 9, wherein the tether is of the formula -Het¹-X¹—, -Het¹-X¹-Het²-X²—, -Het¹-X¹—(C₁-C₄)alkylene-Het²-X²—, -Het¹-X¹-Het²-X²(C₁-C₄)alkylene-, —(CH₂CH₂O)_(o)—(CH₂)_(p)-Het¹-X¹-Het²-(CH₂CH₂O)_(n), —(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹-Het²-X², -Het¹-X¹-Phe-X²—NR^(c)—X³—, —(CH₂CH₂O)_(o)—(CH₂)_(p)-Het¹-X¹-Phe-X²—NR^(c)—(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)NR^(c)-Phe-X¹—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)-Phe-(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)—C(O)—NR^(d)—(CH₂CH₂O)_(o)—(CH₂)_(p)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹-Het²-X²—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)—Het¹-X¹-Het²-X²—(CH₂CH₂O)_(o), —NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-NH—X¹-Het¹-X², —NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-NH—X¹-Het¹-X²—(CH₂CH₂O)_(o), —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Phe-X¹—NR^(c)—(CH₂CH₂O)_(o)—(CH₂)_(p)—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹-X¹—, —(CH₂CH₂O)_(o)—(CH₂)_(p)—NR^(c)—(CH₂CH₂O)_(n)—(CH₂)_(m)-Het¹- X¹—(CH₂CH₂O)_(n)—, —(CH₂CH₂O)_(n)—(CH₂)_(m)—NR^(c)—(CH₂)_(m)—C(O)—NR^(d)-Het¹-X¹-Het²-(CH₂CH₂O)_(o)—(CH₂)_(p), or —NR^(c)—(CH₂)_(m)—C(O)—NR^(d)—(CH₂)_(m)-Het¹-X¹-Het²-X², wherein Het¹ and Het² are each independently phenyl, a 4- to 6-membered heterocyclyl, 5- to 7-membered heteroaryl, or a 4- to 6-membered cycloalkyl; X¹, X², and X³, are each independently C(O) or (CH₂)_(r); R^(c) and Rd are each independently hydrogen or (C₁-C₄)alkyl; and m, n, o, p, q and r are each independently integers selected from 0, 1, 2, 3, 4, 5, and
 6. 11. The protein degradation chimera of claim 1, wherein when administered to a patient having a tumor, the protein degradation chimera is retained in tumorous tissues due to binding to high levels of HSP90 of the chaperone complex present in tumor.
 12. The protein degradation chimera of claim 1, wherein when administered to a patient having a tumor, the protein degradation chimera is retained in tumorous tissues due to binding to high levels of HSP70 of the chaperone complex present in tumor.
 13. A method for treating cancer, comprising administering a therapeutically effective amount of the protein degradation chimera of any one of claims 1-12 to a patient in need thereof. 